annual reportmarch dear shareholders year achievement evolution johnson johnson delivered solid financial performance enhanced value shareholders made progress two significant undertakings preparing johnson johnson operate faster focused two sector company initiating separation consumer health business kenvue year every industry felt effects high inflation geopolitical tension continued supply chain disruption joaquin duato chairman ceo times like remind privileged lead johnson johnson eighth chairman ceo history company navigated total shareholder return tsr many economic cycles addressing outperformed competitor composite healthcares important unmet needs sp contributing tsr nearly years time learned make compounded annual growth rate last decisions longterm ten years significant value creation made possible longterm strategic focus deep commitment credo values outstanding execution teams three determination use size good segments business long made us global leader health focusing patient customer needs reinforces sense medtech purpose urgency thanks performed line ahead competitive employees embody idealsand composite past two years growth driven breadth diversification business focused commercial strategies successful successful year launch differentiated products improvements global procedure recovery performance priorities delivered innovation agenda achieved fullyear operational sales accelerating cadence new products growth adjusted net earnings significantly enhancing medtech pipeline billion adjusted diluted net earnings included programs per share representing increases million net present value potential respectively compared medtech delivered operational sales growth across operational basis adjusted diluted net earnings per businesses orthopaedics surgery share increased interventional solutions vision invested nearly billion rd deployed acquisition abiomed positions us global billion toward acquisitions increased leader heart recovery immediately enhances dividend th consecutive year medtech revenue growth diversifies returned capital shareholders share portfolio includes priority platforms repurchase program billion annual revenue chairmans letter pharmaceutical strengthened position leading delivering world pharmaceutical company delivering th consecutive year abovemarket adjusted operational sales growth excluding covid vaccine rank million access committed programs growth driven several oncology medicine index focused closing immunology medicines including darzalex reflecting decades racial health gap erleada stelara tremfya long strategy part race continue investigate new indications maximize access health equity initiative transformative regimens reach even innovative medicines investments technologies community health patients including darzalex frontline multiple centers health myeloma erleada earlystage prostate cancer literacy education tremfya crohns disease ulcerative colitis increasing racial rybrevant combination lazertinib frontline billion diversity nonsmallcell lung cancer egfr mutations global impact spend healthcare talent investment pipeline strengthened small pipeline workforce portfolio multiple myeloma medicines addition diverse suppliers launches carvykti first cell therapy tecvayli firstinclass bispecific antibody african submitted bla talquetamab investigational consecutive countries offtheshelf bispecific antibody years million recognition commitment consumer health cdp alist rating johnson johnson made significant strides toward separation leadership foundation africa business independent company also climate action frontline first catalytic delivering solid performance year fund providing support community rolled kenvue name brand reflective health workers weeks johnson johnsons storied history kenvues bright future standalone organization paid parental leave qualified johnson billion appointed leadership including thibaut mongon johnson employees ceo designate paul ruh cfo designate larry around world doses vermox merlo former chairman ceo cvs non donated since executive chair designate kenvue facilitate treatment intestinal worms starting began operating consumer business company within company earlier renewable year kenvue filed form sec giving us electricity option pursue ipo potential step separation remain track complete secured process operations brazil direct know greatest impact patients power purchase must continue prioritizing promising agreement opportunities ongoing emphasis building starting digital capabilities including ai data science intelligent automation fuel next wave innovation intersection science technology chairmans letterdelivering investors straight years billion rank increased dividends invested mergers onfortunes admired acquisitions companies list pharmaceutical industry number companies brands platforms world aaa credit rating including billion year free cash flow johnson johnson sales returned shareholders cash flow operating activities less additions property plant equipment billion invested rd opportunity responsibility lead world evolves johnson johnson evolve ahead know weve met customers partners government officials done many times putting patients employees around world first year center keeps us looking forward ceo constantly reminded world open opportunity expects us partner choice people depend us deliver want us succeed achieved success century johnson johnson held highest regard staying true mission serving patients held highest standardsas families doctors nurses employees affirms purpose motivates us every day communities others depend us much world standards set small part theres time waste predecessor alex gorsky deeply honored serve chairman ceo following retirement alex laid strong foundation future anchored sincerely people johnson johnson always greatest strength commitment credo fills confidence inspiration every day joaquin duato chairman ceo one important years historya new chapter one two leading global companies johnson johnson uniquely positioned lead industry fastmoving healthcare landscape nongaap measures operational sales growth excludes effect translational currency adjusted net earnings adjusted net earnings per share excludes special items intangible asset amortization expense adjusted operational net earnings per share excludes special items intangible asset amortization expense effect translational currency see nongaap reconciliation annual report chairmans letter united states securities exchange commission washington dc annual report pursuant section securities exchange act forthefiscalyearendedjanuary transition report pursuant section securities exchange act transition period commissionfilenumber johnson johnson exactnameofregistrantasspecifiedinitscharter newjersey stateofincorporation irsemployeridentificationno onejohnsonjohnsonplaza newbrunswicknewjersey addressofprincipalexecutiveoffices zipcode onejohnsonjohnsonplaza newbrunswicknewjersey addressofprincipalexecutiveoffices registrantstelephonenumberincludingareacode securitiesregisteredpursuanttosectionboftheact titleofeachclass tradingsymbol nameofeachexchangeonwhichregistered commonstockparvalue jnj newyorkstockexchange notesduemay jnjc newyorkstockexchange notesduenovember jnjbp newyorkstockexchange notesduenovember jnj newyorkstockexchange notesduemay jnj newyorkstockexchange indicatebycheckmarkiftheregistrantisawellknownseasonedissuerasdefinedinruleofthesecurities act yes indicatebycheckmarkiftheregistrantisnotrequiredtofilereportspursuanttosectionorsectiondoftheexchange act yes indicatebycheckmarkwhethertheregistranthasfiledallreportsrequiredtobefiledbysectionordofthe exchangeactduringtheprecedingmonthsorforsuchshorterperiodthattheregistrantwasrequiredtofilesuch reportsandhasbeensubjecttosuchfilingrequirementsforthepastdays yes indicatebycheckmarkwhethertheregistranthassubmittedelectronicallyeveryinteractivedatafilerequiredtobesubmitted pursuanttoruleofregulationstduringtheprecedingmonthsorforsuchshorterperiodthattheregistrantwas requiredtosubmitsuchfiles yes indicatebycheckmarkwhethertheregistrantisalargeacceleratedfileranacceleratedfileranonacceleratedfilerasmaller reportingcompanyoremerginggrowthcompanyseethedefinitionsoflargeacceleratedfileracceleratedfilersmaller reportingcompanyandemerginggrowthcompanyinruleboftheexchangeact largeacceleratedfiler acceleratedfiler nonacceleratedfiler smallerreportingcompany emerginggrowthcompany ifanemerginggrowthcompanyindicatebycheckmarkiftheregistranthaselectednottousetheextendedtransitionperiod forcomplyingwithanyneworrevisedfinancialaccountingstandardsprovidedpursuanttosectionaoftheexchange act indicatebycheckmarkwhethertheregistranthasfiledareportonandattestationtoitsmanagementsassessmentofthe effectivenessofitsinternalcontroloverfinancialreportingundersectionbofthesarbanesoxleyactusc bbytheregisteredpublicaccountingfirmthatpreparedorissueditsauditreport yes ifsecuritiesareregisteredpursuanttosectionboftheactindicatebycheckmarkwhetherthefinancialstatementsof theregistrantincludedinthefilingreflectthecorrectionofanerrortopreviouslyissuedfinancialstatements indicatebycheckmarkwhetheranyofthoseerrorcorrectionsarerestatementsthatrequiredarecoveryanalysisofincentive basedcompensationreceivedbyanyoftheregistrantsexecutiveofficersduringtherelevantrecoveryperiodpursuantto db indicatebycheckmarkwhethertheregistrantisashellcompanyasdefinedinruleboftheexchange act yes theaggregatemarketvalueofthecommonstockheldbynonaffiliatescomputedbyreferencetothepriceatwhichthe commonstockwaslastsoldasofthelastbusinessdayoftheregistrantsmostrecentlycompletedsecondfiscalquarter wasapproximatelybillion onfebruarythereweresharesofcommonstockoutstanding documentsincorporatedbyreference partsiandiii portionsofregistrantsproxystatementforitsannualmeetingofshareholdersfiledwithin daysafterthecloseoftheregistrantsfiscalyeartheproxystatementareincorporatedby referencetothisreportonformkthisreportitem parti business general segmentsofbusiness geographicareas rawmaterials patents trademarks seasonality competition environment regulation employeesandhumancapitalmanagement availableinformation riskfactors b unresolvedstaffcomments properties legalproceedings minesafetydisclosures executiveofficersoftheregistrant partii marketforregistrantscommonequityrelatedstockholdermattersandissuerpurchasesof equitysecurities reserved managementsdiscussionandanalysisofresultsofoperationsandfinancialcondition quantitativeandqualitativedisclosuresaboutmarketrisk financialstatementsandsupplementarydata changesinanddisagreementswithaccountantsonaccountingandfinancialdisclosure controlsandprocedures b otherinformation c disclosuresregardingforeignjurisdictionsthatpreventinspections partiii directorsexecutiveofficersandcorporategovernance executivecompensation securityownershipofcertainbeneficialownersandmanagementandrelatedstockholder matters certainrelationshipsandrelatedtransactionsanddirectorindependence principalaccountantfeesandservices partiv exhibitsandfinancialstatementschedules formksummary signatures exhibitindex cautionary note regarding forwardlooking statements thisannualreportonformkandjohnsonjohnsonsotherpubliclyavailabledocumentscontainforwardlooking statementswithinthemeaningofthesafeharborprovisionsoftheunitedstatesprivatesecuritieslitigationreformact ofmanagementandrepresentativesofjohnsonjohnsonanditssubsidiariesthecompanyalsomayfromtimeto timemakeforwardlookingstatementsforwardlookingstatementsdonotrelatestrictlytohistoricalorcurrentfactsand reflectmanagementsassumptionsviewsplansobjectivesandprojectionsaboutthefutureforwardlookingstatements maybeidentifiedbytheuseofwordssuchasplansexpectswillanticipatesestimatesandotherwordsof similarmeaninginconjunctionwithamongotherthingsdiscussionsoffutureoperationsexpectedoperatingresultsand financialperformanceimpactofplannedacquisitionsanddispositionsimpactandtimingofrestructuringinitiatives includingassociatedcostsavingsandotherbenefitstheplannedseparationofthecompanysconsumerhealth businessthecompanysstrategyforgrowthproductdevelopmentactivitiesregulatoryapprovalsmarketpositionand expenditures becauseforwardlookingstatementsarebasedoncurrentbeliefsexpectationsandassumptionsregardingfutureevents theyaresubjecttouncertaintiesrisksandchangesthataredifficulttopredictandmanyofwhichareoutsideofthe companyscontrolinvestorsshouldrealizethatifunderlyingassumptionsproveinaccurateorknownorunknownrisksor uncertaintiesmaterializethecompanysactualresultsandfinancialconditioncouldvarymateriallyfromexpectationsand projectionsexpressedorimpliedinitsforwardlookingstatementsinvestorsarethereforecautionednottorelyonthese forwardlookingstatementsrisksanduncertaintiesincludebutarenotlimitedto risksrelatedtoproductdevelopmentmarketsuccessandcompetition challengesanduncertaintiesinherentininnovationanddevelopmentofnewandimprovedproductsandtechnologies onwhichthecompanyscontinuedgrowthandsuccessdependincludinguncertaintyofclinicaloutcomesadditional analysisofexistingclinicaldataobtainingregulatoryapprovalshealthplancoverageandcustomeraccessandinitial andcontinuedcommercialsuccess challengestothecompanysabilitytoobtainandprotectadequatepatentandotherintellectualpropertyrightsfornew andexistingproductsandtechnologiesintheunitedstatesandotherimportantmarkets theimpactofpatentexpirationstypicallyfollowedbytheintroductionofcompetinggenericbiosimilarorotherproducts andresultingrevenueandmarketsharelosses increasinglyaggressiveandfrequentchallengestothecompanyspatentsbycompetitorsandothersseekingtolaunch competinggenericbiosimilarorotherproductsandincreasedreceptivityofcourtstheunitedstatespatentand trademarkofficeandotherdecisionmakerstosuchchallengespotentiallyresultinginlossofmarketexclusivityand rapiddeclineinsalesfortherelevantproductsoonerthanexpected competitioninresearchanddevelopmentofnewandimprovedproductsprocessesandtechnologieswhichcanresult inproductandprocessobsolescence competitiontoreachagreementwiththirdpartiesforcollaborationlicensingdevelopmentandmarketingagreements forproductsandtechnologies competitionbasedoncosteffectivenessproductperformancetechnologicaladvancesandpatentsattainedby competitorsand allegationsthatthecompanysproductsinfringethepatentsandotherintellectualpropertyrightsofthirdpartieswhich couldadverselyaffectthecompanysabilitytoselltheproductsinquestionandrequirethepaymentofmoneydamages andfutureroyalties risksrelatedtoproductliabilitylitigationandregulatoryactivity productefficacyorsafetyconcernswhetherornotbasedonscientificevidencepotentiallyresultinginproduct withdrawalsrecallsregulatoryactiononthepartoftheunitedstatesfoodanddrugadministrationorinternational counterpartsdecliningsalesreputationaldamageincreasedlitigationexpenseandsharepriceimpact theimpactincludingdecliningsalesandreputationaldamageofsignificantlitigationorgovernmentactionadverseto thecompanyincludingproductliabilityclaimsandallegationsrelatedtopharmaceuticalmarketingpracticesand contractingstrategies theimpactofanadversejudgmentorsettlementandtheadequacyofreservesrelatedtolegalproceedingsincluding patentlitigationproductliabilitypersonalinjuryclaimssecuritiesclassactionsgovernmentinvestigationsemployment andotherlegalproceedings johnsonjohnsonannualreport increasedscrutinyofthehealthcareindustrybygovernmentagenciesandstateattorneysgeneralresultingin investigationsandprosecutionswhichcarrytheriskofsignificantcivilandcriminalpenaltiesincludingbutnotlimited todebarmentfromgovernmentbusiness failuretomeetcomplianceobligationsincomplianceagreementswithgovernmentsorgovernmentagencieswhich couldresultinsignificantsanctions potentialchangestoapplicablelawsandregulationsaffectingunitedstatesandinternationaloperationsincluding relatingtoapprovalofnewproductslicensingandpatentrightssalesandpromotionofhealthcareproductsaccess toandreimbursementandpricingforhealthcareproductsandservicesenvironmentalprotectionandsourcingofraw materials compliancewithlocalregulationsandlawsthatmayrestrictthecompanysabilitytomanufactureorsellitsproductsin relevantmarketsincludingrequirementstocomplywithmedicaldevicereportingregulationsandotherrequirements suchastheeuropeanunionsmedicaldevicesregulation changesindomesticandinternationaltaxlawsandregulationsincreasingauditscrutinybytaxauthoritiesaroundthe worldandexposurestoadditionaltaxliabilitiespotentiallyinexcessofexistingreservesand theissuanceofneworrevisedaccountingstandardsbythefinancialaccountingstandardsboardandregulationsby thesecuritiesandexchangecommission risksrelatedtothecompanysstrategicinitiativeshealthcaremarkettrendsandtheplanned separationofthecompanysconsumerhealthbusiness pricingpressuresresultingfromtrendstowardhealthcarecostcontainmentincludingthecontinuedconsolidation amonghealthcareprovidersandothermarketparticipantstrendstowardmanagedcaretheshifttowardgovernments increasinglybecomingtheprimarypayersofhealthcareexpensessignificantnewentrantstothehealthcaremarkets seekingtoreducecostsandgovernmentpressureoncompaniestovoluntarilyreducecostsandpriceincreases restrictedspendingpatternsofindividualinstitutionalandgovernmentalpurchasersofhealthcareproductsand servicesduetoeconomichardshipandbudgetaryconstraints challengestothecompanysabilitytorealizeitsstrategyforgrowthincludingthroughexternallysourcedinnovations suchasdevelopmentcollaborationsstrategicacquisitionslicensingandmarketingagreementsandthepotential heightenedcostsofanysuchexternalarrangementsduetocompetitivepressures thepotentialthattheexpectedstrategicbenefitsandopportunitiesfromanyplannedorcompletedacquisitionor divestiturebythecompanymaynotberealizedormaytakelongertorealizethanexpected thepotentialthattheexpectedbenefitsandopportunitiesrelatedtopastandongoingrestructuringactionsmaynotbe realizedormaytakelongertorealizethanexpected thecompanysabilitytoconsummatetheplannedseparationofthecompanysconsumerhealthbusinessonatimely basisoratall thecompanysabilitytosuccessfullyseparatethecompanysconsumerhealthbusinessandrealizetheanticipated benefitsfromtheplannedseparationand thenewconsumerhealthcompanysabilitytosucceedasastandalonepubliclytradedcompany risksrelatedtoeconomicconditionsfinancialmarketsandoperatinginternationally therisksassociatedwithglobaloperationsonthecompanyanditscustomersandsuppliersincludingforeign governmentsincountriesinwhichthecompanyoperates theimpactofinflationandfluctuationsininterestratesandcurrencyexchangeratesandthepotentialeffectofsuch fluctuationsonrevenuesexpensesandresultingmargins potentialchangesinexportimportandtradelawsregulationsandpoliciesoftheunitedstatesandothercountries includinganyincreasedtraderestrictionsortariffsandpotentialdrugreimportationlegislation theimpactoninternationaloperationsfromfinancialinstabilityininternationaleconomiessovereignriskpossible impositionofgovernmentalcontrolsandrestrictiveeconomicpoliciesandunstableinternationalgovernmentsandlegal systems theimpactofglobalpublichealthcrisesandpandemicsincludingthenovelcoronaviruscovidpandemic changestoglobalclimateextremeweatherandnaturaldisastersthatcouldaffectdemandforthecompanysproducts andservicescausedisruptionsinmanufacturinganddistributionnetworksaltertheavailabilityofgoodsandservices withinthesupplychainandaffecttheoveralldesignandintegrityofthecompanysproductsandoperationsand theimpactofarmedconflictsandterroristattacksintheunitedstatesandotherpartsoftheworldincludingsocialand economicdisruptionsandinstabilityoffinancialandothermarkets johnsonjohnsonannualreportrisksrelatedtosupplychainandoperations difficultiesanddelaysinmanufacturinginternallythroughthirdpartyprovidersorotherwisewithinthesupplychainthat mayleadtovoluntaryorinvoluntarybusinessinterruptionsorshutdownsproductshortageswithdrawalsor suspensionsofproductsfromthemarketandpotentialregulatoryaction interruptionsandbreachesofthecompanysinformationtechnologysystemsorthoseofthecompanysvendors whichcouldresultinreputationalcompetitiveoperationalorotherbusinessharmaswellasfinancialcostsand regulatoryaction relianceonglobalsupplychainsandproductionanddistributionprocessesthatarecomplexandsubjecttoincreasing regulatoryrequirementsthatmayadverselyaffectsupplysourcingandpricingofmaterialsusedinthecompanys productsand thepotentialthattheexpectedbenefitsandopportunitiesrelatedtorestructuringactionscontemplatedfortheglobal supplychainmaynotberealizedormaytakelongertorealizethanexpectedincludingduetoanyrequiredapprovals fromapplicableregulatoryauthorities investorsalsoshouldcarefullyreadtheriskfactorsdescribedinitemaofthisannualreportonformkfora descriptionofcertainrisksthatcouldamongotherthingscausethecompanysactualresultstodiffermateriallyfrom thoseexpressedinitsforwardlookingstatementsinvestorsshouldunderstandthatitisnotpossibletopredictoridentify allsuchfactorsandshouldnotconsidertherisksdescribedaboveandinitematobeacompletestatementofall potentialrisksanduncertaintiesthecompanydoesnotundertaketopubliclyupdateanyforwardlookingstatementthat maybemadefromtimetotimewhetherasaresultofnewinformationorfutureeventsordevelopments johnsonjohnsonannualreport thispageintentionallyleftblankpart item business general johnsonjohnsonanditssubsidiariesthecompanyhaveapproximatelyemployeesworldwideengagedinthe researchanddevelopmentmanufactureandsaleofabroadrangeofproductsinthehealthcarefieldjohnsonjohnson isaholdingcompanywithoperatingcompaniesconductingbusinessinvirtuallyallcountriesoftheworldthecompanys primaryfocusisproductsrelatedtohumanhealthandwellbeingjohnsonjohnsonwasincorporatedinthestateof newjerseyin theexecutivecommitteeofjohnsonjohnsonistheprincipalmanagementgroupresponsibleforthestrategic operationsandallocationoftheresourcesofthecompanythiscommitteeoverseesandcoordinatestheactivitiesofthe companysthreebusinesssegmentsconsumerhealthpharmaceuticalandmedtechpreviouslyreferredtoasmedical deviceswithinthestrategicparametersprovidedbythecommitteeseniormanagementgroupsatusandinternational operatingcompaniesareeachresponsiblefortheirownstrategicplansandthedaytodayoperationsofthose companieseachsubsidiarywithinthebusinesssegmentsiswithlimitedexceptionsmanagedbyresidentsofthecountry wherelocated segments business thecompanyisorganizedintothreebusinesssegmentsconsumerhealthpharmaceuticalandmedtechadditional informationrequiredbythisitemisincorporatedhereinbyreferencetothenarrativeandtabulardescriptionsofsegments andoperatingresultsunderitemmanagementsdiscussionandanalysisofresultsofoperationsandfinancial conditionofthisreportandnotesegmentsofbusinessandgeographicareasofthenotestoconsolidated financialstatementsincludedinitemofthisreport consumerhealth theconsumerhealthsegmentincludesabroadrangeofproductsfocusedonpersonalhealthcareusedintheskin healthbeautyoverthecountermedicinesbabycareoralcarewomenshealthandwoundcaremarketsmajor brandsinskinhealthbeautyincludetheaveenocleancleardrcilaboneutrogenaandogxproduct linesoverthecounterotcmedicinesincludethebroadfamilyoftylenolacetaminophenproductssudafed coldfluandallergyproductsbenadrylandzyrtecallergyproductsmotrinibibuprofenproductsnicorette smokingcessationproductsoutsidetheuszarbeesproductsinspiredbynatureandthepepcidlineofacidreflux productsbabycareincludesthejohnsonsandaveenobabylineofproductsoralcareincludesthelisterine productlinemajorbrandsinwomenshealthoutsideofnorthamericaarestayfreeandcarefreesanitarypads andobtamponbrandswoundcarebrandsincludethebandaidbrandadhesivebandagesandneosporinfirst aidproductlinestheseproductsaremarketedtothegeneralpublicandsoldonlineecommerceandtoretailoutlets anddistributorsthroughouttheworld innovemberthecompanyannounceditsintentiontoseparatethecompanysconsumerhealthbusinesskenvue asthenamefortheplannednewconsumerhealthcompanywiththeintentiontocreateanewpubliclytraded companybytheendofthefiscalyear pharmaceutical thepharmaceuticalsegmentisfocusedonthefollowingtherapeuticareasimmunologyegrheumatoidarthritis psoriaticarthritisinflammatoryboweldiseaseandpsoriasisinfectiousdiseaseseghivaidsneuroscienceeg mooddisordersneurodegenerativedisordersandschizophreniaoncologyegprostatecancerhematologic malignancieslungcancerandbladdercancercardiovascularandmetabolismegthrombosisdiabetesandmacular degenerationandpulmonaryhypertensionegpulmonaryarterialhypertensionmedicinesinthissegmentare distributeddirectlytoretailerswholesalersdistributorshospitalsandhealthcareprofessionalsforprescriptionusekey productsinthepharmaceuticalsegmentincluderemicadeinfliximabatreatmentforanumberofimmunemediated inflammatorydiseasessimponigolimumabasubcutaneoustreatmentforadultswithmoderatetosevererheumatoid johnsonjohnsonannualreport arthritisactivepsoriaticarthritisactiveankylosingspondylitisandmoderatelyactivetoseverelyactiveulcerativecolitis simponiariagolimumabanintravenoustreatmentforadultswithmoderatetosevererheumatoidarthritisactive psoriaticarthritisandactiveankylosingspondylitisandactivepolyarticularjuvenileidiopathicarthritispjiainpeople yearsofageandolderstelaraustekinumabatreatmentforadultsandchildrenwithmoderatetosevereplaque psoriasisforadultswithactivepsoriaticarthritisforadultswithmoderatelytoseverelyactivecrohnsdiseaseand treatmentofmoderatelytoseverelyactiveulcerativecolitistremfyaguselkumabatreatmentforadultswithmoderate tosevereplaquepsoriasisandactivepsoriaticarthritisedurantrilpivirineprezistadarunavirandprezcobix rezolstadarunavircobicistatantiretroviralmedicinesforthetreatmentofhumanimmunodeficiencyvirushivin combinationwithotherantiretroviralproductsandsymtuzadarunavircobicistatemtricitabinetenofoviralafenamidea oncedailysingletabletregimenforthetreatmentofhivconcertamethylphenidatehclextendedreleasetablets ciiatreatmentforattentiondeficithyperactivitydisorderinvegasustennaxeplionpaliperidonepalmitateforthe treatmentofschizophreniaandschizoaffectivedisorderinadultsinvegatrinzatrevictapaliperidonepalmitatefor thetreatmentofschizophreniainpatientsaftertheyhavebeenadequatelytreatedwithinvegasustennaforatleast fourmonthsrisperdalconstarisperidonelongactinginjectionforthetreatmentofschizophreniaandthe maintenancetreatmentofbipolardisorderinadultszytigaabirateroneacetateatreatmentforpatientswithprostate cancererleadaapalutamideanextgenerationandrogenreceptorinhibitorforthetreatmentofpatientswithprostate cancerimbruvicaibrutinibatreatmentforcertainbcellmalignanciesorbloodcancersandchronicgraftversushost diseasedarzalexdaratumumabatreatmentformultiplemyelomadarzalexfasprodaratumumaband hyaluronidasefihjatreatmentformultiplemyelomaandlightchainalamyloidosisxareltorivaroxabananoral anticoagulantforthepreventionofdeepveinthrombosisdvtwhichmayleadtopulmonaryembolismpeinpatients undergoinghiporkneereplacementsurgerytoreducetheriskofstrokeandsystemicembolisminpatientswith nonvalvularatrialfibrillationandforthetreatmentandreductionofriskofrecurrenceofdvtandpetoreducetheriskof majorcardiovasculareventsinpatientswithcoronaryarterydiseasecadandperipheralarterydiseasepadforthe treatmentandsecondarypreventionofthromboembolisminpediatricpatientsandforthromboprophylaxisinpediatric patientsfollowingthefontanprocedureinvokanacanagliflozinforthetreatmentofadultswithtypediabetes invokametvokanametcanagliflozinmetforminhclacombinationtherapyoffixeddosesofcanagliflozinand metforminhydrochlorideforthetreatmentofadultswithtypediabetesandinvokametxrcanagliflozinmetformin hydrochlorideextendedreleaseaoncedailyfixeddosecombinationtherapyofcanagliflozinandmetformin hydrochlorideextendedreleaseforthetreatmentofadultswithtypediabetesopsumitmacitentanasmonotherapy orincombinationindicatedforthelongtermtreatmentofpulmonaryarterialhypertensionpahuptraviselexipag theonlyapprovedoralandintravenousselectiveipreceptoragonisttargetingaprostacyclinpathwayinpahmanyof thesemedicinesweredevelopedincollaborationwithstrategicpartnersorarelicensedfromothercompaniesand maintainactivelifecycledevelopmentprograms medtech themedtechpreviouslyreferredtoasmedicaldevicessegmentincludesabroadportfolioofproductsusedinthe interventionalsolutionsorthopaedicssurgeryandvisioncategoriesinterventionalsolutionsincludeelectrophysiology productsbiosensewebstertotreatcardiovasculardiseasesneurovascularcarecerenovusthattreatshemorrhagicand ischemicstrokeandtheheartrecoveryportfolioabiomedwhichincludestechnologiestotreatseverecoronaryartery diseaserequiringhighriskpcioramicardiogenicshocktheorthopaedicsportfoliodepuysynthescomprisesproducts insupportofhipskneestraumaandspinesportsotherthesurgeryportfoliosincludeadvancedandgeneralsurgery offeringsethiconsolutionsthatfocusonbreastaestheticsmentorandearnoseandthroatacclarentprocedures johnsonjohnsonvisionproductsincludeacuvuebrandcontactlensesandophthalmictechnologiesrelatedtocataract andlaserrefractivesurgerytheseproductsaredistributedtowholesalershospitalsandretailersandusedpredominantly intheprofessionalfieldsbyphysiciansnurseshospitalseyecareprofessionalsandclinics geographic areas johnsonjohnsonanditssubsidiariesthecompanyhaveapproximatelyemployeesworldwideengagedinthe researchanddevelopmentmanufactureandsaleofabroadrangeofproductsinthehealthcarefieldthecompany conductsbusinessinvirtuallyallcountriesoftheworldwiththeprimaryfocusonproductsrelatedtohumanhealthand wellbeing theproductsmadeandsoldintheinternationalbusinessincludemanyofthosedescribedaboveundersegmentsof businessconsumerhealthpharmaceuticalandmedtechhowevertheprincipalmarketsproductsand methodsofdistributionintheinternationalbusinessvarywiththecountryandtheculturetheproductssoldin internationalbusinessincludethosedevelopedintheusandbysubsidiariesabroad johnsonjohnsonannualreportinvestmentsandactivitiesinsomecountriesoutsidetheusaresubjecttohigherrisksthancomparableusactivities becausetheinvestmentandcommercialclimatemaybeinfluencedbyfinancialinstabilityininternationaleconomies restrictiveeconomicpoliciesandpoliticalandlegalsystemuncertainties raw materials rawmaterialsessentialtothecompanysbusinessaregenerallyreadilyavailablefrommultiplesourceswherethereare exceptionsthetemporaryunavailabilityofthoserawmaterialswouldnotlikelyhaveamaterialadverseeffectonthe financialresultsofthecompany patents thecompanyssubsidiarieshavemadeapracticeofobtainingpatentprotectionontheirproductsandprocesseswhere possibletheyownorarelicensedunderasignificantnumberofpatentsintheusandothercountriesrelatingtotheir productsproductusesformulationsandmanufacturingprocesseswhichintheaggregatearebelievedtobeofmaterial importancetothecompanyintheoperationofitsbusinessesthecompanyssubsidiariesfacepatentchallengesfrom thirdpartiesincludingchallengesseekingtomanufactureandmarketgenericandbiosimilarversionsofthecompanys keypharmaceuticalproductspriortoexpirationoftheapplicablepatentscoveringthoseproductssignificantlegal proceedingsandclaimsinvolvingthecompanyspatentandotherintellectualpropertyaredescribedinnotelegal proceedingsintellectualpropertyofthenotestoconsolidatedfinancialstatementsincludedinitemofthisreport salesofthecompanyslargestproductstelaraustekinumabaccountedforapproximatelyofthecompanys totalrevenuesforfiscalaccordinglythepatentsrelatedtothisproductarebelievedtobematerialtothecompany janssenbiotechincawhollyownedsubsidiaryofjohnsonjohnsonownspatentsspecificallyrelatedtostelara thelatestexpiringunitedstatescompositionofmatterpatentexpiresinthelatestexpiringeuropeancomposition ofmatterpatentexpiresin salesofthecompanyssecondlargestproductcollectivelydarzalexdaratumumabanddarzalexfaspro daratumumabandhyaluronidasefihjaccountedforapproximatelyofthecompanystotalrevenuesforfiscal accordinglythepatentsrelatedtothisproductarebelievedtobematerialtothecompanygenmabasownstwo patentfamiliesrelatedtodarzalexandjanssenbiotechinchasanexclusivelicensetothosepatentfamiliesthetwo patentfamiliesbothexpireintheunitedstatesinthelatestexpiringlicensedeuropeanpatentexpiresin janssenbiotechincownsaseparatepatentportfoliorelatedtodarzalexfaspro trademarks thecompanyssubsidiarieshavemadeapracticeofsellingtheirproductsundertrademarksandofobtainingprotection forthesetrademarksbyallavailablemeansthesetrademarksareprotectedbyregistrationintheusandothercountries wheresuchproductsaremarketedthecompanyconsidersthesetrademarksintheaggregatetobeofmaterial importanceintheoperationofitsbusinesses seasonality worldwidesalesdonotreflectanysignificantdegreeofseasonalityhoweverspendinghastypicallybeenheavierinthe fourthquarterofeachyearthaninotherquartersthisreflectsincreasedspendingdecisionsprincipallyforadvertising andresearchanddevelopmentactivity competition inalloftheirproductlinesthecompanyssubsidiariescompetewithcompaniesbothlocallyandgloballycompetition existsinallproductlineswithoutregardtothenumberandsizeofthecompetingcompaniesinvolvedcompetitionin researchbothinternallyandexternallysourcedinvolvingthedevelopmentandtheimprovementofnewandexisting productsandprocessesisparticularlysignificantthedevelopmentofnewandinnovativeproductsaswellasprotecting theunderlyingintellectualpropertyofthecompanysproductportfolioisimportanttothecompanyssuccessinallareas ofitsbusinessthecompetitiveenvironmentrequiressubstantialinvestmentsincontinuingresearchinadditionthe developmentandmaintenanceofcustomerdemandforthecompanysconsumerproductsinvolvesignificant expendituresforadvertisingandpromotion johnsonjohnsonannualreport environment thecompanyissubjecttoavarietyofusandinternationalenvironmentalprotectionmeasuresthecompanybelieves thatitsoperationscomplyinallmaterialrespectswithapplicableenvironmentallawsandregulationsthecompanys compliancewiththeserequirementsisnotexpectedtohaveamaterialeffectuponitscapitalexpenditurescashflows earningsorcompetitiveposition regulation thecompanysbusinessesaresubjecttovaryingdegreesofgovernmentalregulationinthecountriesinwhichoperations areconductedandthegeneraltrendistowardincreasinglystringentregulationandenforcementthecompanyissubject tocostlyandcomplexusandforeignlawsandgovernmentalregulationsandanyadverseregulatoryactionmay materiallyadverselyaffectthecompanysfinancialconditionandbusinessoperationsintheusthedrugdeviceand cosmeticindustrieshavelongbeensubjecttoregulationbyvariousfederalandstateagenciesprimarilyastoproduct safetyefficacymanufacturingadvertisinglabelingandsafetyreportingtheexerciseofbroadregulatorypowersbythe usfoodanddrugadministrationtheusfdacontinuestoresultinincreasesintheamountsoftestingand documentationrequiredforusfdaapprovalofnewdrugsanddevicesandacorrespondingincreaseintheexpenseof productintroductionsimilartrendsarealsoevidentinmajormarketsoutsideoftheusthenewmedicaldevice regulatoryframeworkandtheevolvingprivacydatalocalizationandemergingcybersecuritylawsandregulationsaround theworldareexamplesofsuchincreasedregulationfiveusstatescaliforniaconnecticutcoloradoutahand virginianowhavecomprehensiveprivacylawsinplaceandchinaintroducedbroadpersonalinformationprotectionand datasecurityregulationsinwithotherjurisdictionsenactingsimilarprivacylawslocaldataprotectionauthorities willforcegreateraccountabilityonthecollectionaccessanduseofpersonaldatainthehealthcareindustry theregulatoryagenciesunderwhosepurviewthecompanyoperateshaveadministrativepowersthatmaysubjectittoactions suchasproductwithdrawalsrecallsseizureofproductsandothercivilandcriminalsanctionsinsomecasesthecompanys subsidiariesmaydeemitadvisabletoinitiateproductrecallsregardlessofwhetherithasbeenrequiredordirectedto theusfdaandregulatoryagenciesaroundtheglobearealsoincreasingtheirenforcementactivitiesiftheusfda weretoconcludethatwearenotincompliancewithapplicablelawsorregulationsorthatanyofourdrugsormedical devicesareineffectiveorposeanunreasonablehealthrisktheusfdacouldbansuchproductsdetainorseize adulteratedormisbrandedproductsorderarecallrepairreplacementorrefundofsuchproductsrefusetogrant pendingapplicationsformarketingauthorizationorrequirecertificatesofforeigngovernmentsforexportsandorrequire ustonotifyhealthprofessionalsandothersthattheproductspresentunreasonablerisksofsubstantialharmtothepublic healththeusfdamayalsoassesscivilorcriminalpenaltiesagainstusourofficersoremployeesandimpose operatingrestrictionsonacompanywidebasisorenjoinandorrestraincertainconductresultinginviolationsof applicablelawtheusfdamayalsorecommendprosecutiontotheusdepartmentofjusticeanyadverseregulatory actiondependingonitsmagnitudemayrestrictusfromeffectivelymarketingandsellingourproductsandlimitourability toobtainfutureclearancesorapprovalsandcouldresultinasubstantialmodificationtoourbusinesspracticesand operationsequivalentenforcementmechanismsexistindifferentcountriesinwhichweconductbusiness thecostsofhumanhealthcarehavebeenandcontinuetobeasubjectofstudyinvestigationandregulationby governmentalagenciesandlegislativebodiesaroundtheworldintheusattentionhasbeenfocusedbystates regulatoryagenciesandcongressonpricesprofitsoverutilizationandthequalityandcostsofhealthcaregenerallylaws andregulationshavebeenenactedtorequireadherencetostrictcompliancestandardsandpreventfraudandabusein thehealthcareindustrythereisincreasedfocusoninteractionsandfinancialrelationshipsbetweenhealthcarecompanies andhealthcareprovidersvarioustransparencylawsandregulationsrequiredisclosuresofpaymentsandothertransfers ofvaluemadetophysiciansandteachinghospitalsandbeginningwithdisclosuresintocertainnonphysician practitionersfederalandforeignlawsgoverninginternationalbusinesspracticesrequirestrictcompliancewithanti briberystandardsandcertainprohibitionswithrespecttopaymentstoanyforeigngovernmentofficialpayersand pharmacybenefitmanagerspbmshavebecomeamorepotentforceinthemarketplaceandincreasedattentionis beingpaidtodrugpricingandappropriatedrugandmedicaldeviceutilization ourbusinesshasbeenandcontinuestobeaffectedbyfederalandstatelegislationthataltersthepricingcoverageand reimbursementlandscapeatthefederallevelinaugustpresidentbidensignedintolawtheinflationreductionactira whichincludesprovisionsthateffectivelyauthorizethegovernmenttoestablishpricesforcertainhighspendsinglesourcedrugs andbiologicsreimbursedbythemedicareprogramstartinginformedicarepartddrugsandformedicarepartb drugsitisnotyetcertainwhichproductsthefederalgovernmentwillselectandsubjecttogovernmentestablishedpricesorhow thefederalgovernmentwillestablishpricesforselectedproductsastheiraspecifiesaceilingpricebutnotaminimumpriceone ormoreofourproductscouldbeselectedandsubjecttothegovernmentestablishedprice johnsonjohnsonannualreporttheiraalsocontainsprovisionsthatimposerebatesifcertainpricesincreaseataratethatoutpacestherateofinflation beginningoctoberformedicarepartddrugsandjanuaryformedicarepartbdrugsseparateira provisionsredesignthemedicarepartdbenefitinvariouswaysincludingbyshiftingagreaterportionofcoststo manufacturerswithincertaincoveragephasesandreplacingthepartdcoveragegapdiscountprogramwithanew manufacturerdiscountingprogramfailuretocomplywithiraprovisionsmaysubjectmanufacturerstovariouspenalties includingcivilmonetarypenaltiestheimpactoftheiraonourbusinessandthebroaderpharmaceuticalindustryremains uncertainasthefederalgovernmenthasyettomakevariousiraimplementationdecisions additionallyweexpectcontinuedscrutinyondrugpricingandgovernmentpricereportingfromcongressagenciesand otherbodiesatthefederalandstatelevels thereareanumberofadditionalbillspendingincongressandhealthcarereformproposalsatthestatelevelthatwould affectdrugpricingincludinginthemedicareandmedicaidprogramsthischanginglegallandscapehasbothpositiveand negativeimpactsontheushealthcareindustrywithmuchremaininguncertainastohowvariousprovisionsoffederal andstatelawandpotentialmodificationorrepealoftheselawswillultimatelyaffecttheindustrytheiraandanyother federalorstatelegislativechangecouldaffectthepricingandmarketconditionsforourproducts inadditionbusinesspracticesinthehealthcareindustryhavecomeunderincreasedscrutinyparticularlyintheusby governmentagenciesandstateattorneysgeneralandresultinginvestigationsandprosecutionscarrytheriskofsignificant civilandcriminalpenaltiesofnoteistheincreasedenforcementactivitybydataprotectionauthoritiesinvarious jurisdictionsparticularlyintheeuropeanunionwheresignificantfineshavebeenleviedoncompaniesfordatabreaches violationsofprivacyrequirementsandunlawfulcrossborderdatatransfersintheusthefederaltradecommission hassteppedupenforcementofdataprivacywithseveralsignificantsettlementsandtherehavebeenamaterialincreasein classactionlawsuitslinkedtothecollectionanduseofbiometricdata furtherthecompanyreliesonglobalsupplychainsandproductionanddistributionprocessesthatarecomplexare subjecttoincreasingregulatoryrequirementsandmaybefacedwithunexpectedchangessuchasthoseresultingfrom thecovidpandemicandbrexitthatmayaffectsourcingsupplyandpricingofmaterialsusedinthecompanys productstheseprocessesalsoaresubjecttocomplexandlengthyregulatoryapprovals employees human capital management asofjanuaryandjanuarythenumberofemployeeswereapproximately employees fulltimeequivalentftepositions employeeisdefinedasanindividualworkingfulltimeorparttimeexcludingfixedtermemployeesinternsandcoopemployees employeedatamaynotincludefullpopulationfrommorerecentlyacquiredcompaniesandindividualsonlongtermdisabilityareexcluded contingentworkerscontractorsandsubcontractorsarealsoexcludedabiomedheadcounthasbeenincludedintheabovetable fterepresentsthetotalnumberoffulltimeequivalentpositionsanddoesnotreflectthetotalnumberofindividualemployeesas someworkparttime employees region percentages asia pacific emea latin america north america johnsonjohnsonannualreport strategy thecompanybelievesthatitsemployeesarecriticaltoitscontinuedsuccessandareanessentialelementofitslong termstrategymanagementisresponsibleforensuringthatitspoliciesandprocessesreflectandreinforcethecompanys desiredcorporatecultureincludingpoliciesandprocessesrelatedtostrategyriskmanagementandethicsand compliancethecompanyshumancapitalmanagementstrategyisbuiltonthreefundamentalfocusareas attractingandrecruitingthebesttalent developingandretainingtalent empoweringandinspiringtalent underpinningthesefocusareasareongoingeffortstocultivateandfosteraculturebuiltondiversityequityandinclusion deiinnovationhealthwellbeingandsafetywherethecompanysemployeesareencouragedtosucceedboth professionallyandpersonallywhilehelpingthecompanyachieveitsbusinessgoals cultureandemployeeengagement atthecompanyemployeesareguidedbyourcredowhichsetsforththecompanysresponsibilitiestopatients consumerscustomershealthcareprofessionalsemployeescommunitiesandshareholdersemployeesworldwidemust adheretothecompanyscodeofbusinessconductwhichsetsbasicrequirementsandservesasafoundationforthe companypoliciesproceduresandguidelinesallofwhichprovideadditionalguidanceonexpectedemployeebehaviorsin everymarketwhereitoperatesthecompanyconductsglobalsurveysthatofferitsemployeestheabilitytoprovide feedbackandvaluableinsighttohelpaddresspotentialhumanresourcesrisksandidentifyopportunitiestoimprovein ofglobalemployeesacrosscountriesparticipatedinourcredosurveywhichwasofferedin languages growthanddevelopment tocontinuetoleadinthechanginghealthcarelandscapeitiscrucialthatthecompanycontinuetoattractandretaintop talentthecompanybelievesthatitsemployeesmustbeequippedwiththerightknowledgeandskillsandbeprovided withopportunitiestogrowanddevelopintheircareersaccordinglyprofessionaldevelopmentprogramsandeducational resourcesareavailabletoallemployeesthecompanysobjectiveistofosteralearningculturethathelpsshapeeach personsuniquecareerpathwhilecreatingarobustpipelineoftalenttodeliveronthecompanyslongtermstrategiesin furtheranceofthisobjectivethecompanydeploysaglobalapproachtoensuredevelopmentisforeveryoneregardlessof wheretheyareontheircareerjourneyinofemployeesinmanagerandabovejobcategorieswhohad movementsincludingupwardpromotionsorlateraltransferstookadvantageofcareeropportunitiesbymovingacross functionscountryorbusinesssegmentlinesexcludingemployeesintheresearchanddevelopmentorganizationsthe companysvoluntaryturnoverratewas diversityequityandinclusiondei thecompanyiscommittedtoworkplacediversityandtocultivatingfosteringandadvancingacultureofequityand inclusioninjohnsonjohnsonintroducedthecompanysevolvedenterprisediversityequityandinclusion strategywhichrecognizeshowdeiacceleratesthecompanysabilitytomeetthechangingneedsofthecommunitiesthe companyservestodeliverourpurposetoprofoundlychangethetrajectoryofhealthforhumanitythecompanysdei visionisbeyourselfchangetheworldthecompanysdeimissionismakediversityequityandinclusionhowwework everydayourevolvedenterprisedeistrategyisalignedtoourdeivisionandmissionandrestsonfourcorepillars accelerateourglobalcultureofinclusionwhereeveryindividualbelongs buildaworkforcethatreflectsthediversityofourcommunities transformtalentandbusinessprocessestoachieveequitableaccessandoutcomesforall driveinnovationandgrowthwithourbusinesstoservediversemarketsaroundtheworld thecompanysdeistrategyisguidedbyinternalandexternalinsightsglobalbestpracticesandcontinualemployee feedbackwhichremindthecompanythatwhilediversitychangesbylocationinclusionisthesameeverywhere johnsonjohnsonannualreportcompensationandbenefits aspartofthecompanystotalrewardsphilosophythecompanyofferscompetitivecompensationandbenefitstoattract andretaintoptalentthecompanyiscommittedtofairnessandequitabletreatmentinitscompensationandbenefitsfor employeesatalllevelsthecompanyobserveslegalminimumwageprovisionsandexceedsthemwherepossiblethe companystotalrewardsofferingsincludeanarrayofprogramstosupportitsemployeeswellbeingincludingannual performanceincentiveopportunitiespensionandretirementsavingsprogramshealthandwelfarebenefitspaidtimeoff leaveprogramsflexibleworkschedulesandemployeeassistanceprogramsinrecognitionofthecompanyscommitment tohelpemployeesbalancetheirpersonalandprofessionalresponsibilitiesthecompanyextendeditspaidparentalleave benefitgloballyfromtoweeksforalleligibleemployeesintheusthebenefitwaseffectiveonjanuary withretroactivecoveragefornewfamilyadditionsasofjuly healthwellnessandsafety thecompanysinvestmentinemployeehealthwellbeingandsafetyisbuiltonitsconvictionthatadvancinghealthfor humanitystartswithadvancingthehealthofitsemployeeswiththerightawarenessfocuspracticesandtoolsthe companyensuresthatallitsemployeesaroundtheworldaswellastemporarycontractorsandvisitorstothecompanys sitescanworksafelythecompanyhascontinuouslyexpandedhealthandwellbeingprogramsthroughoutthecompany andacrosstheglobeincorporatingnewthinkingandtechnologiestokeepitsofferingsbestinclassandtohelpemployees achievetheirpersonalhealthgoalstheprogramsandpracticesthecompanyadvancesfortotalhealthphysicalmental emotionalandfinancialensureemployeehealthprotectionforemerginghealthrisksprotectingandsupportingour employeesasthecovidpandemichasevolvedcontinuestobeatoppriorityandthecompanysapproachincludes ensuringthehealthandsafetyofouremployeesintheworkplacethroughrobustlayersofprotectionenhancedcleaning andaccesstocleaningsuppliesandpersonalprotectiveequipmentsupportingemployeeswithbenefitsandwellbeing toolsthecompanycontinuestoaddressouremployeesneedsthroughjjflexahybridmodelthatempowersthe companysofficebasedemployeestofindtherightproductivityandbalanceofinpersonandremotework available information thecompanysmaincorporatewebsiteaddressiswwwjnjcomallofthecompanyssecfilingsarealsoavailableonthe companyswebsiteatwwwinvestorjnjcomseccfmassoonasreasonablypracticableafterhavingbeenelectronically filedorfurnishedtothesecallsecfilingsarealsoavailableatthesecswebsiteatwwwsecgov investorsandthepublicshouldnotethatthecompanyalsoannouncesinformationat wwwfactsaboutourprescriptionopioidscomwwwfactsabouttalccomandwwwltlmanagementinformationcom weusethesewebsitestocommunicatewithinvestorsandthepublicaboutourproductslitigationandothermattersitis possiblethattheinformationweposttothesewebsitescouldbedeemedtobematerialinformationthereforewe encourageinvestorsandothersinterestedinthecompanytoreviewtheinformationpostedtothesewebsitesin conjunctionwithwwwjnjcomthecompanyssecfilingspressreleasespublicconferencecallsandwebcasts inadditiontheamendedandrestatedcertificateofincorporationbylawsthewrittenchartersoftheauditcommittee thecompensationbenefitscommitteethenominatingcorporategovernancecommitteetheregulatory compliancesustainabilitycommitteethesciencetechnologycommitteeandanyspecialcommitteeoftheboardof directorsandthecompanysprinciplesofcorporategovernancecodeofbusinessconductforemployeescodeof businessconductethicsformembersoftheboardofdirectorsandexecutiveofficersandothercorporate governancematerialsareavailableatwwwinvestorjnjcomgovcfmonthecompanyswebsiteandwillbeprovided withoutchargetoanyshareholdersubmittingawrittenrequestasprovidedabovetheinformationonwwwjnjcom wwwfactsaboutourprescriptionopioidscomwwwfactsabouttalccomandwwwltlmanagementinformationcomisnotand willnotbedeemedapartofthisreportorincorporatedintoanyotherfilingsthecompanymakeswiththesec johnsonjohnsonannualreport itema risk factors aninvestmentinthecompanyscommonstockordebtsecuritiesinvolvesrisksanduncertaintiesthecompanyseeksto identifymanageandmitigateriskstoourbusinessbutuncertaintiesandrisksaredifficulttopredictandmanyareoutside ofthecompanyscontrolandcannotthereforebeeliminatedinadditiontotheotherinformationinthisreportandthe companysotherfilingswiththesecinvestorsshouldconsidercarefullythefactorssetforthbelowinvestorsshouldbe awarethatitisnotpossibletopredictoridentifyallsuchfactorsandthatthefollowingisnotmeanttobeacomplete discussionofallpotentialrisksoruncertaintiesifknownorunknownrisksoruncertaintiesmaterializethecompanys businessresultsofoperationsorfinancialconditioncouldbeadverselyaffectedpotentiallyinamaterialway risks related business industry operations thecompanysbusinessesoperateinhighlycompetitiveproductmarketsandcompetitivepressurescould adverselyaffectthecompanysearnings thecompanyfacessubstantialcompetitioninallthreeoperatingsegmentsandinallgeographicmarketsthecompanys businessescompetewithcompaniesofallsizesonthebasisofcosteffectivenesstechnologicalinnovationsintellectual propertyrightsproductperformancerealorperceivedproductadvantagespricingandavailabilityandrateof reimbursementthecompanyalsocompeteswithothermarketparticipantsinsecuringrightstoacquisitions collaborationsandlicensingagreementswiththirdpartiescompetitionforrightstoproductcandidatesandtechnologies mayresultinsignificantinvestmentandacquisitioncostsandonerousagreementtermsforthecompanycompetitors developmentofmoreeffectiveorlesscostlyproductsandortheirabilitytosecurepatentandotherintellectualproperty rightsandsuccessfullymarketproductsaheadofthecompanycouldnegativelyimpactsalesofthecompanysexisting productsaswellasitsabilitytobringnewproductstomarketdespitesignificantpriorinvestmentintherelatedproduct development forthecompanyspharmaceuticalbusinesseslossofpatentexclusivityforaproductoftenisfollowedbyasubstantial reductioninsalesascompetitorsgainregulatoryapprovalforgenericandothercompetingproductsandenterthemarket similarcompetitioncanbetriggeredbythelossofexclusivityforabiologicalproductforthecompanysmedtech businessestechnologicalinnovationproductqualityreputationandcustomerserviceareespeciallyimportantto competitivenessdevelopmentbyothercompaniesofneworimprovedproductsprocessesandtechnologiescould threatentomakethecompanysproductsortechnologieslessdesirablelesseconomicalorobsoletethecompanys consumerhealthbusinessesfaceintensecompetitionfromotherbrandedproductsandretailersprivatelabelbrandsif thecompanyfailstosufficientlydifferentiateandmarketitsbrandnameconsumerproductsthiscouldadverselyaffect revenuesandprofitabilityofthoseproducts interruptionsanddelaysinmanufacturingoperationscouldadverselyaffectthecompanysbusinesssales andreputation thecompanysmanufactureofproductsrequiresthetimelydeliveryofsufficientamountsofcomplexhighquality componentsandmaterialsthecompanyssubsidiariesoperatemanufacturingfacilitiesaswellassourcingfrom thousandsofsuppliersaroundtheworldthecompanyhasinthepastandmayinthefuturefaceunanticipated interruptionsanddelaysinmanufacturingthroughitsinternalorexternalsupplychainmanufacturingdisruptionscanoccur formanyreasonsincludingregulatoryactionproductionqualitydeviationsorsafetyissueslabordisputeslabor shortagessitespecificincidentssuchasfiresnaturaldisasterssuchashurricanesandothersevereweatherevents rawmaterialshortagespoliticalunrestterroristattacksandepidemicsorpandemicssuchdelaysanddifficultiesin manufacturingcanresultinproductshortagesdeclinesinsalesandreputationalimpactaswellassignificantremediation andrelatedcostsassociatedwithaddressingtheshortage thecompanyreliesonthirdpartiestomanufacturecertainofourproductsanyfailurebyorlossofathird partymanufacturercouldresultindelaysandincreasedcostswhichmayadverselyaffectourbusiness thecompanyreliesonthirdpartiestomanufacturecertainofourproductswedependonthesethirdparty manufacturerstoallocatetousaportionoftheirmanufacturingcapacitysufficienttomeetourneedstoproduceproducts ofacceptablequalityandatacceptablemanufacturingyieldsandtodeliverthoseproductstousonatimelybasisandat acceptablepriceshoweverwecannotguaranteethatthesethirdpartymanufacturerswillbeabletomeetournearterm orlongtermmanufacturingrequirementswhichcouldresultinlostsalesandhaveanadverseeffectonourbusiness otherrisksassociatedwithourrelianceonthirdpartiestomanufacturetheseproductsincluderelianceonthethirdparty forregulatorycomplianceandqualityassurancemisappropriationofthecompanysintellectualpropertylimitedabilityto johnsonjohnsonannualreportmanageourinventorypossiblebreachofthemanufacturingagreementbythethirdpartyandthepossibleterminationor nonrenewalofthemanufacturingagreementbythethirdpartyatatimethatiscostlyorinconvenientforusmoreoverif anyofourthirdpartymanufacturerssuffersanydamagetofacilitieslosesbenefitsundermaterialagreements experiencespoweroutagesencountersfinancialdifficultiesisunabletosecurenecessaryrawmaterialsfromitssuppliers orsuffersanyotherreductioninefficiencythecompanymayexperiencesignificantbusinessdisruptionintheeventof anysuchdisruptionthecompanywouldneedtoseekandsourceotherqualifiedthirdpartymanufacturerslikelyresulting infurtherdelaysandincreasedcostswhichcouldaffectourbusinessadversely counterfeitversionsofourproductscouldharmourpatientsandhaveanegativeimpactonourrevenues earningsreputationandbusiness ourindustrycontinuestobechallengedbythevulnerabilityofdistributionchannelstoillegalcounterfeitingandthe presenceofcounterfeitproductsinagrowingnumberofmarketsandovertheinternetthirdpartiesmayillegallydistribute andsellcounterfeitversionsofourproductswhichdonotmeetourrigorousmanufacturingandtestingstandardsto distributorsandpatientscounterfeitproductsmaybevisuallyindistinguishablefromtheauthenticversioncounterfeit medicinesposearisktopatienthealthandsafetybecauseoftheconditionsunderwhichtheyaremanufacturedoftenin unregulatedunlicenseduninspectedandunsanitarysitesaswellasthelackofregulationoftheircontents theindustrysfailuretomitigatethethreatofcounterfeitmedicinescouldadverselyimpactourbusinessandreputationby impactingpatientconfidenceinourauthenticproductspotentiallyresultinginlostsalesproductrecallsandanincreased threatoflitigationinadditiondiversionofourproductsfromtheirauthorizedmarketintootherchannelsmayresultin reducedrevenuesandnegativelyaffectourprofitability globalhealthcrisespandemicsepidemicsorotheroutbreakscouldadverselydisruptorimpactcertain aspectsofthecompanysbusinessresultsofoperationsandfinancialcondition wearesubjecttorisksassociatedwithglobalhealthcrisesepidemicspandemicsandotheroutbreakssuchincidents ahealthcrisisorhealthcrisesincludingtheglobaloutbreakofcoronavirusanditsvariantscovidthecovid pandemichasadverselyimpactedandmaycontinuetoadverselyimpactcertainaspectsofthecompanysbusiness resultsofoperationsandfinancialconditionincludinglowersalesandreducedcustomerdemandandusageofcertainof ourproductsthecontinuedspreadofcovidorotherhealthcrisesmaycausethecompanytomodifyitsbusiness practicesandtakefurtheractionsasmayberequiredbygovernmentauthoritiesorasthecompanydeterminesareinthe bestinterestsofourpatientscustomersemployeesandbusinesspartnerswhilethecompanyhasrobustbusiness continuityplansinplaceacrossourglobalsupplychainnetworktohelpmitigatetheimpactofhealthcrisestheseefforts maynotcompletelypreventourbusinessfrombeingadverselyaffectedandfutureimpactsremainuncertain whiletheusandothercountrieshavesubstantiallyreopenedtheireconomiestheextenttowhichcovidorother healthcrisescouldimpactthecompanysfutureoperationswilldependonmanyfactorswhichcannotbepredictedwith confidenceincludingthedurationofanoutbreakandimpactofvariantsasurgeincovidorotherhealthcrisescould resultintheimpositionofnewmandatesandprolongedrestrictivemeasuresimplementedinordertocontrolthespreadof diseasetheglobalspreadofcovidorotherhealthcrisescouldadverselyimpactthecompanysoperations includingamongotherthingsourmanufacturingoperationssupplychainthirdpartysupplierssalesandmarketingand clinicaltrialoperationsanyofthesefactorscouldadverselyaffectthecompanysbusinessfinancialresultsandglobal economicconditionsgenerally wealsofaceuncertaintiesrelatedtoourvaccinedevelopmentprogramsincludinguncertaintiesrelatedtotheriskthatour continueddevelopmentprogramsmaynotbesuccessfulcommerciallyviableorreceiveapprovalfromregulatory authoritiesrisksassociatedwithclinicaltrialandrealworlddataincludingfurtheranalysesofitsefficacysafetyand durabilitytheriskthatcontinuedevolutionandmutationofdiseaseandthedurationofaparticularoutbreakmayimpedeour abilitytoconducttrialswithinaspecifiedtimeframetheriskthatdataaresubjecttodifferinginterpretationsand assessmentsincludingduringthepeerreviewpublicationprocessinthescientificcommunitygenerallyandbynational immunizationtechnicaladvisorygroupsnitagsandregulatoryauthoritiesdisruptionsintherelationshipsbetweenusour thirdpartysuppliersexternalmanufacturersandotherthirdpartieswithwhomweengagetheriskthatothercompanies mayproducesuperiororcompetitiveproductstheriskthatdemandforanyproductswemaydevelopmaynolongerexist risksrelatedtotheavailabilityofrawmaterialstomanufactureanysuchproductstheriskthatwemaynotbeabletorecoup costsassociatedwithourrdandmanufacturingeffortsandrisksassociatedwithanychangesinthewayweapproachor provideadditionalresearchfundingforpotentialdrugdevelopmenttheriskthatwemaynotbeabletocreateorscaleup manufacturingcapacityonatimelybasisthatwemaycontinuetoexperiencemanufacturingdelaysonceamanufacturing siteisactivatedorhaveaccesstologisticsorsupplychannelscommensuratewithglobaldemandforanypotential approvedvaccineorproductcandidatewhichwouldnegativelyimpactourabilitytosupplytheestimatednumbersofdoses johnsonjohnsonannualreport ofourvaccinewithintheprojectedtimeperiodsindicatedandotherchallengesandrisksassociatedwiththepaceofour vaccinedevelopmentprogramandpricingandaccesschallengesforsuchproductsincludingintheus risks related government regulation legal proceedings globalsalesinthecompanyspharmaceuticalandmedtechsegmentsmaybenegativelyimpactedby healthcarereformsandincreasingpricingpressures salesofthecompanyspharmaceuticalandmedtechproductsaresignificantlyaffectedbyreimbursementsbythirdparty payerssuchasgovernmenthealthcareprogramsprivateinsuranceplansandmanagedcareorganizationsaspartof variouseffortstocontainhealthcarecoststhesepayersareputtingdownwardpressureonpricesatwhichproductswill bereimbursedintheusincreasedpurchasingpowerofentitiesthatnegotiateonbehalfofmedicaremedicaidand privatesectorbeneficiariesinpartduetocontinuedconsolidationamonghealthcareproviderscouldresultinfurther pricingpressuresinadditionrecentlegislationandongoingpoliticalscrutinyorpricingcoverageandreimbursement couldresultinadditionalpricingpressuresspecificallytheinflationreductionactofiramaysubjectcertain productstogovernmentestablishedpricingpotentiallyimposerebatesandsubjectmanufacturerswhofailtoadhereto thegovernmentsinterpretationsofthelawtopenaltiesoutsidetheusnumerousmajormarketsincludingtheeu unitedkingdomjapanandchinahavepervasivegovernmentinvolvementinfundinghealthcareandinthatregard directlyorindirectlyimposepricecontrolslimitaccesstoorreimbursementforthecompanysproductsorreducethe valueofitsintellectualpropertyprotection thecompanyissubjecttosignificantlegalproceedingsthatcanresultinsignificantexpensesfinesand reputationaldamage intheordinarycourseofbusinessjohnsonjohnsonanditssubsidiariesaresubjecttonumerousclaimsandlawsuits involvingvariousissuessuchasproductliabilitypatentdisputesandclaimsthattheirproductsalesmarketingandpricing practicesviolatevariousantitrustunfairtradepracticesandorconsumerprotectionlawsthecompanysmoresignificant legalproceedingsaredescribedinnotelegalproceedingsundernotestotheconsolidatedfinancialstatements includedinitemofthisreportlitigationingeneralandsecuritiesderivativeactionclassactionandmultidistrict litigationinparticularcanbeexpensiveanddisruptivesomeofthesemattersmayincludethousandsofplaintiffsmay involvepartiesseekinglargeandorindeterminateamountsincludingpunitiveorexemplarydamagesandmayremain unresolvedforseveralyearsforexamplethecompanyisadefendantinnumerouslawsuitsarisingoutoftheuseofbody powderscontainingtalcprimarilyjohnsonsbabypowderandthecompanyssalemanufacturingandmarketingof opioidswhilethecompanybelievesithassubstantialdefensesinthesemattersitisnotfeasibletopredicttheultimate outcomeoflitigationthecompanycouldinthefutureberequiredtopaysignificantamountsasaresultofsettlementsor judgmentsinthesematterspotentiallyinexcessofaccrualsincludingmatterswherethecompanycouldbeheldjointly andseverallyliableamongotherdefendantstheresolutionoforincreaseinaccrualsforoneormoreofthesemattersin anyreportingperiodcouldhaveamaterialadverseeffectonthecompanysresultsofoperationsandcashflowsforthat periodthecompanydoesnotpurchasethirdpartyproductliabilityinsurancehoweverthecompanyutilizesawholly ownedcaptiveinsurancecompanysubjecttocertainlimits productreliabilitysafetyandeffectivenessconcernscanhavesignificantnegativeimpactsonsalesand resultsofoperationsleadtolitigationandcausereputationaldamage concernsaboutproductsafetywhetherraisedinternallyorbylitigantsregulatorsorconsumeradvocatesandwhetheror notbasedonscientificevidencecanresultinsafetyalertsproductrecallsgovernmentalinvestigationsregulatoryaction onthepartoftheusfoodanddrugadministrationoritscounterpartinothercountriesprivateclaimsandlawsuits paymentoffinesandsettlementsdecliningsalesandreputationaldamagethesecircumstancescanalsoresultin damagetobrandimagebrandequityandconsumertrustinthecompanysproductsproductrecallshaveinthepast andcouldinthefuturepromptgovernmentinvestigationsandinspectionstheshutdownofmanufacturingfacilities continuedproductshortagesandrelatedsalesdeclinessignificantremediationcostsreputationaldamagepossiblecivil penaltiesandcriminalprosecution thecompanyfacessignificantregulatoryscrutinywhichimposessignificantcompliancecostsand exposesthecompanytogovernmentinvestigationslegalactionsandpenalties likeothercompaniesinthehealthcareindustrythecompanyissubjecttoextensiveregulationinvestigationsandlegal actionbynationalstateandlocalgovernmentagenciesintheusandothercountriesinwhichitoperatesregulatory issuesregardingcompliancewithcurrentgoodmanufacturingpracticescgmpandcomparablequalityregulationsin foreigncountriesbymanufacturersofdrugsdevicesandconsumerproductscanleadtofinesandpenaltiesproduct johnsonjohnsonannualreportrecallsproductshortagesinterruptionsinproductiondelaysinnewproductapprovalsandlitigationinadditionthe marketingpricingandsaleofthecompanysproductsaresubjecttoregulationinvestigationsandlegalactionsincluding underthefederalfooddrugandcosmeticactthemedicaidrebateprogramfederalandstatefalseclaimsactsstate unfairtradepracticesactsandconsumerprotectionlawsscrutinyofhealthcareindustrybusinesspracticesby governmentagenciesandstateattorneysgeneralintheusandanyresultinginvestigationsandprosecutionscarryrisk ofsignificantcivilandcriminalpenaltiesincludingbutnotlimitedtodebarmentfromparticipationingovernment healthcareprogramsanysuchdebarmentcouldhaveamaterialadverseeffectonthecompanysbusinessandresultsof operationsthemostsignificantcurrentinvestigationsandlitigationbroughtbygovernmentagenciesaredescribedin notelegalproceedingsgovernmentproceedingsundernotestotheconsolidatedfinancialstatementsincluded initemofthisreport changesintaxlawsorexposurestoadditionaltaxliabilitiescouldnegativelyimpactthecompanys operatingresults changesintaxlawsorregulationsaroundtheworldincludingintheusandasledbytheorganizationforeconomic cooperationanddevelopmentsuchastherecentadoptionbytheeuenactmentbysouthkoreaandtheanticipated enactmentbyadditionalcountriesofaglobalminimumtaxcouldnegativelyimpactthecompanyseffectivetaxrateand resultsofoperationsachangeinstatutorytaxrateorcertaininternationaltaxprovisionsinanycountrywouldresultinthe revaluationofthecompanysdeferredtaxassetsandliabilitiesrelatedtothatparticularjurisdictionintheperiodinwhich thenewtaxlawisenactedthischangewouldresultinanexpenseorbenefitrecordedtothecompanysconsolidated statementofearningsthecompanycloselymonitorstheseproposalsastheyariseinthecountrieswhereitoperates changestotaxlawsorregulationsmayoccuratanytimeandanyrelatedexpenseorbenefitrecordedmaybematerialto thefiscalquarterandyearinwhichthelawchangeisenacted seenoteincometaxesundernotestotheconsolidatedfinancialstatementsincludedinitemofthisreportfor additionalinformation thecompanyconductsbusinessandfilestaxreturnsinnumerouscountriesandisaddressingtaxauditsanddisputes withmanytaxauthoritiesinconnectionwithvariousgovernmentinitiativescompaniesarerequiredtodisclosemore informationtotaxauthoritiesonoperationsaroundtheworldwhichmayleadtogreaterauditscrutinyofprofitsearnedin othercountriesthecompanyregularlyassessesthelikelyoutcomesofitstaxauditsanddisputestodeterminethe appropriatenessofitstaxreserveshoweveranytaxauthoritycouldtakeapositionontaxtreatmentthatiscontrarytothe companysexpectationswhichcouldresultintaxliabilitiesinexcessofreserves risks related intellectual property thecompanyfacesincreasedchallengestointellectualpropertyrightscentraltoitsbusiness thecompanyownsorlicensesasignificantnumberofpatentsandotherproprietaryrightsrelatingtoitsproductsand manufacturingprocessestheserightsareessentialtothecompanysbusinessesandmateriallyimportanttothe companysresultsofoperationspublicpolicybothwithinandoutsidetheushasbecomeincreasinglyunfavorable towardintellectualpropertyrightsthecompanycannotbecertainthatitwillobtainadequatepatentprotectionfornew productsandtechnologiesintheunitedstatesandotherimportantmarketsorthatsuchprotectionsoncegrantedwill lastaslongasoriginallyanticipated competitorsroutinelychallengethevalidityorextentofthecompanysownedorlicensedpatentsandproprietaryrights throughlitigationinterferencesoppositionsandotherproceedingssuchasinterpartesreviewiprproceedingsbefore theunitedstatespatenttrademarkofficeusptotheseproceedingsabsorbresourcesandcanbeprotractedas wellasunpredictableinadditionchallengesthatthecompanysproductsinfringethepatentsofthirdpartiescouldresult inaninjunctionandortheneedtopaypastdamagesandfutureroyaltiesandadverselyaffectthecompetitivepositionand salesoftheproductsinquestion thecompanyhasfacedincreasingpatentchallengesfromthirdpartiesseekingtomanufactureandmarketgenericand biosimilarversionsofthecompanyskeypharmaceuticalproductspriortoexpirationoftheapplicablepatentscovering thoseproductsintheusmanufacturersofgenericversionsofinnovativehumanpharmaceuticalproductsmay challengethevalidityorclaimnoninfringementofinnovatorproductsthroughtheabbreviatednewdrugapplicationor andaprocesswiththeusfdaandrelatedandalitigationthebiologicspricecompetitionandinnovationact bpciaenactedinwhichcreatedanewregulatorypathwayfortheapprovalbytheusfdaofbiosimilar alternativestoinnovatordevelopedbiologicalproductsalsocreatedmechanismsforbiosimilarapplicantstochallengethe patentsontheinnovatorbiologicstheiprprocesswiththeusptoisalsobeingusedbycompetitorstochallenge patentsassertedinlitigation johnsonjohnsonannualreport intheeventthecompanyisnotsuccessfulindefendingitspatentsagainstsuchchallengesorupontheatrisklaunch bythegenericorbiosimilarfirmofitsproductthecompanycanloseamajorportionofrevenuesforthereferenced productinaveryshortperiodoftimecurrentlegalproceedingsinvolvingthecompanyspatentsandotherintellectual propertyrightsaredescribedinnotelegalproceedingsintellectualpropertyundernotestotheconsolidated financialstatementsincludedinitemofthisreport risksrelatedtoproductdevelopmentregulatoryapprovalandcommercialization significantchallengesordelaysinthecompanysinnovationanddevelopmentofnewproducts technologiesandindicationscouldhaveanadverseimpactonthecompanyslongtermsuccess thecompanyscontinuedgrowthandsuccessdependsonitsabilitytoinnovateanddevelopnewanddifferentiated productsandservicesthataddresstheevolvinghealthcareneedsofpatientsprovidersandconsumersdevelopmentof successfulproductsandtechnologiesisalsonecessarytooffsetrevenuelosseswhenthecompanysexistingproducts losemarketshareduetovariousfactorssuchascompetitionandlossofpatentexclusivitynewproductsintroduced withinthepastfiveyearsaccountedforapproximatelyofsalesthecompanycannotbecertainwhenor whetheritwillbeabletodeveloplicenseorotherwiseacquirecompaniesproductsandtechnologieswhetherparticular productcandidateswillbegrantedregulatoryapprovalandifapprovedwhethertheproductswillbecommercially successful thecompanypursuesproductdevelopmentthroughinternalresearchanddevelopmentaswellasthroughcollaborations acquisitionsjointventuresandlicensingorotherarrangementswiththirdpartiesinallofthesecontextsdevelopingnew productsparticularlypharmaceuticalandbiotechnologyproductsandmedicaldevicesrequiressignificantinvestmentof resourcesovermanyyearsonlyaveryfewbiopharmaceuticalresearchanddevelopmentprogramsresultincommercially viableproductstheprocessdependsonmanyfactorsincludingtheabilitytodiscernpatientsandhealthcareproviders futureneedsdeveloppromisingnewcompoundsstrategiesandtechnologiesachievesuccessfulclinicaltrialresults secureeffectiveintellectualpropertyprotectionobtainregulatoryapprovalsonatimelybasisandifandwhentheyreach themarketsuccessfullydifferentiatethecompanysproductsfromcompetingproductsandapproachestotreatment newproductsorenhancementstoexistingproductsmaynotbeacceptedquicklyorsignificantlyinthemarketplacedue toproductandpricecompetitionchangesincustomerpreferencesorhealthcarepurchasingpatternsresistanceby healthcareprovidersoruncertaintyoverthirdpartyreimbursementevenfollowinginitialregulatoryapprovalthesuccess ofaproductcanbeadverselyimpactedbysafetyandefficacyfindingsinlargerrealworldpatientpopulationsaswellas marketentryofcompetitiveproducts risks related financial economic market conditions thecompanyfacesavarietyoffinancialeconomiclegalsocialandpoliticalrisksassociatedwith conductingbusinessinternationally thecompanysextensiveoperationsandbusinessactivitythroughouttheworldareaccompaniedbycertainfinancial economiclegalsocialandpoliticalrisksincludingthoselistedbelow foreigncurrencyexchangeinfiscalapproximatelyofthecompanyssalesoccurredoutsideoftheuswith approximatelyineuropeinthewesternhemisphereexcludingtheusandintheasiapacificandafrica regionchangesinnonuscurrenciesrelativetotheusdollarimpactthecompanysrevenuesandexpenseswhile thecompanyusesfinancialinstrumentstomitigatetheimpactoffluctuationsincurrencyexchangeratesonitscashflows unhedgedexposurescontinuetobesubjecttocurrencyfluctuationsinadditiontheweakeningorstrengtheningofthe usdollarmayresultinsignificantfavorableorunfavorabletranslationeffectswhentheoperatingresultsofthe companysnonusbusinessactivityaretranslatedintousdollars inflationandcurrencydevaluationrisksthecompanyfaceschallengesinmaintainingprofitabilityofoperationsin economiesexperiencinghighinflationratesspecificallythecompanyhasaccountedforoperationsinargentinaturkey andvenezuelaashighlyinflationaryasthepriorthreeyearcumulativeinflationratesurpassedwhilethecompany strivestomaintainprofitmarginsintheseareasthroughcostreductionprogramsproductivityimprovementsandperiodic priceincreasesitmightexperienceoperatinglossesasaresultofcontinuedinflationinadditiontheimpactofcurrency devaluationsincountriesexperiencinghighinflationratesorsignificantcurrencyexchangefluctuationscouldnegatively impactthecompanysoperatingresults illegalimportationofpharmaceuticalproductstheillegalimportationofpharmaceuticalproductsfromcountrieswhere governmentpricecontrolsorothermarketdynamicsresultinlowerpricesmayadverselyaffectthecompanyssalesand johnsonjohnsonannualreportprofitabilityintheusandothercountriesinwhichthecompanyoperateswiththeexceptionoflimitedquantitiesof prescriptiondrugsforpersonaluseforeignimportsofpharmaceuticalproductsareillegalundercurrentuslaw howeverthevolumeofillegalimportscontinuestoriseastheabilityofpatientsandothercustomerstoobtainthelower pricedimportshasgrownsignificantly antibriberyandotherregulationsthecompanyissubjecttovariousfederalandforeignlawsthatgovernitsinternational businesspracticeswithrespecttopaymentstogovernmentofficialsthoselawsincludetheusforeigncorrupt practicesactfcpawhichprohibitsuspubliclytradedcompaniesfrompromisingofferingorgivinganythingofvalue toforeignofficialswiththecorruptintentofinfluencingtheforeignofficialforthepurposeofhelpingthecompanyobtain orretainbusinessorgainanyimproperadvantagethecompanysbusinessisheavilyregulatedandthereforeinvolves significantinteractionwithforeignofficialsalsoinmanycountriesoutsidetheusthehealthcareproviderswho prescribehumanpharmaceuticalsareemployedbythegovernmentandthepurchasersofhumanpharmaceuticalsare governmententitiesthereforethecompanysinteractionswiththeseprescribersandpurchasersaresubjecttoregulation underthefcpainadditiontotheusapplicationandenforcementofthefcpavariousjurisdictionsinwhichthe companyoperateshavelawsandregulationsincludingtheukbriberyactaimedatpreventingandpenalizing corruptandanticompetitivebehaviorenforcementactivitiesundertheselawscouldsubjectthecompanytoadditional administrativeandlegalproceedingsandactionswhichcouldincludeclaimsforcivilpenaltiescriminalsanctionsand administrativeremediesincludingexclusionfromhealthcareprograms otherfinancialeconomiclegalsocialandpoliticalrisksotherrisksinherentinconductingbusinessgloballyinclude localandregionaleconomicenvironmentsandpoliciesinthemarketsthatweserveincludinginterestratesmonetary policyinflationeconomicgrowthrecessioncommoditypricesandcurrencycontrolsorotherlimitationsontheability toexpatriatecash protectiveeconomicpoliciestakenbygovernmentssuchastradeprotectionmeasuresandimportexportlicensing requirements compliancewithlocalregulationsandlawsincludinginsomecountriesregulatoryrequirementsrestrictingthe companysabilitytomanufactureorsellitsproductsintherelevantmarket diminishedprotectionofintellectualpropertyandcontractualrightsincertainjurisdictions potentialnationalizationorexpropriationofthecompanysforeignassets politicalorsocialupheavalseconomicinstabilityrepressionorhumanrightsissuesand geopoliticaleventsincludingnaturaldisastersdisruptionstomarketsduetowararmedconflictterrorismepidemicsor pandemics failuretomaintainasatisfactorycreditratingcouldadverselyaffectourliquiditycapitalposition borrowingcostsandaccesstocapitalmarkets wecurrentlymaintaininvestmentgradecreditratingswithmoodysinvestorsserviceandstandardpoorsratings servicesratingagenciesroutinelyevaluateusandtheirratingsofourlongtermandshorttermdebtarebasedona numberoffactorsanydowngradeofourcreditratingsbyacreditratingagencywhetherasaresultofouractionsor factorswhicharebeyondourcontrolcanincreasethecostofborrowingunderanyindebtednesswemayincurreduce marketcapacityforourcommercialpaperorrequirethepostingofadditionalcollateralunderourderivativecontracts therecanbenoassurancethatwewillbeabletomaintainourcreditratingsandanyadditionalactualoranticipated changesordowngradesinourcreditratingsincludinganyannouncementthatourratingsareunderreviewfora downgrademayhaveanegativeimpactonourliquiditycapitalpositionandaccesstocapitalmarkets therussiaukrainewarandactionstakeninresponsetotherussiaukrainewarcouldadverselyaffect ourbusinessresultsofoperationsorfinancialcondition infebruaryrussialaunchedamilitaryinvasionofukrainetheongoingrussiaukrainewarhasprovokedstrong reactionsfromtheunitedstatestheunitedkingdomtheeuropeanunionandvariousothercountriesandeconomicand politicalorganizationsaroundtheworldwehavebeenmonitoringthegeopoliticalsituationinrussiasincethestartofthe russiaukrainewarandhavesuspendedadditionalinvestmentenrollmentofclinicaltrialsandsupplyofourpersonal careproductsinrussiawecontinuetomonitortheneedforhumanitarianreliefintheregionandcontinuetosupplyour medicinesmedicaldevicesandequipmentintheregionincompliancewiththeapplicablesanctionswewillcontinueto monitorthegeopoliticalsituationinrussiaandtoevaluateouractivitiesandfutureoperationsinrussia actionstakeninresponsetotherussiaukrainewarincludetheimpositionofexportcontrolsandbroadfinancialand economicsanctionsagainstrussiabelarusandspecificareasofukraineadditionalsanctionsorothermeasuresmaybe imposedbytheglobalcommunityincludingbutnotlimitedtolimitationsonourabilitytofileprosecuteandmaintain johnsonjohnsonannualreport patentstrademarksandotherintellectualpropertyrightsfurthermoretherussiangovernmenthasalreadytakenaction allowingrussiancompaniesandindividualstoexploitinventionsownedbypatentholdersfromtheunitedstatesand manyothercountrieswithoutconsentorcompensationandwemaynotbeabletopreventthirdpartiesfrompracticingour inventionsinrussiaorfromsellingorimportingproductsinandintorussia wehaveexperiencedandexpecttocontinuetoexperienceotherrisksrelatedtothebroadeconomicconsequencesof therussiaukrainewarincludingforeigncurrencyvolatilitydecreaseddemandforourproductsincountriesaffectedby therussiaukrainewarandchallengestoourglobalsupplychainrelatedtoincreasedcostsofmaterialsandotherinputs forourproductsandsuppliersoperatinginrussiaandukrainewealsocontinuetomonitorthevarioussanctionsand exportcontrolsimposedinresponsetotherussiaukrainewar thefullimpactoftherussiaukrainewarandactionstakeninresponsetotheongoingconflictontheglobaleconomy andgeopoliticalrelationsingeneralandonourbusinessinparticularremainuncertainanyoralloftheforegoingrisks couldhaveanadverseeffectonourbusinessresultsofoperationsorfinancialconditionparticularlyastheconflict continuesforanindefiniteperiodoftimegiventhatdevelopmentsconcerningtherussiaukrainewarareongoingand havebeenconstantlyevolvingadditionalimpactsandrisksmayarisethatarenotpresentlyknowntoustherussia ukrainewarmayalsohavetheeffectofheighteningmanyoftheotherrisksdescribedinthisriskfactorssection risks related planned separation consumer health business theplannedseparationofthecompanysconsumerhealthbusinessmaynotbecompletedontheterms ortimelinecurrentlycontemplatedifatallandmaynotachievetheexpectedresults innovemberthecompanyannounceditsintentiontoseparatethecompanysconsumerhealthbusinesswiththe intentiontocreateastandalonepubliclytradedcompanywhichwassubsequentlynamedkenvueinckenvuethe plannedseparationisintendedtoqualifyasataxfreetransactionforusfederalincometaxpurposesthecompanyis targetingcompletionoftheplannedseparationincompletionoftheplannedseparationwillbesubjecttothe satisfactionofcertainconditionsincludingamongothersconsultationswithworkscouncilsandotheremployee representativebodiesasrequiredfinalapprovalbythecompanysboardofdirectorsthecontinuingeffectivenessand validityofthecompanysprivateletterrulingfromtheinternalrevenueserviceirsandreceiptoffavorableopinionsof thecompanysustaxadvisorswithrespecttothetaxfreenatureofthetransactionandthereceiptofotherregulatory approvalstherecanbenoassuranceregardingtheultimatetimingoftheplannedseparationorthatsuchseparationwill becompletedunanticipateddevelopmentscoulddelaypreventorotherwiseadverselyaffecttheplannedseparation includingbutnotlimitedtodisruptionsingeneralorfinancialmarketconditionsorpotentialproblemsordelaysinobtaining variousregulatoryandtaxapprovalsorclearances thecoststocompletetheplannedseparationwillbesignificantinadditionthecompanymaybeunable toachievesomeorallofthestrategicandfinancialbenefitsthatitexpectstoachievefromtheplanned separationofthecompanysconsumerhealthbusiness thecompanyhasincurredandisexpectedtoincursignificantexpensesinconnectionwiththeplannedseparationin additionthecompanymaynotbeabletoachievethefullstrategicandfinancialbenefitsthatareexpectedtoresultfrom theplannedseparationtheanticipatedbenefitsoftheplannedseparationarebasedonanumberofassumptionssome ofwhichmayproveincorrect followingtheplannedseparationthepriceofsharesofthecompanyscommonstockmay fluctuatesignificantly thecompanycannotpredicttheeffectoftheplannedseparationonthetradingpriceofsharesofitscommonstockand themarketvalueofsharesofitscommonstockmaybelessthanequaltoorgreaterthanthemarketvalueofsharesofits commonstockpriortotheplannedseparationinadditionthepriceofthecompanyscommonstockmaybemorevolatile aroundthetimeoftheplannedseparation theplannedseparationcouldresultinsubstantialtaxliability thecompanyhasreceivedaprivateletterrulingfromtheirsastothetaxfreenatureoftheplannedseparationunderthe usinternalrevenuecodeofasamendedtheplannedseparationisconditionedonamongotherthingsthe continuingeffectivenessandvalidityofthecompanysprivateletterrulingfromtheirsandreceiptoffavorableopinionsof thecompanysustaxadvisorstheprivateletterrulingandopinionswillbebasedonamongotherthingsvariousfacts assumptionsrepresentationsandundertakingsfromthecompanyandkenvueregardingthepastandfutureconductof johnsonjohnsonannualreportthecompaniesrespectivebusinessesandothermattersifanyofthesefactsassumptionsrepresentationsor undertakingsareincorrectornototherwisesatisfiedthecompanyanditsshareholdersmaynotbeabletorelyonthe rulingortheopinionsoftaxadvisorsnotwithstandingtheprivateletterrulingandopinionsoftaxadvisorsifsubsequentto theplannedseparationtheirsdeterminesthatcertainstepsofthetransactiondonotqualifyfortaxfreetreatmentfor usfederalincometaxpurposestheresultingtaxliabilitytothecompanyanditsshareholderscouldbesubstantialthe plannedseparationmayalsonotqualifyfortaxfreetreatmentinothercountriesaroundtheworldandasaresultmay triggersubstantialtaxliabilitytothecompany risks ourbusinessdependsonourabilitytorecruitandretaintalentedhighlyskilledemployeesandadiverse workforce ourcontinuedgrowthrequiresustorecruitandretaintalentedemployeesrepresentingdiversebackgroundsexperiences andskillsetsthemarketforhighlyskilledworkersandleadersinourindustryisextremelycompetitiveandourabilityto competedependsonourabilitytohiredevelopandmotivatehighlyskilledpersonnelinallareasofourorganization maintainingourbrandandreputationaswellasadiverseequitableandinclusiveworkenvironmentenablesustoattract toptalentifwearelesssuccessfulinourrecruitingeffortsorifwecannotretainhighlyskilledworkersandkeyleaders ourabilitytodevelopanddeliversuccessfulproductsandservicesmaybeadverselyaffectedinadditioneffective successionplanningisimportanttoourlongtermsuccessanyunsuccessfulimplementationofoursuccessionplansor failuretoensureeffectivetransferofknowledgeandsmoothtransitionsinvolvingkeyemployeescouldadverselyaffectour businessfinancialconditionorresultsofoperations climatechangeorlegalregulatoryormarketmeasurestoaddressclimatechangemaynegativelyaffect ourbusinessandresultsofoperations climatechangeresultingfromincreasedconcentrationsofcarbondioxideandothergreenhousegasesintheatmosphere couldpresentriskstoouroperationsincludinganadverseimpactonglobaltemperaturesweatherpatternsandthe frequencyandseverityofextremeweatherandnaturaldisastersnaturaldisastersandextremeweatherconditionssuch asahurricanetornadoearthquakewildfireorfloodingmayposephysicalriskstoourfacilitiesanddisrupttheoperation ofoursupplychaintheimpactsofthechangingclimateonwaterresourcesmayresultinwaterscarcitylimitingourability toaccesssufficienthighqualitywaterincertainlocationswhichmayincreaseoperationalcosts concernoverclimatechangemayalsoresultinneworadditionallegalorregulatoryrequirementsdesignedtoreduce greenhousegasemissionsandormitigatetheeffectsofclimatechangeontheenvironmentifsuchlawsorregulations aremorestringentthancurrentlegalorregulatoryobligationswemayexperiencedisruptioninoranincreaseinthecosts associatedwithsourcingmanufacturinganddistributionofourproductswhichmayadverselyaffectourbusinessresults ofoperationsorfinancialconditionfurthertheimpactsofclimatechangehaveaninfluenceoncustomerpreferences andfailuretoprovideclimatefriendlyproductscouldpotentiallyresultinlossofmarketshare aninformationsecurityincidentincludingacybersecuritybreachcouldhaveanegativeimpacttothe companysbusinessorreputation tomeetbusinessobjectivesthecompanyreliesonbothinternalinformationtechnologyitsystemsandnetworksand thoseofthirdpartiesandtheirvendorstoprocessandstoresensitivedataincludingconfidentialresearchbusiness plansfinancialinformationintellectualpropertyandpersonaldatathatmaybesubjecttolegalprotectionandensurethe continuityofthecompanyssupplychaintheextensiveinformationsecurityandcybersecuritythreatswhichaffect companiesgloballyposearisktothesecurityandavailabilityofthesesystemsandnetworksandtheconfidentiality integrityandavailabilityofthecompanyssensitivedatathecompanycontinuallyassessesthesethreatsandmakes investmentstoincreaseinternalprotectiondetectionandresponsecapabilitiesaswellasensurethecompanysthird partyprovidershaverequiredcapabilitiesandcontrolstoaddressthisrisktodatethecompanyhasnotexperiencedany materialimpacttothebusinessoroperationsresultingfrominformationorcybersecurityattackshoweverbecauseofthe frequentlychangingattacktechniquesalongwiththeincreasedvolumeandsophisticationoftheattacksthereisthe potentialforthecompanytobeadverselyimpactedthisimpactcouldresultinreputationalcompetitiveoperationalor otherbusinessharmaswellasfinancialcostsandregulatoryactionthecompanymaintainscybersecurityinsurancein theeventofaninformationsecurityorcyberincidenthoweverthecoveragemaynotbesufficienttocoverallfinancial legalbusinessorreputationallosses asaresultoftherussiaukrainewartherehasbeenandweexpecttherewillcontinuetobeanincreasedriskof informationsecurityorcybersecurityincidentsincludingcyberattacksperpetratedbyrussiaorothersatitsdirection johnsonjohnsonannualreport althoughwehavetakenstepstoenhanceourprotectionsagainsttheseattackswemaynotbeabletoaddressthethreat ofinformationsecurityorcybersecurityincidentsproactivelyorimplementadequatepreventativemeasuresandwemay notbeabletodetectandaddressanysuchdisruptionorsecuritybreachpromptlyoratallwhichcouldadverselyaffect ourbusinessresultsofoperationsorfinancialconditionmoreoverweareawareofincidentsinwhichourthirdparty partnershavebeenthetargetofinformationsecurityorcybersecurityincidentsasaresultoftherussiaukrainewar althoughtodateouritsystemshavenotbeencompromisedbytheseincidentsitispossiblethatfutureinformation securityorcybersecurityincidentsinvolvingourcustomersmanufacturerssuppliersorotherthirdpartypartnerscould successfullycompromiseouritsystemswhichcouldadverselyaffectourbusinessresultsofoperationsorfinancial condition abreachofprivacylawsorunauthorizedaccesslossormisuseofpersonaldatacouldhaveanegative impacttothecompanysbusinessorreputation thecompanyissubjecttoprivacyanddataprotectionlawsacrosstheglobethatimposebroadcomplianceobligations onthecollectionusestorageaccesstransferandprotectionofpersonaldatabreachofsuchrequirementscouldresult insubstantialfinespenaltiesprivaterightofactionsclaimsanddamagetoourreputationandbusinessnewprivacylaws areexpectedinotherterritoriestogetherwithgreaterprivacyenforcementbygovernmentalauthoritiesgloballyparticularly ondatalocalizationrequirementsandinternationaldataflowsthecompanyhasestablishedprivacycomplianceprograms andcontrolsthatourbusinessesworldwidearerequiredtocomplywithbutwithmanytechnologyanddatadriven initiativesbeingprioritizedacrossthecompanyandinvolvingmultiplevendorsandthirdpartiestherearepotentialrisksof controlsimposedoncrossborderdataflowsunauthorizedaccessandlossofpersonaldatathroughinternalandexternal threatsthatcouldimpactourbusinessoperationsandresearchactivities item b unresolved staff comments notapplicable item properties thecompanyssubsidiariesoperatemanufacturingfacilitiesoccupyingapproximatelymillionsquarefeetoffloor spacethemanufacturingfacilitiesareusedbytheindustrysegmentsofthecompanysbusinessapproximatelyas follows squarefeet segment inthousands consumerhealth pharmaceutical medtech worldwidetotal withintheusfourfacilitiesareusedbytheconsumerhealthsegmentfivebythepharmaceuticalsegmentandby themedtechsegmentoutsideoftheusfacilitiesareusedbytheconsumerhealthsegmentbythe pharmaceuticalsegmentandbythemedtechsegment thelocationsofthemanufacturingfacilitiesbymajorgeographicareasoftheworldareasfollows squarefeet geographicarea numberoffacilities inthousands unitedstates europe westernhemisphereexcludingus africaasiaandpacific worldwidetotal inadditiontothemanufacturingfacilitiesdiscussedabovethecompanymaintainsnumerousofficeandwarehouse facilitiesthroughouttheworld johnsonjohnsonannualreportthecompanyssubsidiariesgenerallyseektoownratherthanleasetheirmanufacturingfacilitiesalthoughsome principallyinnonuslocationsareleasedofficeandwarehousefacilitiesareoftenleasedthecompanyalsoengages contractmanufacturers thecompanyiscommittedtomaintainingallofitspropertiesingoodoperatingcondition segmentinformationonadditionstopropertyplantandequipmentiscontainedinnotesegmentsofbusinessand geographicareasofthenotestoconsolidatedfinancialstatementsincludedinitemofthisreport item legal proceedings theinformationcalledforbythisitemisincorporatedhereinbyreferencetotheinformationsetforthinnotelegal proceedingsofthenotestoconsolidatedfinancialstatementsincludedinitemofthisreport item mine safety disclosures notapplicable johnsonjohnsonannualreport executive officers registrant listedbelowaretheexecutiveofficersofthecompanytherearenofamilyrelationshipsbetweenanyoftheexecutive officersandthereisnoarrangementorunderstandingbetweenanyexecutiveofficerandanyotherpersonpursuantto whichtheexecutiveofficerwasselectedattheannualmeetingoftheboardofdirectorstheexecutiveofficersare electedbytheboardtoholdofficeforoneyearanduntiltheirrespectivesuccessorsareelectedandqualifiedoruntil earlierresignationorremoval informationwithregardtothedirectorsofthecompanyisincorporatedhereinbyreferencetothematerialcaptioned itemelectionofdirectorsintheproxystatement name age position vanessabroadhurst memberexecutivecommitteeexecutivevicepresidentglobal corporateaffairsa joaquinduato chairmanoftheboardchiefexecutiveofficerb petermfasolophd memberexecutivecommitteeexecutivevicepresidentchiefhuman resourcesofficerc elizabethforminard memberexecutivecommitteeexecutivevicepresidentgeneral counseld williamnhaitmdphd memberexecutivecommitteeexecutivevicepresidentchief externalinnovationandmedicalsafetyofficerinterimhead janssenrde ashleymcevoy memberexecutivecommitteeexecutivevicepresidentworldwide chairmanmedtechf thibautmongon memberexecutivecommitteeexecutivevicepresidentworldwide chairmanconsumerhealthg jamesswanson memberexecutivecommitteeexecutivevicepresidentchief informationofficerh jenniferltaubert memberexecutivecommitteeexecutivevicepresidentworldwide chairmanpharmaceuticalsi kathrynewengel memberexecutivecommitteeexecutivevicepresidentchief technicaloperationsriskofficerj josephjwolk memberexecutivecommitteeexecutivevicepresidentchief financialofficerk msvbroadhurstjoinedthecompanyinasworldwidevicepresidentanemiaoncologysupportivecareshethenwent ontobecomevicepresidentofthecardiovascularinstitutionalfranchiseinandpresidentofjanssentherapeuticsin beforebecominguspresidentinternalmedicineinfromtosheheldgeneralmanagerrolesatamgenin inflammationcardiovascularandcardiovascularboneinmsbroadhurstrejoinedjohnsonjohnsonasuspresident cardiovascularmetabolismandamemberofthejanssenamericasleadershipteaminthisroleshealsoprovidedoperational oversightofthefullportfolioofjanssenmedicinesinpuertoricoandcanadainshewasappointedcompanygroup chairmanglobalcommercialstrategyorganizationinmsbroadhurstwasnamedexecutivevicepresidentglobal corporateaffairsandamemberoftheexecutivecommitteeleadingthecompanysglobalmarketingcommunicationglobalpublic healthandphilanthropyfunctions b mrjduatobecamechairmanoftheboardofdirectorsinjanuarysubsequenttohisappointmentaschiefexecutiveofficer andadirectorinjanuaryhejoinedthecompanyinwithjanssenfarmaceuticasaspainasubsidiaryofthe companyandheldexecutivepositionsofincreasingresponsibilityinallbusinesssectorsandacrossmultiplegeographiesand functionsinhewasnamedcompanygroupchairmanpharmaceuticalsandinhewasnamedworldwidechairman pharmaceuticalsinmrduatobecameamemberoftheexecutivecommitteeandwasnamedexecutivevicepresident worldwidechairmanpharmaceuticalsinjulymrduatowaspromotedtovicechairmanoftheexecutivecommitteewhere heprovidedstrategicdirectionforthepharmaceuticalandconsumerhealthsectorsandoversawboththeglobalsupplychain informationtechnologyandhealthwellnessteamsasadualcitizenofspainandtheunitedstatesmrduatosinternational perspectiveandgloballensgiveshimadeepappreciationofdiversethoughtsandopinions c drpmfasolojoinedthecompanyinasworldwidevicepresidenthumanresourcesinthemedtechsegmentand subsequentlyservedasthecompanyschieftalentofficerheleftjohnsonjohnsonintojoinkohlbergkravisroberts coaschieftalentofficerdrfasoloreturnedtothecompanyinasthevicepresidentglobalhumanresourcesandin hebecameamemberoftheexecutivecommitteeinaprilhewasnamedexecutivevicepresidentchiefhuman resourcesofficerdrfasolohasresponsibilityforglobaltalentrecruitingdiversitycompensationbenefitsemployeerelationsand johnsonjohnsonannualreportallaspectsofthehumanresourcesagendaforthecompanyhealsoservesontheboardsofthehumanresourcespolicy associationtuftsuniversityandsavethechildrenandwasnamedafellowofthenationalacademyofhumanresourcesin mselizabethforminardjoinedthecompanyinasvicepresidentlawconsumerhealthcareglobalbusinessunitand continuedtoserveinrolesofincreasingresponsibilityinshewaspromotedtogeneralcounselmedicaldevices diagnosticsandbecamegeneralcounselconsumergroupsupplychaininshewasappointedworldwidevice presidentcorporategovernanceinfromtosheservedasgeneralcounselpharmaceuticalsinoctober shewasnamedexecutivevicepresidentgeneralcounselandbecameamemberoftheexecutivecommitteemsforminardhas worldwideresponsibilityforthelegalandprivacyfunctionsandleadsthedevelopmentandexecutionofthecompanysenvironment socialandgovernancestrategy e drwhaitjoinedthecompanyinasseniorvicepresidentworldwideheadofoncologyresearchhethenservedasthe firstglobaltherapeuticareaheadforoncologyfromtoandthenasglobalheadjanssenresearchdevelopment fromthroughfromtohewasglobalheadjohnsonjohnsonglobalexternalinnovationinhe becameexecutivevicepresidentchiefexternalinnovationmedicalsafetyandglobalpublichealthofficerandamemberofthe executivecommitteeheisresponsibleforleadingexternalsourcingandcreationoftransformationalinnovationtohelpjohnson johnsonachieveitsmissiontoimprovehumanhealthutilizingthecompanysexcellenceinpharmaceuticalsmedicaldevicesand consumerproductshealsohasoversightoverglobalpublichealthandtheofficeofthechiefmedicalofficerasinterimheadof janssenrddrhaitsmissionistofocusthebestresearchanddevelopmentteamsintheworldattheintersectionofunmet medicalneedandbreakthroughsinscienceandtechnologytomakemedicineswithbenefitforpatientsworldwide f msamcevoyjoinedthecompanyinasassistantbrandmanagerofmcneilconsumerhealthasubsidiaryofthecompany advancingthroughpositionsofincreasingresponsibilitiesuntilshewasappointedcompanygroupchairmanvisioncarein followedbycompanygroupchairmanconsumermedicaldevicesininjulymsmcevoywaspromotedtoexecutive vicepresidentworldwidechairmanmedtechandbecameamemberoftheexecutivecommitteemsmcevoyhasresponsibility forthesurgeryorthopaedicsinterventionalsolutionsandeyehealthbusinessesacrossethicondepuysynthesbiosensewebster abiomedandjohnsonjohnsonvision g mrtmongonjoinedthecompanyinasdirectorofmarketingforthevisioncaregroupinfranceandsubsequentlyheld positionsofincreasingresponsibilityuntilhetransitionedtothepharmaceuticalsectorinastheglobalcommercialstrategy leaderfortheneurosciencetherapeuticareainhejoinedtheconsumerhealthsectorascompanygroupchairmanasia pacificinhewaspromotedtoexecutivevicepresidentandworldwidechairmanconsumerhealthandbecameamember oftheexecutivecommitteemrmongonhasresponsibilityfortheglobaldevelopmentofjohnsonjohnsonshealthandwellness productsandsolutionsinbeautyotcoralcarebabycarewomenshealthandwoundcare h mrjswansonrejoinedthecompanyinaschiefinformationofficerofjohnsonjohnsonfrombayercropsciencewhere heservedasamemberoftheexecutiveleadershipteamandascioandheadofdigitaltransformationfromto mrswansonheldpositionsofincreasingresponsibilityatthecompanyincludingprojectmanagerdirectoritsrdirectoritand vicepresidentchiefinformationofficermrswansonisresponsibleforenhancingjohnsonjohnsonsbusinessimpactand shapingitsdirectionthroughthestrategicuseoftechnologymrswansonexecutivevicepresidententerprisechiefinformation officerjoinedtheexecutivecommitteeeffectivejanuary msjltaubertjoinedthecompanyinasworldwidevicepresidentandsheheldseveralexecutivepositionsofincreasing responsibilityinthepharmaceuticalsectorinshewasappointedcompanygroupchairmannorthamericapharmaceuticals andinbecamecompanygroupchairmantheamericaspharmaceuticalsinjulymstaubertwaspromotedto executivevicepresidentworldwidechairmanpharmaceuticalsandbecameamemberoftheexecutivecommitteemstaubertis responsibleforthepharmaceuticalsectorgloballyincludingshapingthecompanysstrategyoftransformationalmedicalinnovation andforsuccessfullybringingtomarketcriticalnewmedicinesthatsignificantlyimprovethelivesofpatientslivingwithcancer immunerelateddiseasescardiovasculardiseaseinfectiousdiseasespulmonaryhypertensionandseriousmentalillness j mskewengeljoinedthecompanyinasprojectengineerandengineeringsupervisoratjanssenasubsidiaryofthe companyduringhertenurewiththecompanyshehasheldavarietyofstrategicleadershipandexecutivepositionsincludingin roleswithinoperationsqualityengineeringnewproductsinformationtechnologyandothertechnicalandbusinessfunctionsin shewasnamedexecutivevicepresidentchiefglobalsupplychainofficerandbecameamemberoftheexecutive committeeinjanuaryshewasappointedexecutivevicepresidentchieftechnicaloperationsriskofficermswengel hasenterprisewideresponsibilitiesforkeytechnicaloperationsfunctionsincludingprocurementengineeringpropertyservices sustainabilityandcrosssectorsupplychainteamsfocusedonstandardsservicesstrategicprogramsanddatascienceand servesaschairofthecompanyssupplychainmanagementcommitteeshealsooverseescriticalriskfunctionsincluding qualitycompliancehealthcarecomplianceenvironmentalhealthsafetyglobalsecurityandglobalbrandprotection k mrjjwolkjoinedthecompanyinasfinancemanagerbusinessdevelopmentfororthomcneilasubsidiaryofthe companyandthroughtheyearsheldavarietyofseniorleadershiprolesinseveralsegmentsandfunctionsacrossthecompanys subsidiariesinpharmaceuticalsmedicaldevicesandsupplychainfromtoheservedasvicepresidentfinanceand chieffinancialofficerofthejanssenpharmaceuticalcompaniesofjohnsonjohnsoninmrwolkbecamethevice presidentinvestorrelationsinjulyhewasappointedexecutivevicepresidentchieffinancialofficerandbecameamember oftheexecutivecommitteemrwolkplaysastrategicroleintheoverallmanagementofthecompanyandleadsthedevelopment andexecutionofthecompanysgloballongtermfinancialstrategy johnsonjohnsonannualreport part ii item market registrants common equity related stockholder matters issuer purchases equity securities asoffebruarytherewererecordholdersofcommonstockofthecompanyadditionalinformation calledforbythisitemisincorporatedhereinbyreferencetothefollowingsectionsofthisreportnotecommon stockstockoptionplansandstockcompensationagreementsofthenotestoconsolidatedfinancialstatements includedinitemanditemsecurityownershipofcertainbeneficialownersandmanagementandrelated stockholdermattersequitycompensationplaninformation issuer purchases equity securities onseptemberthecompanyannouncedthatitsboardofdirectorsapprovedasharerepurchaseprogram authorizingthecompanytopurchaseuptobillionofthecompanyscommonstocksharerepurchasesmaybe madeatmanagementsdiscretionfromtimetotimeontheopenmarketorthroughprivatelynegotiatedtransactionsthe repurchaseprogramhasnotimelimitandmaybesuspendedforperiodsordiscontinuedatanytime thefollowingtableprovidesinformationwithrespecttocommonstockpurchasesbythecompanyduringthefiscalfourth quarterofcommonstockpurchasesontheopenmarketaremadeaspartofasystematicplantomeettheneeds ofthecompanyscompensationprogramstherepurchasesbelowalsoincludethestockforstockoptionexercisesthat settledinthefiscalfourthquarter totalnumberof maximumnumberor sharesorunits approximatedollar purchasedaspart valueofsharesorunits totalnumber ofpublicly thatmayyetbe ofshares avgprice announcedplans purchasedunderthe fiscalperiod purchased paidpershare orprograms plansorprograms octoberthroughoctober octoberthrough november novemberthroughjanuary total duringthefiscalfourthquarterofthecompanyrepurchasedanaggregateofsharesofjohnsonjohnson commonstockinopenmarkettransactionsofwhichshareswerepurchasedpursuanttotherepurchaseprogramthat waspubliclyannouncedonseptemberandofwhichshareswerepurchasedaspartofasystematicplanto meettheneedsofthecompanyscompensationprograms asofjanuaryanaggregateofshareswerepurchasedforatotalofbillionsincetheinceptionofthe repurchaseprogramannouncedonseptember asofjanuarythemaximumnumberofsharesthatmayyetbepurchasedundertheplanisbasedontheclosing priceofjohnsonjohnsoncommonstockonthenewyorkstockexchangeondecemberofpershare item reserved johnsonjohnsonannualreportitem managements discussion analysis results operations financial condition organization business segments descriptionofthecompanyandbusinesssegments johnsonjohnsonanditssubsidiariesthecompanyhaveapproximatelyemployeesworldwideengagedinthe researchanddevelopmentmanufactureandsaleofabroadrangeofproductsinthehealthcarefieldthecompany conductsbusinessinvirtuallyallcountriesoftheworldwiththeprimaryfocusonproductsrelatedtohumanhealthand wellbeing thecompanyisorganizedintothreebusinesssegmentsconsumerhealthpharmaceuticalandmedtechthe consumerhealthsegmentincludesabroadrangeofproductsusedinthebabycareoralcareskinhealthbeauty overthecounterpharmaceuticalwomenshealthandwoundcaremarketstheseproductsaremarketedtothe generalpublicandsoldonlineecommerceandtoretailoutletsanddistributorsthroughouttheworldthe pharmaceuticalsegmentisfocusedonthefollowingtherapeuticareasincludingimmunologyinfectiousdiseases neuroscienceoncologypulmonaryhypertensionandcardiovascularandmetabolicdiseasesproductsinthissegment aredistributeddirectlytoretailerswholesalersdistributorshospitalsandhealthcareprofessionalsforprescriptionuse themedtechsegmentincludesabroadportfolioofproductsusedintheorthopaedicsurgeryinterventionalsolutions cardiovascularandneurovascularandvisionfieldstheseproductsaredistributedtowholesalershospitalsandretailers andusedprincipallyintheprofessionalfieldsbyphysiciansnurseshospitalseyecareprofessionalsandclinics theexecutivecommitteeofjohnsonjohnsonistheprincipalmanagementgroupresponsibleforthestrategic operationsandallocationoftheresourcesofthecompanythiscommitteeoverseesandcoordinatestheactivitiesofthe consumerhealthpharmaceuticalandmedtechbusinesssegments inallofitsproductlinesthecompanycompeteswithothercompaniesbothlocallyandgloballythroughouttheworld competitionexistsinallproductlineswithoutregardtothenumberandsizeofthecompetingcompaniesinvolved competitioninresearchinvolvingthedevelopmentandtheimprovementofnewandexistingproductsandprocessesis particularlysignificantthedevelopmentofnewandinnovativeproductsaswellasprotectingtheunderlyingintellectual propertyofthecompanysproductportfolioisimportanttothecompanyssuccessinallareasofitsbusinessthe competitiveenvironmentrequiressubstantialinvestmentsincontinuingresearchinadditionthedevelopmentand maintenanceofcustomerdemandforthecompanysconsumerproductsinvolvessignificantexpendituresforadvertising andpromotion managementsobjectives withourcredoasthefoundationthecompanyspurposeistoblendheartscienceandingenuitytoprofoundly changethetrajectoryofhealthforhumanitythecompanyiscommittedtobringingitsfullbreadthanddepthtoensure healthforpeopletodayandforfuturegenerationsunitedaroundthiscommonambitionthecompanyispoisedtofulfillits purposeandsuccessfullymeetthedemandsoftherapidlyevolvingmarketsinwhichitcompetes thecompanyisbroadlybasedinhumanhealthcareandiscommittedtocreatingvaluebydevelopingaccessiblehigh qualityinnovativeproductsandservicesnewproductsintroducedwithinthepastfiveyearsaccountedforapproximately ofsalesinbillionwasinvestedinresearchanddevelopmentreflectingmanagements commitmenttocreatelifeenhancinginnovationsandtocreatevaluethroughpartnershipsthatwillprofoundlychangethe trajectoryofhealthforhumanity acriticaldriverofthecompanyssuccessisthediversityofitsemployeesworldwideemployeesare empoweredandinspiredtoleadwithourcredoandpurposeasguidesthisallowseveryemployeetousethe companysreachandsizetoadvancethecompanyspurposeandtoalsoleadwithagilityandurgencyleveragingthe extensiveresourcesacrosstheenterpriseenablesthecompanytoinnovateandexecutewithexcellencethisensuresthe companycanremainfocusedonaddressingtheunmetneedsofsocietyeverydayandinvestforanenduringimpact ultimatelydeliveringvaluetoitspatientsconsumersandhealthcareprofessionalsemployeescommunitiesand shareholders johnsonjohnsonannualreport snoillib ni snoillib ni srallod ni research acquisicidons net dividends paid development cash acquired per share results operations analysisofconsolidatedsales fordiscussiononresultsofoperationsandfinancialconditionpertainingtothefiscalyearsandseethe companysannualreportonformkforthefiscalyearendedjanuaryitemmanagementsdiscussionand analysisofresultsofoperationsandfinancialcondition inworldwidesalesincreasedtobillionascomparedtoanincreaseofinthesesales changesconsistedofthefollowing salesincreasedecreasedueto volume price currency total thenetimpactofacquisitionsanddivestituresontheworldwidesalesgrowthwasanegativeimpactofinand anegativeimpactofin salesbyuscompanieswerebillioninandbillioninthisrepresentsincreasesofin andinsalesbyinternationalcompanieswerebillioninandbillioninthisrepresents adecreaseofinandanincreaseofin thefiveyearcompoundannualgrowthratesforworldwideusandinternationalsaleswereand respectivelythetenyearcompoundannualgrowthratesforworldwideusandinternationalsaleswereand respectively insalesbycompaniesineuropeexperiencedadeclineofascomparedtotheprioryearwhichincluded operationalgrowthofandanegativecurrencyimpactofsalesbycompaniesinthewesternhemisphere excludingtheusachievedgrowthofascomparedtotheprioryearwhichincludedoperationalgrowthof andanegativecurrencyimpactofsalesbycompaniesintheasiapacificafricaregionexperiencedadeclineof ascomparedtotheprioryearincludingoperationalgrowthofandanegativecurrencyimpactof inthecompanyutilizedthreewholesalersdistributingproductsforallthreesegmentsthatrepresented approximatelyandofthetotalconsolidatedrevenuesinthecompanyhadthreewholesalers distributingproductsforallthreesegmentsthatrepresentedapproximatelyandofthetotal consolidatedrevenues johnsonjohnsonannualreport sales geographic region billions sales segment billions europe western hemisphere ex us consumer health pharmaceutical asiapacific africa us medtech notevaluesmayhavebeenrounded analysis sales business segments consumerhealthsegment consumerhealthsegmentsalesinwerebillionadecreaseoffromwhichincluded operationalgrowthandanegativecurrencyimpactofusconsumerhealthsegmentsaleswerebillionan increaseofinternationalsaleswerebillionadecreaseofwhichincludedoperationalgrowthanda negativecurrencyimpactofinacquisitionsanddivestitureshadanetnegativeimpactofonthe operationalsalesgrowthoftheworldwideconsumerhealthsegment majorconsumerhealthfranchisesales total operations currency dollarsinmillions change change change otc skinhealthbeauty oralcare babycare womenshealth woundcareother totalconsumerhealthsales certainprioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation fiscalreflectsapproximatelybillionofcertaininternationalotcproductsprimarilyinchinawhichwerereclassifiedfrom thepharmaceuticalsegmenttotheconsumerhealthsegmentbasedonoperationalchanges theotcfranchisesalesofbillionincreasedascomparedtotheprioryearoperationalgrowthwasprimarily attributabletoincreasedcoughcoldfluadultandpediatricincidencespriceactionsprimarilyintheusandincreased consumptioninchinaduetoeasingofcovidrestrictionsgrowthwaspartiallyoffsetbysupplyconstraints theskinhealthbeautyfranchisesalesofbilliondeclinedascomparedtotheprioryeartheoperational declinewasdrivenbysupplyconstraintsintheuspartiallyoffsetbypriceactionsandstrongnewproductperformance intheasiapacificandlatinamericaregion theoralcarefranchisesalesofbilliondeclinedascomparedtotheprioryeartheoperationaldeclinewas duetoportfoliosimplificationintheuscompetitivepressuresinemeaandchinacategorydeclineandpricing pressuresinemeaaswellassuspensionofpersonalcaresalesinrussiaandnegativecovidimpactsinchina johnsonjohnsonannualreport thebabycarefranchisesalesofbilliondeclinedascomparedtotheprioryeartheoperationaldeclinewas drivenbycategorydecelerationandcompetitivepressuresintheussuspensionofpersonalcaresalesinrussiaand weaknessinindia thewomenshealthfranchisesalesofbilliondeclinedascomparedtotheprioryearoperationalgrowth drivenbylappingprioryearsupplyconstraintsinemeastrengthinindiaandpriceactionsinlatamwaspartiallyoffset bysuspensionofpersonalcaresalesinrussiaandnegativecurrencyimpacts thewoundcareotherfranchisesalesofbilliondeclinedascomparedtotheprioryeartheoperational declinewasdrivenbylappingstrongprioryearconsumptioncompetitivepressureintheusanddecreased consumptioninchina innovemberthecompanyannounceditsintentiontoseparatethecompanysconsumerhealthbusinesskenvue asthenamefortheplannednewconsumerhealthcompanywiththeintentiontocreateanewpubliclytraded companybytheendofthefiscalyear johnsonjohnsonannualreportpharmaceutical segment pharmaceuticalsegmentsalesinwerebillionanincreaseoffromwhichincludedoperational growthofandanegativecurrencyimpactofussaleswerebillionanincreaseofinternational saleswerebillionanincreaseofwhichincludedoperationalgrowthandanegativecurrencyimpact ofinacquisitionsanddivestitureshadanetnegativeimpactofontheoperationalsalesgrowthofthe worldwidepharmaceuticalsegmentadjustmentstoprevioussalesreserveestimateswereapproximatelybillionand billioninfiscalyearsandrespectively majorpharmaceutical therapeuticareasales total operations currency dollarsinmillions change change change totalimmunology remicade simponisimponiaria stelara tremfya otherimmunology totalinfectiousdiseases covidvaccine edurantrilpivirine prezistaprezcobixrezolstasymtuza otherinfectiousdiseases totalneuroscience concertamethylphenidate invegasustennaxeplioninvegatrinzatrevicta risperdalconsta otherneuroscience totaloncology darzalex erleada imbruvica zytigaabirateroneacetate otheroncology totalpulmonaryhypertension opsumit uptravi otherpulmonaryhypertension totalcardiovascularmetabolismother xarelto invokanainvokamet totalpharmaceuticalsales certainprioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation inclusiveofprocriteprexwhichwaspreviouslydisclosedseparately fiscalreflectsapproximatelybillionofcertaininternationalotcproductsprimarilyinchinawhichwerereclassifiedfrom thepharmaceuticalsegmenttotheconsumerhealthsegmentbasedonoperationalchanges johnsonjohnsonannualreport immunologyproductsachievedsalesofbillioninrepresentinganincreaseofascomparedtotheprior yearoperationalgrowthwasdrivenbystronguptakeofstelaraustekinumabincrohnsdiseaseandulcerative colitisandstrengthoftremfyaguselkumabinpsoriasisanduptakeinpsoriaticarthritisthiswaspartiallyoffsetby lowersalesofremicadeinfliximabduetobiosimilarcompetition biosimilarversionsofremicadehavebeenintroducedintheunitedstatesandcertainmarketsoutsidetheunited statesandadditionalcompetitorscontinuetoenterthemarketcontinuedinfliximabbiosimilarcompetitionwillresultina furtherreductioninsalesofremicade thelatestexpiringunitedstatespatentforstelaraustekinumabwillexpireinseptemberstelara ustekinumabussalesinfiscalwereapproximatelybillionandtheexpirationofthisproductpatentorlossof marketexclusivitywillresultinareductioninsales infectiousdiseaseproductssaleswerebillioninrepresentingadeclineofascomparedtotheprioryear operationalgrowthwasdrivenbythecovidvaccineoutsidetheuspartiallyoffsetbylowersalesofprezistaand prezcobixrezolstadarunavircobicistatduetoincreasedcompetitionandlossofexclusivityofprezistain certaincountriesoutsidetheus neuroscienceproductssaleswerebillioninrepresentingadeclineofascomparedtotheprioryear theoperationalsalesgrowthofinvegasustennaxeplionpaliperidonepalmitateandinvegatrinzatrevicta fromnewpatientstartsandpersistenceaswellasthelaunchofinvegahafyerawasoffsetbynegativecurrency impactsandlowersalesofrisperdalconsta oncologyproductsachievedsalesofbillioninrepresentinganincreaseofascomparedtotheprior yearcontributionstooperationalgrowthwerestrongsalesofdarzalexdaratumumabdrivenbysharegainsinall regionscontinuedstrongmarketgrowthanduptakeofthesubcutaneousformulationaswellasthecontinuedglobal launchuptakeoferleadaapalutamidethiswaspartiallyoffsetbydecliningsalesofimbruvicaibrutinibdueto competitivepressuresandmarketsuppressionandzytigaduetolossofexclusivityintheeuropeanunioninthesecond halfof pulmonaryhypertensionproductssaleswerebillionadeclineofascomparedtotheprioryearthe operationalsalesgrowthofopsumitmacitentananduptraviselexipagduetocontinuedsharegainsandmarket growthwasoffsetbycovidrelatedimpactsandcontinueddeclinesinotherpulmonaryhypertension cardiovascularmetabolismotherproductssaleswerebillionadeclineofascomparedtotheprioryearthe operationaldeclinewasprimarilyattributabletolowersalesofinvokanainvokametcanagliflozinduetoshare erosionandprocriteprexepoetinalfaduetobiosimilarcompetition thecompanyupdateditspolicysothatnoendcustomerwillbepermitteddirectdeliveryofproducttoalocationother thanthebillinglocationthepolicyimpactscontractpharmacytransactionsinvolvingnongranteebcoveredentities formostofthecompanysdrugssubjecttomultipleexceptionsbothgranteeandnongranteecoveredentitiescan maintaincertaincontractpharmacyarrangementsunderpolicyexceptionsthecompanyhasbeenandwillcontinueto offerbdiscountstocoveredentitiesonallofitscoveredoutpatientdrugsanditbelievesitspolicywillimproveits abilitytoidentifyinappropriateduplicatediscountsanddiversionprohibitedbythebstatutethebdrugpricing programisausfederalgovernmentprogramrequiringdrugmanufacturerstoprovidesignificantdiscountsoncovered outpatientdrugstocoveredentitiesthispolicyupdatehaddiscountimplicationswhichpositivelyimpactedsalesto customersin johnsonjohnsonannualreportduringthecompanyadvanceditspipelinewithseveralregulatorysubmissionsandapprovalsfornewdrugsand additionalindicationsforexistingdrugsasfollows productnamechemical us eu us eu name indication approval approval filing filing aprocitentan treatmentfordifficulttotreathypertension cabenuvarilpivirineand hivtreatmentforadolescents cabotegravir carvykticiltacabtagene treatmentforpatientswithrelapsedorrefractorymultiple autoleucel myeloma erleadaapalutamide tabletreduction imbruvicaibrutinib treatmentforpediatricpatientswithchronicgraftversushost disease treatmentforfrontlinechroniclymphocyticleukemiaiv fixeddurationglow niraparib treatmentoflprostatecancermetastaticcastrationresistantin combinationwithabirateroneacetateandprednisone stelaraustekinumab treatmentofpediatricpatientswithjuvenilepsoriaticarthritis talquetamab treatmentofpatientswithrelapsedrefractorymultiplemyeloma teclistamabbcmacd treatmentofpatientswithrelapsedrefractorymultiplemyeloma johnsonjohnsonannualreport medtechsegment themedtechsegmentsalesinwerebillionanincreaseoffromwhichincludedoperational growthofandanegativecurrencyimpactofussaleswerebillionanincreaseofascompared totheprioryearinternationalsaleswerebillionadecreaseofascomparedtotheprioryearwhichincluded operationalgrowthofandanegativecurrencyimpactofinthenetimpactofacquisitionsand divestituresonthemedtechsegmentworldwideoperationalsalesgrowthwasapositive majormedtechfranchisesales total operations currency dollarsinmillions change change change surgery advanced general orthopaedics hips knees trauma spinesportsother vision contactlensesother surgical interventionalsolutions totalmedtechsales certainprioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation previouslyreferredtoasmedicaldevices thesurgeryfranchisesaleswerebillioninrepresentingadeclineoffromtheoperationalgrowth inadvancedsurgerywasprimarilydrivenbythefollowingendocuttermarketrecoveryandnewproductspartiallyoffset bycompetitivepressuresintheusbiosurgerymarketrecoveryandthesuccessofnewproductspartiallyoffsetby strongusmarketdemandintheprioryearforinfectionpreventionproductsandenergyproductsdrivenbymarket recoveryandnewproductpenetrationcoupledwithcompetitivesupplychallengestheoperationalgrowthingeneral surgerywasprimarilydrivenbymarketrecoveryandtechnologypenetration theorthopaedicsfranchisesaleswerebillioninwhichwasflattotheprioryeartheorthopaedicsfranchise includedoperationalsalesgrowthofoffsetbyanegativecurrencyimpactoftheoperationalgrowthinhips reflectsthemarketrecoverycombinedwithcontinuedstrengthoftheportfolioincludingtheactisstemandenabling technologieskinciseandvelyshipnavigationthisgrowthwaspartiallyoffsetbyimpactsofvolumebased procurementinchinaandthetimingoftendersoutsidetheustheoperationalgrowthinkneeswasprimarilydrivenby procedurerecoverystrengthoftheattuneportfolioandpullthroughrelatedtothevelysroboticassistedsolution thisgrowthwaspartiallyoffsetbyimpactsofvolumebasedprocurementinchinaandtimingoftendersoutsidetheus theoperationalgrowthintraumawasdrivenbyglobalmarketrecoveryanduptakeofnewproductstheoperational growthinspinesportsotherwasprimarilydrivenbyprocedurerecoveryandnewproductintroductionsthisgrowth waspartiallyoffsetbycompetitivepressuresinspineandimpactsofvolumebasedprocurementinchina thevisionfranchiseachievedsalesofbillioninrepresentinganincreaseoffromthecontact lensesotheroperationalgrowthwasduetomarketrecoverypriceactionscommercialexecutionandbenefitsfromnew productssurgicalvisionoperationalgrowthwasprimarilyduetomarketrecoveryandthesuccessofnewproductsand waspartiallyoffsetbyahigherprioryearusrefractorymarket theinterventionalsolutionsfranchiseachievedsalesofbillioninrepresentinganincreaseoffrom operationalgrowthwasdrivenbymarketrecoveryandsuccessofnewproductsandcommercialstrategiesinterventional solutionsalsoincludessalesfromabiomedincabiomedwhichwerereflectedasofdecember johnsonjohnsonannualreportanalysisofconsolidatedearningsbeforeprovisionfortaxesonincome consolidatedearningsbeforeprovisionfortaxesonincomewasbillionandbillionfortheyearsand respectivelyasapercenttosalesconsolidatedearningsbeforeprovisionfortaxesonincomewasand inandrespectively earnings provision taxes dollars billions percentages chart percent total sales costofproductssoldandsellingmarketingandadministrativeexpenses cost products sold selling markecidng administracidve dollars billions percentages chart percent total sales costofproductssoldincreasedasapercenttosalesdrivenby onetimecovidvaccinemanufacturingexitrelatedcosts currencyimpactsinthepharmaceuticalsegment commodityinflationinthemedtechandconsumerhealthsegments partiallyoffsetby supplychainbenefitsintheconsumerhealthsegment theintangibleassetamortizationexpenseincludedincostofproductssoldwasbillionandbillionforthefiscal yearsandrespectively sellingmarketingandadministrativeexpensesdecreasedasapercenttosalesdrivenby reductionofbrandmarketingexpensesinthepharmaceuticalandconsumerhealthbusinesses johnsonjohnsonannualreport researchanddevelopmentexpense researchanddevelopmentexpensebysegmentofbusinesswasasfollows dollarsinmillions amount ofsales amount ofsales consumerhealth pharmaceutical medtech totalresearchanddevelopmentexpense percentincreasedecreaseovertheprioryear asapercenttosegmentsales researchanddevelopmentactivitiesrepresentasignificantpartofthecompanysbusinesstheseexpendituresrelateto theprocessesofdiscoveringtestinganddevelopingnewproductsupfrontpaymentsanddevelopmentalmilestones improvingexistingproductsaswellasensuringproductefficacyandregulatorycompliancepriortolaunchthecompany remainscommittedtoinvestinginresearchanddevelopmentwiththeaimofdeliveringhighqualityandinnovativeproducts researchanddevelopmentdecreasedasapercenttosalesprimarilydrivenby lowermilestonepaymentsinthepharmaceuticalbusiness inprocessresearchanddevelopmentiprdinthefiscalyearthecompanyrecordedanintangibleasset impairmentchargeofapproximatelybillionrelatedtoaninprocessresearchanddevelopmentassetbermekimab jnjaninvestigationaldrugforthetreatmentofatopicdermatitisadandhidradenitissuppurativahs additionalinformationregardingefficacyoftheadindicationandhsindicationbecameavailablewhichledthecompany tothedecisiontoterminatethedevelopmentofbermekimabforbothadandhsthecompanyacquiredallrightsto bermekimabfromxbiotechincinthefiscalyearinfiscalyearthecompanyrecordedapartialiprdcharge ofbillionprimarilyrelatedtoexpecteddevelopmentdelaysinthegeneralsurgerydigitalroboticsplatformottava acquiredwiththeaurishealthacquisitionintheimpairmentchargewascalculatedbasedonrevisionstothe discountedcashflowvaluationmodelreflectingadelayoffirstinhumanproceduresofapproximatelytwoyearsfromthe initialacquisitionmodelassumptionofthesecondhalfofthecompanywillcontinuetomonitortheremaining billionottavaplatformintangibleassetasdevelopmentprogramactivitiesareongoing otherincomeexpensenetotherincomeexpensenetistheaccountwherethecompanyrecordsgainsand lossesrelatedtothesaleandwritedownofcertaininvestmentsinequitysecuritiesheldbyjohnsonjohnson innovationjjdcincjjdcchangesinthefairvalueofsecuritiesinvestmentincomelossrelatedtoemployeebenefit programsgainsandlossesondivestiturescertaintransactionalcurrencygainsandlossesacquisitionanddivestiture relatedcostslitigationaccrualsandsettlementsaswellasroyaltyincome otherincomeexpensenetforthefiscalyearwasunfavorablebybillionascomparedtotheprioryear primarilyduetothefollowing dollarsinbillionsincomeexpense change consumerhealthseparationcosts litigationrelated changesinthefairvalueofsecurities onetimecovidvaccinemanufacturingexitrelatedcosts acquisitionintegrationanddivestiturerelated restructuringrelated employeebenefitplanrelated totalotherincomeexpensenet wasprimarilyrelatedtopelvicmeshandwasprimarilyrelatedtotalcandrisperdalgynecomastia wasprimarilycostsrelatedtotheacquisitionofabiomedwasprimarilyrelatedtodivestituregainsoftwopharmaceutical brandsoutsidetheus johnsonjohnsonannualreportinterestincomeexpenseinterestincomeexpenseinthefiscalofwasnetinterestincomeofmillionas comparedtointerestexpenseofmillioninthefiscalyearprimarilyduetohigherratesofinterestearnedon cashbalancescashcashequivalentsandmarketablesecuritiestotaledbillionattheendofandaveraged billionascomparedtothecashcashequivalentsandmarketablesecuritiestotalofbillionandbillion averagecashbalanceinthetotaldebtbalanceattheendofwasbillionwithanaveragedebtbalance ofbillionascomparedtobillionattheendofandanaveragedebtbalanceofbillionthelower averagecashcashequivalentsandmarketablesecuritiesandhigheraveragedebtbalancewereprimarilyduetothe acquisitionofabiomedinlatedecemberof incomebeforetaxbysegment incomelossbeforetaxbysegmentofbusinesswereasfollows percentof incomebeforetax segmentsales segmentsales dollarsinmillions consumerhealth pharmaceutical medtech segmentearningsbeforetax lessexpensesnotallocatedtosegments lessconsumerhealthseparationcosts worldwideincomebeforetax seenotetotheconsolidatedfinancialstatementsformoredetails amountsnotallocatedtosegmentsincludeinterestincomeexpenseandgeneralcorporateincomeexpense prioryearincomebeforetaxofapproximatelybillionhasbeenreclassifiedascertaininternationalotcproductsprimarilyin chinawerereclassifiedfromthepharmaceuticalsegmenttotheconsumerhealthsegmentbasedonoperationalchanges consumerhealthsegmentintheconsumerhealthsegmentincomebeforetaxasapercentofsaleswas versusintheincreaseintheincomebeforetaxasapercentofsaleswasprimarilydrivenbythe following lowerlitigationexpenseofbillioninversusbillionprimarilytalcrelatedin reductioninbrandmarketingexpensesinversus supplychainbenefitsin partiallyoffsetby commodityinflationin pharmaceuticalsegmentinthepharmaceuticalsegmentincomebeforetaxasapercenttosaleswas versusinthedecreaseintheincomebeforetaxasapercentofsaleswasprimarilydrivenbythefollowing onetimecovidvaccinemanufacturingexitrelatedcostsofbillionin unfavorablechangesinthefairvalueofsecuritiesbillionlossinvsbilliongainin aniprdchargeofbillioninrelatedtobermekimabjnjaninvestigationaldrugforthe treatmentofatopicdermatitisadandhidradenitissuppurativahs lowerdivestituregainsofbillioninversusbillionrelatedtotwopharmaceuticalbrandsoutsidetheus infiscal currencyimpactsincostofproductssold johnsonjohnsonannualreport partiallyoffsetby lowerlitigationrelatedexpenseofbillioninversusbillionprimarilyrelatedtorisperdalgynecomastia lowerresearchdevelopmentmilestonepaymentsin lowerbrandmarketingexpensesinversus infiscalandthecompanyenteredintoaseriesofcontractmanufacturingarrangementsforvaccine productionwiththirdpartycontractmanufacturingorganizationsthesearrangementsprovidedthecompanywith supplementalcommercialcapacityforvaccineproductionandpotentiallytransferablerightstosuchproductionifcapacity isnotrequiredthecompanycontinuestoevaluateandmonitorbothitsinternalandexternalsupplyarrangementsin fiscalthecovidvaccinerelatedcostsmentionedaboveincludedtheremainingcommitmentsand obligationsincludingexternalmanufacturingnetworkexitandrelatedinventorycostsandrequiredclinicaltrialexpenses associatedwiththecompanysmodificationofitscovidvaccineresearchprogramandmanufacturingcapacityto levelsthatmeetallremainingcustomercontractualrequirements medtechsegmentinthemedtechsegmentincomebeforetaxasapercenttosaleswasversus intheincreaseintheincomebeforetaxasapercenttosaleswasprimarilydrivenbythefollowing aniprdchargeofbillioninrelatedtothegeneralsurgeryofferingindigitalroboticsottavaacquiredwith theaurishealthacquisitionin partiallyoffsetby higherlitigationrelatedexpenseofbillioninprimarilyrelatedtopelvicmeshcostsversusbillionin acquisitionrelatedcostsofbillioninrelatedtotheabiomedacquisitionversusbillionin restructuringinthefiscalsecondquarterofthecompanyannouncedplanstoimplementactionsacrossits globalsupplychainthatareintendedtoenablethecompanytofocusresourcesandincreaseinvestmentsincritical capabilitiestechnologiesandsolutionsnecessarytomanufactureandsupplyitsproductportfolioofthefutureenhance agilityanddrivegrowththeglobalsupplychainactionsincludedexpandingitsuseofstrategiccollaborationsand bolsteringitsinitiativestoreducecomplexityimprovingcostcompetitivenessenhancingcapabilitiesandoptimizingits supplychainnetworkthecompanyhasachievedapproximatelybillioninannualpretaxcostsavingsasoutlinedin therestructuringactionsinthecompanyrecordedapretaxchargeofbillionwhichisincludedonthe followinglinesoftheconsolidatedstatementofearningsbillioninrestructuringbillioninotherincome expenseandbillionincostofproductssoldtotalprojectcostsofapproximatelybillionhavebeenrecorded sincetherestructuringwasannouncedtheprogramwascompletedinthefiscalfourthquarterof seenotetotheconsolidatedfinancialstatementsforadditionaldetailsrelatedtotherestructuringprograms provisionfortaxesonincometheworldwideeffectiveincometaxratewasinandin inthefiscalthecompanyincurredapproximatelybillionnetincrementalinternationaltaxcostrelatedtothe legalseparationoftheconsumerhealthbusinessandmaycontinuetoincuradditionalcostinfiscal ondecembertheeuropeanunioneumemberstatesformallyadoptedtheeuspillartwodirectivewhich generallyprovidesforaminimumeffectivetaxrateofasestablishedbytheorganizationforeconomiccooperation anddevelopmentoecdpillartwoframeworkthatwassupportedbyovercountriesworldwidetheeueffective datesarejanuaryandjanuaryfordifferentaspectsofthedirective asignificantnumberofothercountriesareexpectedtoalsoimplementsimilarlegislationincludingsouthkoreawhich approvedlegislationondecemberwithafulleffectivedateofjanuarythecompanyiscontinuingto evaluatethepotentialimpactonfutureperiodsofthepillartwoframeworkpendinglegislativeadoptionbyadditional individualcountriesincludingthosewithintheeuropeanunion fordiscussionrelatedtothefiscalprovisionfortaxesrefertonotetotheconsolidatedfinancialstatements johnsonjohnsonannualreportliquidity capital resources liquiditycashflows cashandcashequivalentswerebillionattheendofascomparedtobillionattheendof theprimarysourcesandusesofcashthatcontributedtothebilliondecreasewere dollarsinbillions qcashandcashequivalentsbalance cashgeneratedfromoperatingactivities netcashusedbyinvestingactivities netcashusedbyfinancingactivities effectofexchangerateandrounding qcashandcashequivalentsbalance inadditionthecompanyhadbillioninmarketablesecuritiesattheendoffiscalyearandbillionatthe endoffiscalyearseenotetotheconsolidatedfinancialstatementsforadditionaldetailsoncashcash equivalentsandmarketablesecurities cashflowfromoperationsofbillionwastheresultof dollarsinbillions netearnings noncashexpensesandotheradjustmentsprimarilyfordepreciationandamortizationstockbasedcompensation andassetwritedownspartiallyoffsetbythedeferredtaxprovisionnetgainonsaleofassetsbusinessesand creditlossesandaccountsreceivableallowances adecreaseincurrentandnoncurrentliabilities adecreaseinothercurrentandnoncurrentassets anincreaseinaccountspayableandaccruedliabilities anincreaseinaccountsreceivableandinventories cashflowfromoperations investingactivitiesuseofbillionofcashwasprimarilyusedfor dollarsinbillions additionstopropertyplantandequipment acquisitions proceedsfromthedisposalofassetsbusinessesnet netsalesofinvestments creditsupportagreementsactivitynet otherprimarilylicensesandmilestonesandrounding netcashusedforinvestingactivities johnsonjohnsonannualreport financingactivitiesuseofbillionofcashwasprimarilyusedfor dollarsinbillions dividendstoshareholders repurchaseofcommonstock netproceedsfromshortandlongtermdebt proceedsfromstockoptionsexercisedemployeewithholdingtaxonstockawardsnet netcashusedforfinancingactivities asofjanuarythecompanysnotespayableandlongtermdebtwasinexcessofcashcashequivalentsand marketablesecuritiesasofjanuarythenetdebtpositionwasbillionascomparedtotheprioryearof billiontheincreasewasprimarilyduetotheacquisitionofabiomedincindecemberthedebtbalanceatthe endofwasbillionascomparedtobillioninconsideringrecentmarketconditionsthecompany hasreevaluateditsoperatingcashflowsandliquidityprofileanddoesnotforeseeanysignificantincrementalriskthe companyanticipatesthatoperatingcashflowstheabilitytoraisefundsfromexternalsourcesborrowingcapacityfrom existingcommittedcreditfacilitiesandaccesstothecommercialpapermarketswillcontinuetoprovidesufficient resourcestofundoperatingneedsincludingthecompanysremainingbalancetobepaidontheagreementtosettle opioidlitigationforapproximatelybillionandtheestablishmentofthebilliontrustfortalcrelatedliabilitiessee notetotheconsolidatedfinancialstatementsforadditionaldetailsinadditionthecompanymonitorstheglobal capitalmarketsonanongoingbasisandfromtimetotimemayraisecapitalwhenmarketconditionsarefavorable effectivebeginninginfiscaltheustaxcutsandjobactoftcjarequiresthecompanytodeductus andinternationalresearchanddevelopmentexpendituresfortaxpurposesovertoyearsinsteadofinthecurrent fiscalyearasaresultinfiscalthecompanyexperiencedanincreaseinannualcashtaxpaymentsofapproximately billionabovewhatotherwisewouldhavebeenremittedtotheustreasurythecompanyconcurrentlyrecordsa deferredtaxbenefitforthefutureamortizationoftheresearchanddevelopmentrdfortaxpurposestherequirement toexpenserdasincurredisunchangedforusgaappurposesandtheimpacttopretaxrdexpenseisnotaffected bythisprovision onseptemberthecompanyannouncedthatitsboardofdirectorsapprovedasharerepurchaseprogram authorizingthecompanytopurchaseuptobillionofthecompanyscommonstocksharerepurchasesmaybe madeatmanagementsdiscretionfromtimetotimeontheopenmarketorthroughprivatelynegotiatedtransactionsthe repurchaseprogramhasnotimelimitandmaybesuspendedforperiodsordiscontinuedatanytimeanysharesacquired willbeavailableforgeneralcorporatepurposesthecompanyintendstofinancethesharerepurchaseprogramthrough availablecashthroughjanuaryapproximatelybillionhasbeenrepurchasedundertheprogram thefollowingtablesummarizesthecompanysmaterialcontractualobligationsandtheiraggregatematuritiesasof januarytosatisfytheseobligationsthecompanyintendstousecashfromoperations tax intereston legislation debt debt dollarsinmillions tcja obligations obligations total total fortaxmattersseenotetotheconsolidatedfinancialstatements johnsonjohnsonannualreportfinancingandmarketrisk thecompanyusesfinancialinstrumentstomanagetheimpactofforeignexchangeratechangesoncashflows accordinglythecompanyentersintoforwardforeignexchangecontractstoprotectthevalueofcertainforeigncurrency assetsandliabilitiesandtohedgefutureforeigncurrencytransactionsprimarilyrelatedtoproductcostsgainsorlosses onthesecontractsareoffsetbythegainsorlossesontheunderlyingtransactionsaappreciationoftheusdollar fromthejanuarymarketrateswouldincreasetheunrealizedvalueofthecompanysforwardcontractsby billionconverselyadepreciationoftheusdollarfromthejanuarymarketrateswoulddecreasethe unrealizedvalueofthecompanysforwardcontractsbybillionineitherscenariothegainorlossontheforward contractwouldbeoffsetbythegainorlossontheunderlyingtransactionandthereforewouldhavenoimpactonfuture anticipatedearningsandcashflows thecompanyhedgestheexposuretofluctuationsincurrencyexchangeratesandtheeffectoncertainassetsand liabilitiesinforeigncurrencybyenteringintocurrencyswapcontractsachangeinthespreadbetweenusand foreigninterestratesonthecompanysinterestratesensitivefinancialinstrumentswouldeitherincreaseordecreasethe unrealizedvalueofthecompanysswapcontractsbyapproximatelybillionineitherscenarioatmaturitythegainor lossontheswapcontractwouldbeoffsetbythegainorlossontheunderlyingtransactionandthereforewouldhaveno impactonfutureanticipatedcashflows thecompanydoesnotenterintofinancialinstrumentsfortradingorspeculativepurposesfurtherthecompanyhasa policyofonlyenteringintocontractswithpartiesthathaveatleastaninvestmentgradecreditratingthecounterpartiesto thesecontractsaremajorfinancialinstitutionsandthereisnosignificantconcentrationofexposurewithanyone counterpartymanagementbelievestheriskoflossisremotethecompanyenteredintocreditsupportagreements csawithcertainderivativecounterpartiesestablishingcollateralthresholdsbasedonrespectivecreditratingsand nettingagreementsseenotetotheconsolidatedfinancialstatementsforadditionaldetailsoncreditsupport agreements thecompanyinvestsinbothfixedrateandfloatingrateinterestearningsecuritieswhichcarryadegreeofinterestrate riskthefairmarketvalueoffixedratesecuritiesmaybeadverselyimpactedduetoariseininterestrateswhilefloating ratesecuritiesmayproducelessincomethanpredictedifinterestratesfallabasispointschangeinspreadon thecompanysinterestratesensitiveinvestmentswouldeitherincreaseordecreasetheunrealizedvalueofcash equivalentsandcurrentmarketablesecuritiesbylessthanbillion thecompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwideinseptemberthe companysecuredanewdaycreditfacilityofbillionwhichexpiresonseptemberinnovember thecompanysecuredanadditionaldayrevolvingcreditfacilityofbillionwhichhasanexpirationof novemberinterestchargedonborrowingsunderthecreditlineagreementisbasedoneithersecured overnightfinancingratesofrreferencerateorotherapplicablemarketrateasallowedplusapplicablemargins commitmentfeesundertheagreementarenotmaterial totalborrowingsattheendofandwerebillionandbillionrespectivelytheincreasein borrowingswasduetotheacquisitionofabiomedincinnetdebtcashandcurrentmarketablesecuritiesnetof debtwasbillioncomparedtonetdebtofbillionintotaldebtrepresentedoftotalcapital shareholdersequityandtotaldebtinandoftotalcapitalinshareholdersequitypershareattheend ofwascomparedtoatyearend asummaryofborrowingscanbefoundinnotetotheconsolidatedfinancialstatements dividends thecompanyincreaseditsdividendinforthethconsecutiveyearcashdividendspaidwerepersharein andpersharein onjanuarytheboardofdirectorsdeclaredaregularcashdividendofpersharepayableonmarch toshareholdersofrecordasoffebruary information criticalaccountingpoliciesandestimates managementsdiscussionandanalysisofresultsofoperationsandfinancialconditionarebasedonthecompanys consolidatedfinancialstatementsthathavebeenpreparedinaccordancewithaccountingprinciplesgenerallyacceptedin johnsonjohnsonannualreport theusgaapthepreparationofthesefinancialstatementsrequiresthatmanagementmakeestimatesand assumptionsthataffecttheamountsreportedforrevenuesexpensesassetsliabilitiesandotherrelateddisclosures actualresultsmayormaynotdifferfromtheseestimatesthecompanybelievesthattheunderstandingofcertainkey accountingpoliciesandestimatesareessentialinachievingmoreinsightintothecompanysoperatingresultsand financialconditionthesekeyaccountingpoliciesincluderevenuerecognitionincometaxeslegalandselfinsurance contingenciesvaluationoflonglivedassetsassumptionsusedtodeterminetheamountsrecordedforpensionsandother employeebenefitplansandaccountingforstockbasedawards revenuerecognitionthecompanyrecognizesrevenuefromproductsaleswhenobligationsunderthetermsofa contractwiththecustomeraresatisfiedgenerallythisoccurswiththetransferofcontrolofthegoodstocustomersthe companysglobalpaymenttermsaretypicallybetweentodaysprovisionsforcertainrebatessalesincentives tradepromotionscouponsproductreturnsdiscountstocustomersandgovernmentalclawbackprovisionsareaccounted forasvariableconsiderationandrecordedasareductioninsales productdiscountsgrantedarebasedonthetermsofarrangementswithdirectindirectandothermarketparticipantsas wellasmarketconditionsincludingconsiderationofcompetitorpricingrebatesareestimatedbasedoncontractual termshistoricalexperiencepatientoutcomestrendanalysisandprojectedmarketconditionsinthevariousmarkets servedthecompanyevaluatesmarketconditionsforproductsorgroupsofproductsprimarilythroughtheanalysisof wholesalerandotherthirdpartysellthroughandmarketresearchdataaswellasinternallygeneratedinformation salesreturnsareestimatedandrecordedbasedonhistoricalsalesandreturnsinformationproductsthatexhibitunusual salesorreturnpatternsduetodatingcompetitionorothermarketingmattersarespecificallyinvestigatedandanalyzedas partoftheaccountingforsalesreturnaccruals salesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpirationdestructioninthefield orinspecificareasproductrecallthesalesreturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarket asapercenttogrosssalesinaccordancewiththecompanysaccountingpoliciesthecompanygenerallyissuescredit tocustomersforreturnedgoodsthecompanyssalesreturnsreservesareaccountedforinaccordancewiththe usgaapguidanceforrevenuerecognitionwhenrightofreturnexistssalesreturnsreservesarerecordedatfullsales valuesalesreturnsintheconsumerhealthandpharmaceuticalsegmentsarealmostexclusivelynotresalablesales returnsforcertainfranchisesinthemedtechsegmentaretypicallyresalablebutarenotmaterialthecompany infrequentlyexchangesproductsfrominventoryforreturnedproductsthesalesreturnsreserveforthetotalcompanyhas beenapproximatelyofannualnettradesalesduringthefiscalyearsand promotionalprogramssuchasproductlistingallowancesandcooperativeadvertisingarrangementsarerecordedinthe sameperiodasrelatedsalescontinuingpromotionalprogramsincludecouponsandvolumebasedsalesincentive programstheredemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvalue volumebasedincentiveprogramsarebasedontheestimatedsalesvolumesfortheincentiveperiodandarerecordedas productsaresoldthesearrangementsareevaluatedtodeterminetheappropriateamountstobedeferredorrecordedas areductionofrevenuethecompanyalsoearnsprofitsharepaymentsthroughcollaborativearrangementsofcertain productswhichareincludedinsalestocustomersprofitsharepaymentswerelessthanofthetotalrevenuesin fiscalyearandlessthanofthetotalrevenuesinfiscalyearsandandareincludedinsalesto customers inadditionthecompanyentersintocollaborationarrangementsthatcontainmultiplerevenuegeneratingactivities amountsduefromcollaborativepartnersforthesearrangementsarerecognizedaseachactivityisperformedordelivered basedontherelativesellingpriceupfrontfeesreceivedaspartofthesearrangementsaredeferredandrecognizedover theperformanceperiodseenotetotheconsolidatedfinancialstatementsforadditionaldisclosuresoncollaborations reasonablylikelychangestoassumptionsusedtocalculatetheaccrualsforrebatesreturnsandpromotionsarenot anticipatedtohaveamaterialeffectonthefinancialstatementsthecompanycurrentlydisclosestheimpactofchanges toassumptionsinthequarterlyorannualfilinginwhichthereisamaterialfinancialstatementimpact johnsonjohnsonannualreportbelowaretablesthatshowtheprogressionofaccruedrebatesreturnspromotionsreservefordoubtfulaccountsand reserveforcashdiscountsbysegmentofbusinessforthefiscalyearsendedjanuaryandjanuary consumerhealthsegment balanceat balanceat beginning payments endof dollarsinmillions ofperiod accruals credits period accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total includesreserveforcustomerrebatesofmillionatjanuaryandmillionatjanuaryrecordedasacontra asset pharmaceutical segment balanceat balanceat beginning payments endof dollarsinmillions ofperiod accruals credits period accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total includesreserveforcustomerrebatesofmillionatjanuaryandmillionatjanuaryrecordedasacontra asset includespriorperiodadjustments johnsonjohnsonannualreport medtechsegment balanceat balanceat beginning payments endof dollarsinmillions ofperiod accruals credits period accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total includesreserveforcustomerrebatesofmillionatjanuaryandmillionatjanuaryrecordedasacontra asset incometaxesincometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludethe resultsofanydifferencebetweenusgaapaccountingandtaxreportingrecordedasdeferredtaxassetsorliabilities thecompanyestimatesdeferredtaxassetsandliabilitiesbasedonenactedtaxregulationsandratesfuturechangesin taxlawsandratesmayaffectrecordeddeferredtaxassetsandliabilities thecompanyhasunrecognizedtaxbenefitsforuncertaintaxpositionsthecompanyfollowsusgaapwhich prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof ataxpositiontakenorexpectedtobetakeninataxreturnmanagementbelievesthatchangesintheseestimateswould nothaveamaterialeffectonthecompanysresultsofoperationscashflowsorfinancialposition thecompanyhasrecordeddeferredtaxliabilitiesonallundistributedearningspriortodecemberfromits internationalsubsidiariesthecompanyhasnotprovideddeferredtaxesontheundistributedearningssubsequentto januaryfromcertaininternationalsubsidiarieswheretheearningsareconsideredtobeindefinitelyreinvestedthe companyintendstocontinuetoreinvesttheseearningsinthoseinternationaloperationsifthecompanydecidesata laterdatetorepatriatetheseearningstotheusthecompanywouldberequiredtoprovideforthenettaxeffectson theseamountsthecompanyestimatesthatthetaxeffectofthisrepatriationwouldbeapproximatelybillionunder currentlyenactedtaxlawsandregulationsandatcurrentcurrencyexchangeratesthisamountdoesnotincludethe possiblebenefitofusforeigntaxcreditswhichmaysubstantiallyoffsetthiscost seenoteandnotetotheconsolidatedfinancialstatementsforfurtherinformationregardingincometaxes legalandselfinsurancecontingenciesthecompanyrecordsaccrualsforvariouscontingenciesincludinglegal proceedingsandproductliabilityclaimsastheseariseinthenormalcourseofbusinesstheaccrualsarebasedon managementsjudgmentastotheprobabilityoflossesandwhereapplicableactuariallydeterminedestimatesthe companyhasselfinsurancethroughawhollyownedcaptiveinsurancecompanyinadditiontoaccrualsintheself insuranceprogramclaimsthatexceedtheinsurancecoverageareaccruedwhenlossesareprobableandamountscanbe reasonablyestimated thecompanyfollowstheprovisionsofusgaapwhenrecordinglitigationrelatedcontingenciesaliabilityisrecorded whenalossisprobableandcanbereasonablyestimated johnsonjohnsonannualreportseenotesandtotheconsolidatedfinancialstatementsforfurtherinformationregardingproductliabilityandlegal proceedings longlivedandintangibleassetsthecompanyassesseschangesbothqualitativelyandquantitativelyineconomic conditionsandmakesassumptionsregardingestimatedfuturecashflowsinevaluatingthevalueofthecompanys propertyplantandequipmentgoodwillandintangibleassetsastheseassumptionsandestimatesmaychangeovertime itmayormaynotbenecessaryforthecompanytorecordimpairmentcharges employeebenefitplansthecompanysponsorsvariousretirementandpensionplansincludingdefinedbenefit definedcontributionandterminationindemnityplanswhichcovermostemployeesworldwidetheseplansarebasedon assumptionsforthediscountrateexpectedreturnonplanassetsmortalityratesexpectedsalaryincreaseshealthcare costtrendratesandattritionratesseenotetotheconsolidatedfinancialstatementsforfurtherdetailsonthese rates stockbasedcompensationthecompanyrecognizescompensationexpenseassociatedwiththeissuanceofequity instrumentstoemployeesfortheirservicesbasedonthetypeofequityinstrumentthefairvalueisestimatedonthedate ofgrantusingeithertheblackscholesoptionvaluationmodeloracombinationofboththeblackscholesoption valuationmodelandmontecarlovaluationmodelandisexpensedinthefinancialstatementsovertheserviceperiodthe inputassumptionsusedindeterminingfairvaluearetheexpectedlifeexpectedvolatilityriskfreerateandexpected dividendyieldforperformanceshareunitsthefairmarketvalueiscalculatedforthetwocomponentgoalsatthedateof grantadjustedoperationalearningspershareandrelativetotalshareholderreturnthefairvaluesfortheearningsper sharegoalofeachperformanceshareunitwasestimatedonthedateofgrantusingthefairmarketvalueofthesharesat thetimeoftheawarddiscountedfordividendswhicharenotpaidontheperformanceshareunitsduringthevesting periodthefairvaluefortherelativetotalshareholderreturngoalofeachperformanceshareunitwasestimatedonthe dateofgrantusingthemontecarlovaluationmodelseenotetotheconsolidatedfinancialstatementsforadditional information newaccountingpronouncements refertonotetotheconsolidatedfinancialstatementsforrecentlyadoptedaccountingpronouncementsandrecently issuedaccountingpronouncementsnotyetadoptedasofjanuary economicandmarketfactors thecompanyisawarethatitsproductsareusedinanenvironmentwhereformorethanadecadepolicymakers consumersandbusinesseshaveexpressedconcernsabouttherisingcostofhealthcareinresponsetotheseconcerns thecompanyhasalongstandingpolicyofpricingproductsresponsiblyfortheperiodintheusthe weightedaveragecompoundannualgrowthrateofthecompanysnetpriceincreasesforhealthcareproducts prescriptionandoverthecounterdrugshospitalandprofessionalproductswasbelowtheusconsumerpriceindex cpi thecompanyoperatesincertaincountrieswheretheeconomicconditionscontinuetopresentsignificantchallengesthe companycontinuestomonitorthesesituationsandtakeappropriateactionsinflationratescontinuetohaveaneffecton worldwideeconomiesandconsequentlyonthewaycompaniesoperatethecompanyhasaccountedforoperationsin argentinaandvenezuelaashighlyinflationaryasthepriorthreeyearcumulativeinflationratesurpassedbeginning inthefiscalsecondquarterofthecompanyaccountedforoperationsinturkeyashighlyinflationaryastheprior threeyearcumulativeinflationratesurpassedthisdidnothaveamaterialimpacttothecompanysresultsinthe periodinthefaceofincreasingcoststhecompanystrivestomaintainitsprofitmarginsthroughcostreductionprograms productivityimprovementsandperiodicpriceincreases russiaukrainewar althoughthelongtermimplicationsofrussiasinvasionofukrainearedifficulttopredictatthistimethefinancialimpact oftheconflictinthefiscalincludingaccountsreceivableorinventoryreserveswasnotmaterialasofboththefiscal yearsendingjanuaryandjanuarythebusinessofthecompanysukrainesubsidiariesrepresentedless thanofthecompanysconsolidatedassetsandrevenuesasofboththefiscalyearsendingjanuaryand januarythebusinessofthecompanysrussiansubsidiariesrepresentedlessthanofthecompanys consolidatedassetsandrepresentedofrevenues inearlymarchthecompanytookstepstosuspendalladvertisingenrollmentinclinicaltrialsandanyadditional investmentinrussiaadditionallyattheendofmarchthecompanymadethedecisiontosuspendsupplyofpersonal johnsonjohnsonannualreport careproductsinrussiathecompanycontinuestosupplyitsotherproductsaspatientsrelyonmanyoftheproductsfor healthcarepurposes thecompanyisexposedtofluctuationsincurrencyexchangeratesachangeinthevalueoftheusdollaras comparedtoallforeigncurrenciesinwhichthecompanyhadsalesincomeorexpenseinwouldhaveincreasedor decreasedthetranslationofforeignsalesbyapproximatelybillionandnetincomebyapproximatelybillion governmentsaroundtheworldconsidervariousproposalstomakechangestotaxlawswhichmayincludeincreasingor decreasingexistingstatutorytaxratesinconnectionwithvariousgovernmentinitiativescompaniesarerequiredto disclosemoreinformationtotaxauthoritiesonoperationsaroundtheworldwhichmayleadtogreaterauditscrutinyof profitsearnedinothercountriesachangeinstatutorytaxrateinanycountrywouldresultintherevaluationofthe companysdeferredtaxassetsandliabilitiesrelatedtothatparticularjurisdictionintheperiodinwhichthenewtaxlawis enactedthischangewouldresultinanexpenseorbenefitrecordedtothecompanysconsolidatedstatementof earningsthecompanycloselymonitorstheseproposalsastheyariseinthecountrieswhereitoperateschangestothe statutorytaxratemayoccuratanytimeandanyrelatedexpenseorbenefitrecordedmaybematerialtothefiscalquarter andyearinwhichthelawchangeisenacted thecompanyfacesvariousworldwidehealthcarechangesthatmaycontinuetoresultinpricingpressuresthatinclude healthcarecostcontainmentandgovernmentlegislationrelatingtosalespromotionspricingandreimbursementof healthcareproducts changesinthebehaviorandspendingpatternsofpurchasersofhealthcareproductsandservicesincludingdelaying medicalproceduresrationingprescriptionmedicationsreducingthefrequencyofphysicianvisitsandforegoing healthcareinsurancecoverageasaresultofthecurrentglobaleconomicdownturnmaycontinuetoimpactthe companysbusinesses thecompanyalsooperatesinanenvironmentincreasinglyhostiletointellectualpropertyrightsfirmshavefiled abbreviatednewdrugapplicationsorbiosimilarbiologicalproductapplicationswiththeusfdaorotherwise challengedthecoverageandorvalidityofthecompanyspatentsseekingtomarketgenericorbiosimilarformsofmany ofthecompanyskeypharmaceuticalproductspriortoexpirationoftheapplicablepatentscoveringthoseproductsinthe eventthecompanyisnotsuccessfulindefendingthepatentclaimschallengedintheresultinglawsuitsgenericor biosimilarversionsoftheproductsatissuewillbeintroducedtothemarketresultinginthepotentialforsubstantialmarket shareandrevenuelossesforthoseproductsandwhichmayresultinanoncashimpairmentchargeinanyassociated intangibleassetthereisalsoariskthatoneormorecompetitorscouldlaunchagenericorbiosimilarversionofthe productatissuefollowingregulatoryapprovaleventhoughoneormorevalidpatentsareinplace legalproceedings johnsonjohnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability intellectualpropertycommercialemploymentindemnificationandothermattersgovernmentalinvestigationsandother legalproceedingsthatarisefromtimetotimeintheordinarycourseofbusiness thecompanyrecordsaccrualsforlosscontingenciesassociatedwiththeselegalmatterswhenitisprobablethata liabilitywillbeincurredandtheamountofthelosscanbereasonablyestimatedasofjanuarythecompanyhas determinedthattheliabilitiesassociatedwithcertainlitigationmattersareprobableandcanbereasonablyestimatedthe companyhasaccruedforthesemattersandwillcontinuetomonitoreachrelatedlegalissueandadjustaccrualsasmight bewarrantedbasedonnewinformationandfurtherdevelopmentsinaccordancewithascfortheseand otherlitigationandregulatorymattersdiscussedbelowforwhichalossisprobableorreasonablypossiblethecompany isunabletoestimatethepossiblelossorrangeoflossbeyondtheamountsaccruedamountsaccruedforlegal contingenciesoftenresultfromacomplexseriesofjudgmentsaboutfutureeventsanduncertaintiesthatrelyheavilyon estimatesandassumptionsincludingtimingofrelatedpaymentstheabilitytomakesuchestimatesandjudgmentscanbe affectedbyvariousfactorsincludingamongotherthingswhetherdamagessoughtintheproceedingsare unsubstantiatedorindeterminatescientificandlegaldiscoveryhasnotcommencedorisnotcompleteproceedingsarein earlystagesmatterspresentlegaluncertaintiestherearesignificantfactsindisputeproceduralorjurisdictionalissues theuncertaintyandunpredictabilityofthenumberofpotentialclaimsabilitytoachievecomprehensivemultiparty settlementscomplexityofrelatedcrossclaimsandcounterclaimsandortherearenumerouspartiesinvolvedtothe extentadverseawardsjudgmentsorverdictshavebeenrenderedagainstthecompanythecompanydoesnotrecordan accrualuntilalossisdeterminedtobeprobableandcanbereasonablyestimated johnsonjohnsonannualreportinthecompanysopinionbasedonitsexaminationofthesemattersitsexperiencetodateanddiscussionswithcounsel theultimateoutcomeoflegalproceedingsnetofliabilitiesaccruedinthecompanysbalancesheetisnotexpectedto haveamaterialadverseeffectonthecompanysfinancialpositionhowevertheresolutionoforincreaseinaccrualsfor oneormoreofthesemattersinanyreportingperiodmayhaveamaterialadverseeffectonthecompanysresultsof operationsandcashflowsforthatperiod seenotetotheconsolidatedfinancialstatementsincludedinitemofthisreportforfurtherinformationregarding legalproceedings commonstock thecompanyscommonstockislistedonthenewyorkstockexchangeunderthesymboljnjasoffebruary therewererecordholdersofcommonstockofthecompany item quantitative qualitative disclosures market risk theinformationcalledforbythisitemisincorporatedhereinbyreferencetoitemmanagementsdiscussionand analysisofresultsofoperationsandfinancialconditionliquidityandcapitalresourcesfinancingandmarket riskofthisreportandnotesummaryofsignificantaccountingpoliciesfinancialinstrumentsofthenotesto consolidatedfinancialstatementsincludedinitemofthisreport item financial statements supplementary data indextoauditedconsolidatedfinancialstatements consolidatedbalancesheets consolidatedstatementsofearnings consolidatedstatementsofcomprehensiveincome consolidatedstatementsofequity consolidatedstatementsofcashflows notestoconsolidatedfinancialstatements reportofindependentregisteredpublicaccountingfirmpcaobid managementsreportoninternalcontroloverfinancialreporting johnsonjohnsonannualreport johnson johnson subsidiaries consolidated balance sheets atjanuaryandjanuary dollarsinmillionsexceptshareandpershareamountsnote assets currentassets cashandcashequivalentsnotesand marketablesecuritiesnotesand accountsreceivabletradelessallowancesfordoubtfulaccounts inventoriesnotesand prepaidexpensesandotherreceivables totalcurrentassets propertyplantandequipmentnetnotesand intangibleassetsnetnotesand goodwillnotesand deferredtaxesonincomenote otherassets totalassets liabilitiesandshareholdersequity currentliabilities loansandnotespayablenote accountspayable accruedliabilities accruedrebatesreturnsandpromotions accruedcompensationandemployeerelatedobligations accruedtaxesonincomenote totalcurrentliabilities longtermdebtnote deferredtaxesonincomenote employeerelatedobligationsnotesand longtermtaxespayablenote otherliabilities totalliabilities commitmentsandcontingenciesnote shareholdersequity preferredstockwithoutparvalueauthorizedandunissuedshares commonstockparvaluepersharenoteauthorizedsharesissued shares accumulatedothercomprehensiveincomelossnote retainedearnings lesscommonstockheldintreasuryatcostnotesharesandshares totalshareholdersequity totalliabilitiesandshareholdersequity seenotestoconsolidatedfinancialstatements johnsonjohnsonannualreportjohnson johnson subsidiaries consolidated statements earnings dollarsandsharesinmillionsexceptpershareamountsnote salestocustomers costofproductssold grossprofit sellingmarketingandadministrativeexpenses researchanddevelopmentexpense inprocessresearchanddevelopmentnote interestincome interestexpensenetofportioncapitalizednote otherincomeexpensenet restructuringnote earningsbeforeprovisionfortaxesonincome provisionfortaxesonincomenote netearnings netearningspersharenotesand basic diluted averagesharesoutstandingnotesand basic diluted seenotestoconsolidatedfinancialstatements johnsonjohnsonannualreport johnson johnson subsidiaries consolidated statements comprehensive income dollarsinmillionsnote netearnings othercomprehensiveincomelossnetoftax foreigncurrencytranslation securities unrealizedholdinggainlossarisingduringperiod reclassificationstoearnings netchange employeebenefitplans priorservicecreditcostnetofamortization gainlossnetofamortization effectofexchangerates netchange derivativeshedges unrealizedgainlossarisingduringperiod reclassificationstoearnings netchange othercomprehensiveincomeloss comprehensiveincome thetaxeffectsinothercomprehensiveincomeforthefiscalyearsandrespectivelyforeigncurrency translationmillionmillionandmillionsecuritiesmillionandmillioninand employeebenefitplansmillionmillionandmillionderivativeshedgesmillionmillion andmillion seenotestoconsolidatedfinancialstatements johnsonjohnsonannualreportjohnson johnson subsidiaries consolidated statements equity dollarsinmillionsnote accumulated common stock treasury retained comprehensive issued stock total earnings incomeloss amount amount balancedecember netearnings cashdividendspaidpershare employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomelossnetoftax balancejanuary netearnings cashdividendspaidpershare employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomelossnetoftax balancejanuary netearnings cashdividendspaidpershare employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomelossnetoftax balancejanuary seenotestoconsolidatedfinancialstatements johnsonjohnsonannualreport johnson johnson subsidiaries consolidated statements cash flows dollarsinmillionsnote cashflowsfromoperatingactivities netearnings adjustmentstoreconcilenetearningstocashflowsfromoperatingactivities depreciationandamortizationofpropertyandintangibles stockbasedcompensation assetwritedowns contingentconsiderationreversal netgainonsaleofassetsbusinesses deferredtaxprovision creditlossesandaccountsreceivableallowances changesinassetsandliabilitiesnetofeffectsfromacquisitionsanddivestitures increasedecreaseinaccountsreceivable increaseininventories increaseinaccountspayableandaccruedliabilities decreaseincreaseinothercurrentandnoncurrentassets decreaseincreaseinothercurrentandnoncurrentliabilities netcashflowsfromoperatingactivities cashflowsfrominvestingactivities additionstopropertyplantandequipment proceedsfromthedisposalofassetsbusinessesnet acquisitionsnetofcashacquirednote purchasesofinvestments salesofinvestments creditsupportagreementsactivitynet otherprimarilylicensesandmilestones netcashusedbyinvestingactivities cashflowsfromfinancingactivities dividendstoshareholders repurchaseofcommonstock proceedsfromshorttermdebt repaymentofshorttermdebt proceedsfromlongtermdebtnetofissuancecosts repaymentoflongtermdebt proceedsfromtheexerciseofstockoptionsemployeewithholdingtaxonstockawardsnet creditsupportagreementsactivitynet netcashusedbyfinancingactivities effectofexchangeratechangesoncashandcashequivalents decreaseincreaseincashandcashequivalents cashandcashequivalentsbeginningofyearnote cashandcashequivalentsendofyearnote supplementalcashflowdata cashpaidduringtheyearfor interest interestnetofamountcapitalized incometaxes supplementalscheduleofnoncashinvestingandfinancingactivities treasurystockissuedforemployeecompensationandstockoptionplansnetofcashproceedsemployee withholdingtaxonstockawards conversionofdebt acquisitions fairvalueofassetsacquired fairvalueofliabilitiesassumed netcashpaidforacquisitionsnote seenotestoconsolidatedfinancialstatements johnsonjohnsonannualreportnotes consolidated financial statements summary significant accounting policies principlesofconsolidation theconsolidatedfinancialstatementsincludetheaccountsofjohnsonjohnsonanditssubsidiariesthecompany intercompanyaccountsandtransactionsareeliminatedcolumnsandrowswithintablesmaynotaddduetorounding percentageshavebeencalculatedusingactualnonroundedfigures descriptionofthecompanyandbusinesssegments thecompanyhasapproximatelyemployeesworldwideengagedintheresearchanddevelopmentmanufacture andsaleofabroadrangeofproductsinthehealthcarefieldthecompanyconductsbusinessinvirtuallyallcountriesof theworldanditsprimaryfocusisonproductsrelatedtohumanhealthandwellbeing thecompanyisorganizedintothreebusinesssegmentsconsumerhealthpharmaceuticalandmedtechthe consumerhealthsegmentincludesabroadrangeofproductsusedinthebabycareoralcareskinhealthbeauty overthecounterpharmaceuticalwomenshealthandwoundcaremarketstheseproductsaremarketedtothe generalpublicandsoldonlineecommerceandtoretailoutletsanddistributorsthroughouttheworldthe pharmaceuticalsegmentisfocusedonthefollowingtherapeuticareasincludingimmunologyinfectiousdiseases neuroscienceoncologypulmonaryhypertensionandcardiovascularandmetabolicdiseasesproductsinthissegment aredistributeddirectlytoretailerswholesalersdistributorshospitalsandhealthcareprofessionalsforprescriptionuse themedtechsegmentincludesabroadportfolioofproductsusedintheorthopaedicsurgeryinterventionalsolutions cardiovascularandneurovascularandvisionfieldstheseproductsaredistributedtowholesalershospitalsandretailers andusedprincipallyintheprofessionalfieldsbyphysiciansnurseshospitalseyecareprofessionalsandclinics innovemberthecompanyannounceditsintentiontoseparatethecompanysconsumerhealthbusinesskenvue asthenamefortheplannednewconsumerhealthcompanywiththeintentiontocreateanewpubliclytraded companybytheendofthefiscalyear newaccountingstandards recentlyadoptedaccountingstandards therewerenonewmaterialaccountingstandardsadoptedinfiscal recentlyissuedaccountingstandards notadoptedasofjanuary asuliabilitiessupplierfinanceprogramstopicdisclosureofsupplierfinanceprogram obligations thisupdaterequiresthatabuyerinasupplierfinanceprogramdiscloseadditionalinformationabouttheprogramtoallow financialstatementuserstobetterunderstandtheeffectoftheprogramsonanentitysworkingcapitalliquidityandcash flowsthisupdatewillbeeffectiveforthecompanyforfiscalyearsbeginningafterdecemberexceptforthe amendmentonrollforwardinformationwhichiseffectiveforfiscalyearsbeginningafterdecemberearly adoptionispermittedthecompanyiscurrentlyassessingtheimpactofthisupdateonitsdisclosuresandwilladoptthis standardinthefiscalfirstquarterof cashequivalents thecompanyclassifiesallhighlyliquidinvestmentswithstatedmaturitiesofthreemonthsorlessfromdateofpurchase ascashequivalentsandallhighlyliquidinvestmentswithstatedmaturitiesofgreaterthanthreemonthsfromthedateof purchaseascurrentmarketablesecuritiesthecompanyhasapolicyofmakinginvestmentsonlywithcommercial institutionsthathaveatleastaninvestmentgradecreditratingthecompanyinvestsitscashprimarilyingovernment securitiesandobligationscorporatedebtsecuritiesmoneymarketfundsandreverserepurchaseagreementsrras rrasarecollateralizedbydepositsintheformofgovernmentsecuritiesandobligationsforanamountnotlessthan oftheirvaluethecompanydoesnotrecordanassetorliabilityasthecompanyisnotpermittedtosellor johnsonjohnsonannualreport repledgetheassociatedcollateralthecompanyhasapolicythatthecollateralhasatleastanaorequivalentcredit ratingthecompanyutilizesathirdpartycustodiantomanagetheexchangeoffundsandensurethatcollateralreceivedis maintainedatofthevalueoftherrasonadailybasisrraswithstatedmaturitiesofgreaterthanthreemonths fromthedateofpurchaseareclassifiedasmarketablesecurities investments investmentsclassifiedasheldtomaturityinvestmentsarereportedatamortizedcostandrealizedgainsorlossesare reportedinearningsinvestmentsclassifiedasavailableforsaledebtsecuritiesarecarriedatestimatedfairvaluewith unrealizedgainsandlossesrecordedasacomponentofaccumulatedothercomprehensiveincomeavailableforsale securitiesavailableforcurrentoperationsareclassifiedascurrentassetsotherwisetheyareclassifiedaslongterm managementdeterminestheappropriateclassificationofitsinvestmentindebtandequitysecuritiesatthetimeof purchaseandreevaluatessuchdeterminationateachbalancesheetdatethecompanyreviewsitsinvestmentsfor impairmentandadjuststheseinvestmentstofairvaluethroughearningsasrequired propertyplantandequipmentanddepreciation propertyplantandequipmentarestatedatcostthecompanyutilizesthestraightlinemethodofdepreciationoverthe estimatedusefullivesoftheassets buildingandbuildingequipment years landandleaseholdimprovements years machineryandequipment years thecompanycapitalizescertaincomputersoftwareanddevelopmentcostsincludedinmachineryandequipmentwhen incurredinconnectionwithdevelopingorobtainingcomputersoftwareforinternalusecapitalizedsoftwarecostsare amortizedovertheestimatedusefullivesofthesoftwarewhichgenerallyrangefromtoyears thecompanyreviewslonglivedassetstoassessrecoverabilityusingundiscountedcashflowswhencertaineventsor changesinoperatingoreconomicconditionsoccuranimpairmentassessmentmaybeperformedontherecoverabilityof thecarryingvalueoftheseassetsiftheassetisdeterminedtobeimpairedthelossismeasuredbasedonthedifference betweentheassetsfairvalueanditscarryingvalueifquotedmarketpricesarenotavailablethecompanywillestimate fairvalueusingadiscountedvalueofestimatedfuturecashflows revenue recognition thecompanyrecognizesrevenuefromproductsaleswhenobligationsunderthetermsofacontractwiththecustomer aresatisfiedgenerallythisoccurswiththetransferofcontrolofthegoodstocustomersthecompanysglobalpayment termsaretypicallybetweentodaysprovisionsforcertainrebatessalesincentivestradepromotionscoupons productreturnsdiscountstocustomersandgovernmentalclawbackprovisionsareaccountedforasvariable considerationandrecordedasareductioninsalestheliabilityisrecognizedwithinaccruedrebatesreturnsand promotionsontheconsolidatedbalancesheet productdiscountsgrantedarebasedonthetermsofarrangementswithdirectindirectandothermarketparticipantsas wellasmarketconditionsincludingconsiderationofcompetitorpricingrebatesareestimatedbasedoncontractual termshistoricalexperiencepatientoutcomestrendanalysisandprojectedmarketconditionsinthevariousmarkets servedasignificantportionoftheliabilityrelatedtorebatesisfromthesaleofthecompanyspharmaceuticalproducts withintheusprimarilythemanagedcaremedicareandmedicaidprogramswhichamountedtobillionand billionasofjanuaryandjanuaryrespectivelythecompanyevaluatesmarketconditionsfor productsorgroupsofproductsprimarilythroughtheanalysisofwholesalerandotherthirdpartysellthroughandmarket researchdataaswellasinternallygeneratedinformation salesreturnsareestimatedandrecordedbasedonhistoricalsalesandreturnsinformationproductsthatexhibitunusual salesorreturnpatternsduetodatingcompetitionorothermarketingmattersarespecificallyinvestigatedandanalyzedas partoftheaccountingforsalesreturnaccruals johnsonjohnsonannualreportsalesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpirationdestructioninthefield orinspecificareasproductrecallthesalesreturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarket asapercenttogrosssalesinaccordancewiththecompanysaccountingpoliciesthecompanygenerallyissuescredit tocustomersforreturnedgoodsthecompanyssalesreturnsreservesareaccountedforinaccordancewiththe usgaapguidanceforrevenuerecognitionwhenrightofreturnexistssalesreturnsreservesarerecordedatfullsales valuesalesreturnsintheconsumerhealthandpharmaceuticalsegmentsarealmostexclusivelynotresalablesales returnsforcertainfranchisesinthemedtechsegmentaretypicallyresalablebutarenotmaterialthecompany infrequentlyexchangesproductsfrominventoryforreturnedproductsthesalesreturnsreserveforthetotalcompanyhas beenapproximatelyofannualnettradesalesduringeachofthefiscalyearsand promotionalprogramssuchasproductlistingallowancesandcooperativeadvertisingarrangementsarerecordedinthe sameperiodasrelatedsalescontinuingpromotionalprogramsincludecouponsandvolumebasedsalesincentive programstheredemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvalue volumebasedincentiveprogramsarebasedontheestimatedsalesvolumesfortheincentiveperiodandarerecordedas productsaresoldthesearrangementsareevaluatedtodeterminetheappropriateamountstobedeferredorrecordedas areductionofrevenuethecompanyalsoearnsprofitsharepaymentsthroughcollaborativearrangementsforcertain productswhichareincludedinsalestocustomersprofitsharepaymentswerelessthanofthetotalrevenuesin fiscalyearandlessthanofthetotalrevenuesinfiscalyearsandandareincludedinsalesto customers seenotetotheconsolidatedfinancialstatementsforfurtherdisaggregationofrevenue shippingandhandling shippingandhandlingcostsincurredwerebillionbillionandbillioninfiscalyearsand respectivelyandareincludedinsellingmarketingandadministrativeexpensetheamountofrevenuereceivedfor shippingandhandlingislessthanofsalestocustomersforallperiodspresented inventories inventoriesarestatedatthelowerofcostornetrealizablevaluedeterminedbythefirstinfirstoutmethod intangibleassetsandgoodwill theauthoritativeliteratureonusgaaprequiresthatgoodwillandintangibleassetswithindefinitelivesbeassessed annuallyforimpairmentthecompanycompleteditsannualimpairmenttestforinthefiscalfourthquarterfuture impairmenttestswillbeperformedannuallyinthefiscalfourthquarterorsoonerifwarrantedpurchasedinprocess researchanddevelopmentisaccountedforasanindefinitelivedintangibleassetuntiltheunderlyingprojectiscompleted atwhichpointtheintangibleassetwillbeaccountedforasadefinitelivedintangibleassetifwarrantedthepurchasedin processresearchanddevelopmentcouldbewrittenofforpartiallyimpaireddependingontheunderlyingprogram intangibleassetsthathavefiniteusefullivescontinuetobeamortizedovertheirusefullivesandarereviewedfor impairmentwhenwarrantedbyeconomicconditionsseenoteforfurtherdetailsonintangibleassetsandgoodwill financialinstruments asrequiredbyusgaapallderivativeinstrumentsarerecordedonthebalancesheetatfairvaluefairvalueistheexit pricethatwouldbereceivedtosellanassetorpaidtotransferaliabilityfairvalueisamarketbasedmeasurement determinedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliabilitytheauthoritativeliterature establishesathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluewithlevelhavingthehighest priorityandlevelhavingthelowestchangesinthefairvalueofderivativesarerecordedeachperiodincurrentearnings orothercomprehensiveincomedependingonwhetherthederivativeisdesignatedaspartofahedgetransactionandif sothetypeofhedgetransaction thecompanydocumentsallrelationshipsbetweenhedgeditemsandderivativestheoverallriskmanagementstrategy includesreasonsforundertakinghedgetransactionsandenteringintoderivativestheobjectivesofthisstrategyare minimizeforeigncurrencyexposuresimpactonthecompanysfinancialperformanceprotectthecompanyscash johnsonjohnsonannualreport flowfromadversemovementsinforeignexchangeratesensuretheappropriatenessoffinancialinstrumentsand managetheenterpriseriskassociatedwithfinancialinstitutionsseenoteforadditionalinformationonfinancial instruments leases thecompanydetermineswhetheranarrangementisaleaseatcontractinceptionbyestablishingifthecontractconveys therighttocontroltheuseofidentifiedpropertyplantorequipmentforaperiodoftimeinexchangeforconsideration rightofuserouassetsandleaseliabilitiesforoperatingleasesareincludedinotherassetsaccruedliabilitiesand otherliabilitiesontheconsolidatedbalancesheettherouassetsrepresenttherighttouseanunderlyingassetforthe leasetermandleaseliabilitiesrepresentanobligationtomakeleasepaymentsarisingfromtheleasecommitmentsunder financeleasesarenotsignificantandareincludedinpropertyplantandequipmentloansandnotespayableandlong termdebtontheconsolidatedbalancesheet rouassetsandleaseliabilitiesarerecognizedattheleasecommencementdatebasedonthepresentvalueofall minimumleasepaymentsovertheleasetermthecompanyusesitsincrementalborrowingratebasedontheinformation availableatcommencementdateindeterminingthepresentvalueofleasepaymentswhentheimplicitrateisnotreadily determinableleasetermsmayincludeoptionstoextendorterminatetheleasetheseoptionsareincludedinthelease termwhenitisreasonablycertainthatthecompanywillexercisethatoptionoperatingleaseexpenseisrecognizedona straightlinebasisovertheleasetermthecompanyhaselectedthefollowingpolicyelectionsonadoptionuseof portfolioapproachonleasesofassetsundermasterserviceagreementsexclusionofshorttermleasesonthebalance sheetandnotseparatingleaseandnonleasecomponents thecompanyprimarilyhasoperatingleaseforspacevehiclesmanufacturingequipmentanddataprocessingequipment therouassetpertainingtooperatingleaseswasbillionandbillioninfiscalyearsand respectivelytheleaseliabilitywasbillionandbillioninfiscalyearsandrespectivelytheoperating leasecostswerebillioninfiscalyearsandrespectivelycashpaidforamountsincludedinthe measurementofleaseliabilitieswerebillioninfiscalyearsandrespectively productliability accrualsforproductliabilityclaimsarerecordedonanundiscountedbasiswhenitisprobablethataliabilityhasbeen incurredandtheamountoftheliabilitycanbereasonablyestimatedbasedonexistinginformationandactuarially determinedestimateswhereapplicabletheaccrualsareadjustedperiodicallyasadditionalinformationbecomes availablethecompanyaccruesanestimateofthelegaldefensecostsneededtodefendeachmatterwhenthosecosts areprobableandcanbereasonablyestimatedtotheextentadverseverdictshavebeenrenderedagainstthecompany thecompanydoesnotrecordanaccrualuntilalossisdeterminedtobeprobableandcanbereasonablyestimated thecompanyhasselfinsurancethroughawhollyownedcaptiveinsurancecompanyinadditiontoaccrualsintheself insuranceprogramclaimsthatexceedtheinsurancecoverageareaccruedwhenlossesareprobableandamountscanbe reasonablyestimated researchanddevelopment researchanddevelopmentexpensesareexpensedasincurredinaccordancewithascresearchand developmentupfrontandmilestonepaymentsmadetothirdpartiesinconnectionwithresearchanddevelopment collaborationsareexpensedasincurreduptothepointofregulatoryapprovalpaymentsmadetothirdpartiessubsequent toregulatoryapprovalarecapitalizedandamortizedovertheremainingusefullifeoftherelatedproductamounts capitalizedforsuchpaymentsareincludedinotherintangiblesnetofaccumulatedamortization thecompanyentersintocollaborativearrangementstypicallywithotherpharmaceuticalorbiotechnologycompaniesto developandcommercializedrugcandidatesorintellectualpropertythesearrangementstypicallyinvolvetwoormore partieswhoareactiveparticipantsinthecollaborationandareexposedtosignificantrisksandrewardsdependentonthe commercialsuccessoftheactivitiesthesecollaborationsusuallyinvolvevariousactivitiesbyoneormoreparties includingresearchanddevelopmentmarketingandsellinganddistributionoftenthesecollaborationsrequireupfront milestoneandroyaltyorprofitsharepaymentscontingentupontheoccurrenceofcertainfutureeventslinkedtothe successoftheassetindevelopmentamountsduefromcollaborativepartnersrelatedtodevelopmentactivitiesare generallyreflectedasareductionofresearchanddevelopmentexpensebecausetheperformanceofcontract johnsonjohnsonannualreportdevelopmentservicesisnotcentraltothecompanysoperationsingeneraltheincomestatementpresentationforthese collaborationsisasfollows naturetypeofcollaboration statementofearningspresentation thirdpartysaleofproductprofitsharepaymentsreceived salestocustomers royaltiesmilestonespaidtocollaborativepartnerpost costofproductssold regulatoryapproval royaltiesreceivedfromcollaborativepartner otherincomeexpensenet upfrontpaymentsmilestonespaidtocollaborativepartner researchanddevelopmentexpense preregulatoryapproval researchanddevelopmentpaymentstocollaborative researchanddevelopmentexpense partner researchanddevelopmentpaymentsreceivedfrom reductionofresearchanddevelopmentexpense collaborativepartnerorgovernmententity milestonesarecapitalizedasintangibleassetsandamortizedtocostofproductssoldovertheusefullife forallyearspresentedtherewasnoindividualprojectthatrepresentedgreaterthanofthetotalannualconsolidated researchanddevelopmentexpense thecompanyhasanumberofproductsandcompoundsdevelopedincollaborationwithstrategicpartnersincluding xareltocodevelopedwithbayerhealthcareagandimbruvicadevelopedincollaborationandcomarketedwith pharmacyclicsllcanabbviecompany separatelythecompanyhasanumberoflicensingarrangementsforproductsandcompoundsincludingdarzalex licensedfromgenmabas advertising costsassociatedwithadvertisingareexpensedintheyearincurredandareincludedinsellingmarketingand administrativeexpensesadvertisingexpensesworldwidewhichcomprisedtelevisionradioprintmediaandinternet advertisingwerebillionbillionandbillioninfiscalyearsandrespectively incometaxes incometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludetheresultsofany differencebetweenusgaapaccountingandtaxreportingrecordedasdeferredtaxassetsorliabilitiesthecompany estimatesdeferredtaxassetsandliabilitiesbasedonenactedtaxregulationsandratesfuturechangesintaxlawsand ratesmayaffectrecordeddeferredtaxassetsandliabilitiesinthefuture thecompanyhasunrecognizedtaxbenefitsforuncertaintaxpositionsthecompanyfollowsusgaapwhich prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof ataxpositiontakenorexpectedtobetakeninataxreturnmanagementbelievesthatchangesintheseestimateswould nothaveamaterialeffectonthecompanysresultsofoperationscashflowsorfinancialposition intheunitedstatesenactedintolawnewustaxlegislationtheustaxcutsandjobsacttcjathislaw includedprovisionsforacomprehensiveoverhaulofthecorporateincometaxcodeincludingareductionofthestatutory corporatetaxratefromtoeffectiveonjanuarythetcjaincludedaprovisionforataxonall previouslyundistributedearningsofuscompanieslocatedinforeignjurisdictionsundistributedearningsintheformof cashandcashequivalentsweretaxedatarateofandallotherearningsweretaxedatarateofthistaxis payableoveryearsandwillnotaccrueinterestthesepaymentsbeganinandwillcontinuethroughthe remainingbalanceattheendofthewasapproximatelybillionofwhichbillionisclassifiedasnoncurrent andreflectedaslongtermtaxespayableonthecompanysbalancesheetthebalanceofthisaccountisrelatedto receivablesfromtaxauthoritiesnotexpectedtobereceivedinthenextmonths thetcjaalsoincludesprovisionsforataxonglobalintangiblelowtaxedincomegiltigiltiisdescribedasthe excessofausshareholderstotalnetforeignincomeoveradeemedreturnontangibleassetsasprovidedbythetcja johnsonjohnsonannualreport injanuarythefasbissuedguidancethatallowscompaniestoelectasanaccountingpolicywhethertorecordthe taxeffectsofgiltiintheperiodthetaxliabilityisgeneratedieperiodcostorprovidefordeferredtaxassetsand liabilitiesrelatedtobasisdifferencesthatexistandareexpectedtoeffecttheamountofgiltiinclusioninfutureyears uponreversaliedeferredmethodthecompanyhaselectedtoaccountforgiltiunderthedeferredmethodthe deferredtaxamountsrecordedarebasedontheevaluationoftemporarydifferencesthatareexpectedtoreverseasgilti isincurredinfutureperiods thecompanyhasrecordeddeferredtaxliabilitiesonallundistributedearningspriortodecemberfromits internationalsubsidiariesthecompanyhasnotprovideddeferredtaxesontheundistributedearningssubsequentto januaryfromcertaininternationalsubsidiarieswheretheearningsareconsideredtobeindefinitelyreinvestedthe companyintendstocontinuetoreinvesttheseearningsinthoseinternationaloperationsifthecompanydecidesata laterdatetorepatriatetheseearningstotheusthecompanywouldberequiredtoprovideforthenettaxeffectson theseamountsthecompanyestimatesthatthetaxeffectofthisrepatriationwouldbeapproximatelybillionunder currentlyenactedtaxlawsandregulationsandatcurrentcurrencyexchangeratesthisamountdoesnotincludethe possiblebenefitofusforeigntaxcreditswhichmaysubstantiallyoffsetthiscost seenotetotheconsolidatedfinancialstatementsforfurtherinformationregardingincometaxes netearningspershare basicearningspershareiscomputedbydividingnetearningsavailabletocommonshareholdersbytheweightedaverage numberofcommonsharesoutstandingfortheperioddilutedearningspersharereflectsthepotentialdilutionthatcould occurifsecuritieswereexercisedorconvertedintocommonstockusingthetreasurystockmethod useofestimates thepreparationofconsolidatedfinancialstatementsinconformitywithaccountingprinciplesgenerallyacceptedinthe usrequiresmanagementtomakeestimatesandassumptionsthataffecttheamountsreportedestimatesareusedwhen accountingforsalesdiscountsrebatesallowancesandincentivesproductliabilitiesincometaxeswithholdingtaxes depreciationamortizationemployeebenefitscontingenciesandintangibleassetandliabilityvaluationsactualresults mayormaynotdifferfromthoseestimates thecompanyfollowstheprovisionsofusgaapwhenrecordinglitigationrelatedcontingenciesaliabilityisrecorded whenalossisprobableandcanbereasonablyestimatedthebestestimateofalosswithinarangeisaccruedhowever ifnoestimateintherangeisbetterthananyothertheminimumamountisaccrued annualclosingdate thecompanyfollowstheconceptofafiscalyearwhichendsonthesundaynearesttotheendofthemonthof decembernormallyeachfiscalyearconsistsofweeksbuteveryfiveorsixyearsthefiscalyearconsistsofweeks andthereforeincludesadditionalshippingdaysaswasthecaseinfiscalyearandwillbethecaseagaininfiscal year reclassification certainpriorperiodamountshavebeenreclassifiedtoconformtocurrentyearpresentation johnsonjohnsonannualreport cash cash equivalents current marketable securities attheendofthefiscalyearandcashcashequivalentsandcurrentmarketablesecuritieswerecomprisedof estimated cash current carrying unrecognized fair cash marketable dollarsinmillions amount loss value equivalents securities cash usreverserepurchaseagreements corporatedebtsecurities moneymarketfunds timedeposits subtotal usgovtsecurities usgovtagencies corporateandotherdebtsecurities subtotalavailableforsale totalcashcashequivalentsandcurrentmarketable securities estimated cash current carrying unrecognized fair cash marketable dollarsinmillions amount loss value equivalents securities cash nonussovereignsecurities usreverserepurchaseagreements corporatedebtsecurities moneymarketfunds timedeposits subtotal usgovtsecurities corporateandotherdebtsecurities subtotalavailableforsale totalcashcashequivalentsandcurrentmarketable securities heldtomaturityinvestmentsarereportedatamortizedcostandrealizedgainsorlossesarereportedinearnings availableforsaledebtsecuritiesarereportedatfairvaluewithunrealizedgainsandlossesreportednetoftaxesinother comprehensiveincome fairvalueofgovernmentsecuritiesandobligationsandcorporatedebtsecuritieswereestimatedusingquotedbroker pricesandsignificantotherobservableinputs johnsonjohnsonannualreport thecontractualmaturitiesoftheavailableforsaledebtsecuritiesatjanuaryareasfollows cost fair dollarsinmillions basis value duewithinoneyear dueafteroneyearthroughfiveyears dueafterfiveyearsthroughtenyears totaldebtsecurities thecompanyinvestsitsexcesscashinbothdepositswithmajorbanksthroughouttheworldandotherhighquality moneymarketinstrumentsthecompanyhasapolicyofmakinginvestmentsonlywithcommercialinstitutionsthathaveat leastaninvestmentgradecreditrating inventories attheendoffiscalyearsandinventorieswerecomprisedof dollarsinmillions rawmaterialsandsupplies goodsinprocess finishedgoods totalinventories property plant equipment attheendoffiscalyearsandpropertyplantandequipmentatcostandaccumulateddepreciationwere dollarsinmillions landandlandimprovements buildingsandbuildingequipment machineryandequipment constructioninprogress totalpropertyplantandequipmentgross lessaccumulateddepreciation totalpropertyplantandequipmentnet thecompanycapitalizesinterestexpenseaspartofthecostofconstructionoffacilitiesandequipmentinterestexpense capitalizedinfiscalyearsandwasmillionmillionandmillionrespectively depreciationexpenseincludingtheamortizationofcapitalizedinterestinfiscalyearsandwas billionbillionandbillionrespectively uponretirementorotherdisposalofpropertyplantandequipmentthecostsandrelatedamountsofaccumulated depreciationoramortizationareeliminatedfromtheassetandaccumulateddepreciationaccountsrespectivelythe differenceifanybetweenthenetassetvalueandtheproceedsarerecordedinearnings johnsonjohnsonannualreport intangible assets goodwill attheendoffiscalyearsandthegrossandnetamountsofintangibleassetswere dollarsinmillions intangibleassetswithdefinitelives patentsandtrademarksgross lessaccumulatedamortization patentsandtrademarksnet customerrelationshipsandotherintangiblesgross lessaccumulatedamortization customerrelationshipsandotherintangiblesnet intangibleassetswithindefinitelives trademarks purchasedinprocessresearchanddevelopment totalintangibleassetswithindefinitelives totalintangibleassetsnet thechangewasprimarilyrelatedtotheintangibleassetsacquiredwiththeacquisitionofabiomedincwhichwaspartiallyoffsetby amortizationexpenseofpreviouslyexistingintangibleassetsandtheresultofcurrencytranslationeffects themajorityiscomprisedofcustomerrelationships thereductionwasprimarilyrelatedtoanintangibleassetimpairmentchargeofapproximatelybillionrecordedinthefiscalyear relatedtoaninprocessresearchanddevelopmentassetbermekimabjnjaninvestigationaldrugforthe treatmentofatopicdermatitisadandhidradenitissuppurativahsacquiredwiththeacquisitionofxbiotechincinthefiscal yearadditionalinformationregardingefficacyoftheadandhsindicationsbecameavailablewhichledthecompanytothe decisiontoterminatethedevelopmentofbermekimabforadandhsanadditionalreductionofbillionwasdrivenbymonarch assetsthatreachedcommercializationandarenowclassifiedashavingdefinitelivesthiswaspartiallyoffsetbyapproximately billionofiprdacquiredwithabiomedinc goodwillasofjanuaryandjanuaryasallocatedbysegmentofbusinesswasasfollows dollarsinmillions consumerhealth pharmaceutical medtech total goodwillatjanuary goodwillrelatedtoacquisitions goodwillrelatedtodivestitures currencytranslationother goodwillatjanuary goodwillrelatedtoacquisitions goodwillrelatedtodivestitures currencytranslationother goodwillatjanuary theweightedaverageamortizationperiodforpatentsandtrademarksisyearstheweightedaverageamortization periodforcustomerrelationshipsandotherintangibleassetsisyearstheamortizationexpenseofamortizableassets includedincostofproductssoldwasbillionbillionandbillionbeforetaxforthefiscalyearsended januaryjanuaryandjanuaryrespectivelyintangibleassetwritedownsareincludedinother incomeexpensenet johnsonjohnsonannualreport theestimatedamortizationexpenseforapprovedproductsbeforetaxforthefivesucceedingyearsisapproximately dollarsinmillions seenotetotheconsolidatedfinancialstatementsforadditionaldetailsrelatedtoacquisitionsanddivestitures fair value measurements thecompanyusesforwardforeignexchangecontractstomanageitsexposuretothevariabilityofcashflowsprimarily relatedtotheforeignexchangeratechangesoffutureintercompanyproductsandthirdpartypurchasesofmaterials denominatedinaforeigncurrencythecompanyusescrosscurrencyinterestrateswapstomanagecurrencyrisk primarilyrelatedtoborrowingsbothtypesofderivativesaredesignatedascashflowhedges additionallythecompanyprimarilyusesinterestrateswapsasaninstrumenttomanageinterestrateriskrelatedtofixed rateborrowingsthesederivativesaredesignatedasfairvaluehedgesthecompanyusescrosscurrencyinterestrate swapsandforwardforeignexchangecontractsdesignatedasnetinvestmenthedgesadditionallythecompanyuses forwardforeignexchangecontractstooffsetitsexposuretocertainforeigncurrencyassetsandliabilitiestheseforward foreignexchangecontractsarenotdesignatedashedgesandthereforechangesinthefairvaluesofthesederivativesare recognizedinearningstherebyoffsettingthecurrentearningseffectoftherelatedforeigncurrencyassetsandliabilities inthefiscalfourthquarterofthecompanyenteredintoforwardstartinginterestrateswapswithnotionalamounts totalingbillionincontemplationofhedginginterestrateriskassociatedwithlongtermfinancingfortheconsumer healthsegmentseparationtheseforwardstartinginterestrateswapsarenotdesignatedashedgesandtherefore changesinthefairvaluesofthesederivativesarerecognizedinearningsattheendofthefiscalyearthechanges infairvaluewasnotmaterialandthereforenotincludedinthetablebelow thecompanydoesnotenterintoderivativefinancialinstrumentsfortradingorspeculativepurposesorthatcontaincredit riskrelatedcontingentfeaturesthecompanymaintainscreditsupportagreementscsawithcertainderivative counterpartiesestablishingcollateralthresholdsbasedonrespectivecreditratingsandnettingagreementsasof januarythetotalamountofcashcollateralpaidbythecompanyunderthecsaamountedtobillionnet relatedtonetinvestmentandcashflowhedgesonanongoingbasisthecompanymonitorscounterpartycreditratings thecompanyconsiderscreditnonperformancerisktobelowbecausethecompanyprimarilyentersintoagreements withcommercialinstitutionsthathaveatleastaninvestmentgradecreditratingrefertothetableonsignificantfinancial assetsandliabilitiesmeasuredatfairvaluecontainedinthisfootnoteforreceivablesandpayableswiththesecommercial institutionsasofjanuarythecompanyhadnotionalamountsoutstandingforforwardforeignexchange contractscrosscurrencyinterestrateswapsandinterestrateswapsofbillionbillionandbillion respectivelyasofjanuarythecompanyhadnotionalamountsoutstandingforforwardforeignexchange contractscrosscurrencyinterestrateswapsandinterestrateswapsofbillionbillionandbillion respectively allderivativeinstrumentsarerecordedonthebalancesheetatfairvaluechangesinthefairvalueofderivativesare recordedeachperiodincurrentearningsorothercomprehensiveincomedependingonwhetherthederivativeis designatedaspartofahedgetransactionandifsothetypeofhedgetransaction thedesignationasacashflowhedgeismadeattheentrancedateofthederivativecontractatinceptionallderivatives areexpectedtobehighlyeffectiveforeignexchangecontractsdesignatedascashflowhedgesareaccountedforunder theforwardmethodandallgainslossesassociatedwiththesecontractswillberecognizedintheincomestatementwhen thehedgeditemimpactsearningschangesinthefairvalueofthesederivativesarerecordedinaccumulatedother comprehensiveincomeuntiltheunderlyingtransactionaffectsearningsandarethenreclassifiedtoearningsinthesame accountasthehedgedtransaction gainsandlossesassociatedwithinterestrateswapsandchangesinfairvalueofhedgeddebtattributabletochangesin interestratesarerecordedtointerestexpenseintheperiodinwhichtheyoccurgainsandlossesonnetinvestment hedgesareaccountedthroughthecurrencytranslationaccountwithinaccumulatedothercomprehensiveincomethe portionexcludedfromeffectivenesstestingisrecordedthroughinterestincomeexpenseusingthespotmethodonan ongoingbasisthecompanyassesseswhethereachderivativecontinuestobehighlyeffectiveinoffsettingchangesof hedgeditemsifandwhenaderivativeisnolongerexpectedtobehighlyeffectivehedgeaccountingisdiscontinued johnsonjohnsonannualreportthecompanydesignateditseurodenominatednotesissuedinmaywithduedatesrangingfromtoas anetinvestmenthedgeofthecompanysinvestmentsincertainofitsinternationalsubsidiariesthatusetheeuroastheir functionalcurrencyinordertoreducethevolatilitycausedbychangesinexchangerates asofjanuarythebalanceofdeferrednetlossonderivativesincludedinaccumulatedothercomprehensive incomewasmillionaftertaxforadditionalinformationseetheconsolidatedstatementsofcomprehensiveincome andnotethecompanyexpectsthatsubstantiallyalloftheamountsrelatedtoforwardforeignexchangecontractswill bereclassifiedintoearningsoverthenextmonthsasaresultoftransactionsthatareexpectedtooccuroverthat periodthemaximumlengthoftimeoverwhichthecompanyishedgingtransactionexposureismonthsexcluding interestratecontractsandnetinvestmenthedgestheamountultimatelyrealizedinearningsmaydifferasforeign exchangerateschangerealizedgainsandlossesareultimatelydeterminedbyactualexchangeratesatmaturityofthe derivative thefollowingtableisasummaryoftheactivityrelatedtoderivativesandhedgesforthefiscalyearsendedjanuary andjanuarynetoftax january january costof interest costof interest products rd income income products rd income income dollarsinmillions sales sold expense expense expense sales sold expense expense expense theeffectsoffairvaluenetinvestmentand cashflowhedging gainlossonfairvaluehedging relationship interestrateswapscontracts hedgeditems derivativesdesignatedashedging instruments gainlossonnetinvestment hedgingrelationship crosscurrencyinterestrateswaps contracts amountofgainorlossrecognizedin incomeonderivativeamountexcluded fromeffectivenesstesting amountofgainorlossrecognizedin aoci gainlossoncashflowhedging relationship forwardforeignexchangecontracts amountofgainorlossreclassifiedfrom aociintoincome amountofgainorlossrecognizedin aoci crosscurrencyinterestrateswaps contracts amountofgainorlossreclassifiedfrom aociintoincome amountofgainorlossrecognizedin aoci johnsonjohnsonannualreport asofjanuaryandjanuarythefollowingamountswererecordedontheconsolidatedbalancesheet relatedtocumulativebasisadjustmentforfairvaluehedges cumulativeamountof fairvaluehedging adjustmentincludedin lineitemintheconsolidatedbalancesheetin carryingamountofthe thecarryingamountof whichthehedgeditemisincluded hedgedliability thehedgedliability january january january january dollarsinmillions longtermdebt thefollowingtableistheeffectofderivativesnotdesignatedashedginginstrumentforthefiscalyearsendedjanuary andjanuary locationofgain gainloss lossrecognizedin recognizedin dollarsinmillions incomeonderivative incomeonderivative derivativesnotdesignatedashedginginstruments january january foreignexchangecontracts otherincomeexpense thefollowingtableistheeffectofnetinvestmenthedgesforthefiscalyearsendedjanuaryandjanuary gainloss gainloss locationofgainorlossreclassified reclassifiedfrom recognizedin fromaccumulatedothercomprehensive accumulatedoci accumulatedoci incomeintoincome intoincome january january january january dollarsinmillions debt interestincomeexpense crosscurrencyinterestrateswaps interestincomeexpense thecompanyholdsequityinvestmentswithreadilydeterminablefairvaluesandequityinvestmentswithoutreadily determinablefairvaluesthecompanymeasuresequityinvestmentsthatdonothavereadilydeterminablefairvaluesat costminusimpairmentifanyplusorminuschangesresultingfromobservablepricechangesinorderlytransactionsfor theidenticalorasimilarinvestmentofthesameissuer thefollowingtableisasummaryoftheactivityrelatedtoequityinvestmentsforthefiscalyearsendedjanuary andjanuary january january non changesinfairvalue current reflectedinnet sales dollarsinmillions carryingvalue income purchasesother carryingvalue assets equityinvestmentswithreadilydeterminable value equityinvestmentswithoutreadily determinablevalue january january non changesinfairvalue current reflectedinnet sales dollarsinmillions carryingvalue income purchasesother carryingvalue assets equityinvestmentswithreadilydeterminable value equityinvestmentswithoutreadily determinablevalue recordedinotherincomeexpense otherincludesimpactofcurrency johnsonjohnsonannualreportforthefiscalyearsendedjanuaryandjanuaryforequityinvestmentswithoutreadilydeterminablemarket valuesmillionandmillionrespectivelyofthechangesinfairvaluereflectedinnetincomeweretheresultof impairmentstherewereoffsettingimpactsofmillionandmillionrespectivelyofchangesinthefairvalue reflectedinnetincomeduetochangesinobservablepricesandgainsonthedisposalofinvestmentstheimpactinfiscal yearwasdrivenbythegainondisposalofthegrailinvestmentinfiscalyearthecompanysoldallofits equityinvestmentsinargenxseforproceedsofbillion fairvalueistheexitpricethatwouldbereceivedtosellanassetorpaidtotransferaliabilityfairvalueisamarketbased measurementdeterminedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliabilityin accordancewithascathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluethelevelswithinthe hierarchyaredescribedbelowwithlevelhavingthehighestpriorityandlevelhavingthelowest thefairvalueofaderivativefinancialinstrumentieforwardforeignexchangecontractsinterestratecontractsisthe aggregationbycurrencyofallfuturecashflowsdiscountedtoitspresentvalueattheprevailingmarketinterestratesand subsequentlyconvertedtotheusdollaratthecurrentspotforeignexchangeratethecompanydoesnotbelievethat fairvaluesofthesederivativeinstrumentsmateriallydifferfromtheamountsthatcouldberealizeduponsettlementor maturityorthatthechangesinfairvaluewillhaveamaterialeffectonthecompanysresultsofoperationscashflowsor financialpositionthecompanyalsoholdsequityinvestmentswhichareclassifiedaslevelanddebtsecuritieswhich areclassifiedaslevelthecompanyholdsacquisitionrelatedcontingentliabilitiesbaseduponcertainregulatoryand commercialeventswhichareclassifiedaslevelwhosevaluesaredeterminedusingdiscountedcashflow methodologiesorsimilartechniquesforwhichthedeterminationoffairvaluerequiressignificantjudgmentorestimations thefollowingthreelevelsofinputsareusedtomeasurefairvalue levelquotedpricesinactivemarketsforidenticalassetsandliabilities levelsignificantotherobservableinputs levelsignificantunobservableinputs thecompanyssignificantfinancialassetsandliabilitiesmeasuredatfairvalueasofthefiscalyearendedjanuary andjanuarywereasfollows dollarsinmillions level level level total total derivativesdesignatedashedginginstruments assets forwardforeignexchangecontracts interestratecontracts total liabilities forwardforeignexchangecontracts interestratecontracts total derivativesnotdesignatedashedginginstruments assets forwardforeignexchangecontracts liabilities forwardforeignexchangecontracts availableforsaleotherinvestments equityinvestments debtsecurities otherliabilities contingentconsideration johnsonjohnsonannualreport grosstonetderivativereconciliation dollarsinmillions totalgrossassets creditsupportagreementcsa totalnetasset totalgrossliabilities creditsupportagreementcsa totalnetliabilities summarizedinformationaboutchangesinliabilitiesforcontingentconsiderationisasfollows dollarsinmillions beginningbalance changesinestimatedfairvalue additions payments endingbalance assetsandliabilitiesareallclassifiedaslevelwiththeexceptionofequityinvestmentsofmillionwhichareclassified aslevelandcontingentconsiderationofmillionclassifiedaslevel includescrosscurrencyinterestrateswapsandinterestrateswaps classifiedasnoncurrentotherassets classifiedascashequivalentsandcurrentmarketablesecurities includesmillionmillionandmillionclassifiedasnoncurrentotherliabilitiesasofjanuaryjanuary andjanuaryrespectivelyincludesmillionmillionandmillionclassifiedascurrentliabilitiesasof januaryjanuaryandjanuaryrespectively ongoingfairvalueadjustmentamountsarerecordedprimarilyinresearchanddevelopmentexpensethecompanyrecordeda contingentconsiderationreversalofmillioninrelatedtothetimingofcertaindevelopmentalmilestonesassociatedwith theaurishealthacquisitionthereversalofthecontingentconsiderationwasrecordedinotherincomeandexpense infiscalyearthecompanyrecordedmillionofcontingentconsiderationrelatedtoabiomed seenotesandforfinancialassetsandliabilitiesheldatcarryingamountontheconsolidatedbalancesheet johnsonjohnsonannualreport borrowings thecomponentsoflongtermdebtareasfollows effective effective dollarsinmillions rate rate notesduebeuro notesdue debenturesdue notesdue notesdue notesduemmeurommeuro notesduemmgbpmmgbp notesdue notesdue notesdue notesdue notesdue notesduemmeurommeuro notesdue notesdue notesdue debenturesdue notesdue notesduebeurobeuro notesdue notesdue notesdue debenturesdue notesdue debenturesdue notesdue notesdue notesdue notesdue notesdue notesdue notesdue notesdue subtotal lesscurrentportion totallongtermdebt weightedaverageeffectiverate translationrateatjanuary translationrateatjanuary johnsonjohnsonannualreport theexcessofthecarryingvalueoverthefairvalueofdebtwasbillionattheendoffiscalyearandtheexcessofthefair valueoverthecarryingvalueofdebtwasbillionattheendoffiscalyear fairvalueofthelongtermdebtwasestimatedusingmarketpriceswhichwerecorroboratedbyquotedbrokerpricesand significantotherobservableinputs thecompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwideinseptemberthe companysecuredanewdaycreditfacilityofbillionwhichexpiresonseptemberinnovember thecompanysecuredanadditionaldaycreditfacilityofbillionwhichexpiresonnovemberinterest chargedonborrowingsunderthecreditlineagreementisbasedoneitherthetermsofrreferencerateorother applicablemarketratesasallowedunderthetermsoftheagreementplusapplicablemarginscommitmentfeesunderthe agreementsarenotmaterial throughoutfiscalyearsandthecompanycontinuedtohaveaccesstoliquiditythroughthecommercialpaper marketshorttermborrowingsandthecurrentportionoflongtermdebtamountedtoapproximatelybillionand billionattheendoffiscalyearsandrespectivelythecurrentportionofthelongtermdebtwas billionandbillioninandrespectivelyandtheremainderiscommercialpaperandlocalborrowingby internationalsubsidiaries thecurrentdebtbalanceasofjanuaryincludesbillionofcommercialpaperwhichhasaweightedaverage interestrateofandaweightedaveragematurityofapproximatelytwomonths aggregatematuritiesoflongtermdebtobligationscommencinginare dollarsinmillions income taxes theprovisionfortaxesonincomeconsistsof dollarsinmillions currentlypayable ustaxes internationaltaxes totalcurrentlypayable deferred ustaxes internationaltaxes totaldeferred provisionfortaxesonincome johnsonjohnsonannualreportacomparisonofincometaxexpenseattheusstatutoryrateofinfiscalyearsandtothe companyseffectivetaxrateisasfollows dollarsinmillions us international earningsbeforetaxesonincome taxrates usstatutoryrate internationaloperations consumerhealthseparation ustaxesoninternationalincome taxbenefitsfromlossoncapitalassets taxbenefitsonsharebasedcompensation allother effectiverate forallperiodspresentedthecompanyhassubsidiariesoperatinginpuertoricoundervarioustaxincentivesinternational operationsreflecttheimpactsofoperationsinjurisdictionswithstatutorytaxratesdifferentthantheusparticularlyireland switzerlandandpuertoricowhichisafavorableimpactontheeffectivetaxrateascomparedwiththeusstatutoryratethe amountsincludethereorganizationofinternationalsubsidiariestheamountsincludetheimpactofthenewtaxlegislation enactmentinswitzerlandbothofwhicharefurtherdescribedbelow includestheimpactofthegiltitaxtheforeignderivedintangibleincomedeductionandotherforeignincomethatistaxableunder theustaxcodetheamountincludestheimpactofcertainprovisionsofthetcjathatbecameeffectiveinfiscal theamountsincludethereorganizationofinternationalsubsidiariestheamountsincludetheimpactofthenewtax legislationenactmentinswitzerlandbothofwhicharefurtherdescribedbelow certainprioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation thefiscalyeareffectivetaxrateincreasedascomparedtothefiscalyeareffectivetaxrateaspartofthe plannedseparationofthecompanysconsumerhealthbusinessthecompanyhasrecognizedapproximatelybillion innetincrementaltaxcostsinfiscalyearwhichincreasedtheeffectivetaxratebyapproximately additionallythecompanyrecordedcertainnonrecurringfavorabletaxitemsinfiscalyearwhichresultedinan unfavorableimpacttothecompanysfiscaleffectivetaxratewhencomparedtothepriorfiscalyeartheseitemsare describedbelowthecompanystaxratealsobenefitedfromcertainprovisionsofthetaxcutsandjobsactof thatbecameeffectiveinfiscaltheimpairmentofbermekimabforadandhsiprdforfurtherinformation seenoteofthekconsolidatedfinancialstatementsandchangesinthefairvalueofsecuritiesinthe companysinvestmentportfoliobothrecordedattheusstatutoryrate thefiscalyeartaxratedecreasedbycomparedtothefiscalyeartaxratewhichwasprimarilydrivenby thefollowingitemsinfiscalyearthecompanyreorganizedtheownershipstructureofcertainwhollyowned internationalsubsidiariesaspartofthisreorganizationthecompanyincreasedthetaxbasisofcertainassetstofairvalue inaccordancewithapplicablelocalregulationsthenetimpactofthisrestructuringwasapproximatelybillionnet benefitorbenefittothecompanysannualeffectivetaxratecomprisedofthefollowingitems approximatelybillionoflocaldeferredtaxassetstorecordtheremeasurementofthetaxbasisoftheseassetsto fairvaluethisbenefithasbeenreflectedasinternationaloperationsonthecompanyseffectivetaxratereconciliation approximatelybillionofusdeferredtaxexpenserelatingtothegiltideferredtaxliabilityresultingfromthe remeasurementofthesedeferredtaxassetsthisexpensehasbeenreflectedasustaxoninternationalincomeon thecompanyseffectivetaxratereconciliation alsointhefiscalfourthquarterofthecompanyrecognizedalossoncertainusaffiliatesrelatedtothepreviously impairedbookvalueofcertainintangibleswhichreducedthetaxratebyapproximatelywhichisreflectedasa johnsonjohnsonannualreport taxbenefitsfromlossoncapitalassetsontheeffectivetaxratereconciliationadditionallyotherfiscalimpactsto theratewereprimarilydrivenbylitigationandacquisitionrelateditemsasfollows thecompanyaccruedadditionallegalexpensesofapproximatelybillionfortalcataneffectivetaxrateof andbillionforrisperdalgynecomastiasettlementsataneffectivetaxrateofseenotetothe consolidatedfinancialstatementsformoredetails thecompanyrecordedapartialiprdchargeofbillionfortheottavaintangibleassetacquiredwiththeauris healthacquisitioninataneffectiverateof infiscalyearswitzerlandenactedthefederalactontaxreformandahvfinancingtrafandbecameeffective forfiscalyearthefederaltransitionalprovisionsoftrafallowcompaniesundercertainconditionstoadjustthe taxbasisincertainassetstofairvalueiestepuptobedepreciatedandamortizedresultinginanincrementalswiss taxdeductionoverthetransitionalperiod trafalsoprovidesforparameterswhichenabletheswisscantonstoestablishlocalizedtaxratesandregulationsfor companiesthenewcantonaltaxparametersincludefavorabletaxbenefitsforpatentsandadditionalresearchand developmenttaxdeductionsthecantonaltransitionalprovisionsoftrafallowedcompaniestoelecteithertaxbasis stepupsimilartothefederaltransitionbenefitoralternativestatutorytaxrateforaperiodnottoexceedyearsthe companyhasoperationslocatedinvariousswisscantons duringthefiscalyearthefinalcantonwherethecompanymaintainssignificantoperationsenactedtraf legislationadditionallythecompanyreceivedrulingsfromtheswissfederalandcantonaltaxauthoritiesintheremaining jurisdictionswhereithassignificantoperationstheserulingsresultedinthecompanyrevisingitsestimateonthetax basisadjustmentiestepupforitsassetsandasaresultthecompanyrecordedadditionaldeferredtaxbenefitsin thecompanyrecognizedanetbenefitinthefiscalyearforswisstaxreformofapproximatelybillionor benefittothecompanysannualeffectivetaxratecomprisedofthefollowingitems approximatelybilliontaxbenefitrelatingtotheremeasurementofswissdeferredtaxassetsandliabilitiesforthe changeinthefederalandcantonaltaxrateswhereenactmentoccurredinthefiscalyearthisbenefithasbeen reflectedasinternationaloperationsonthecompanyseffectivetaxratereconciliation amilliondeferredtaxassetrelatedtotheestimatedvalueofafederaltaxbasisstepupofthecompanysswiss subsidiariesassetsasdescribedabovethisbenefithasbeenreflectedasinternationaloperationsonthecompanys effectivetaxratereconciliation approximatelybillionofusdeferredtaxexpenserelatingtothegiltideferredtaxliabilityresultingfromthe remeasurementoftheswissdeferredtaxassetsandliabilitiesinthefiscalyearthisbenefithasbeenreflectedas ustaxoninternationalincomeonthecompanyseffectivetaxratereconciliation thecompanydoesnotexpecttoreceivefuturerulingsregardingthetransitionalprovisionsoftraf alsointhefiscalyearthecompanyrecognizedacapitallossoncertainusaffiliatesrelatedtothepreviously impairedbookvalueofcertainintangibleswhichreducedthetaxratebyapproximatelywhichisreflectedasa taxbenefitsfromlossoncapitalassetsontheeffectivetaxratereconciliationinadditioninthefiscalyearthe companyhadlowerincomeinhighertaxjurisdictionsprimarilydrivenby theimpactoftheaccrualoflitigationcostsrelatedtotalcforbillionwhichreducedtheusearningsbeforetaxes ataneffectivetaxrateof theaccrualofadditionallegalcostsincludinganadditionalbillionassociatedwitharevisedagreementinprinciple tosettleopioidlitigationataneffectivetaxrateof thecompanyalsoreducedthecontingentconsiderationliabilityrelatedtotheaurishealthacquisitioninand reversedsomeofitsunrecognizedtaxbenefitsduetothecompletionofseveralyearsoftaxexaminationsincertain jurisdictionsduringthefiscalyear johnsonjohnsonannualreporttemporarydifferencesandcarryforwardsattheendoffiscalyearsandwereasfollows deferredtax deferredtax dollarsinmillions asset liability asset liability employeerelatedobligations stockbasedcompensation depreciationofpropertyplantandequipment goodwillandintangibles rdcapitalizedfortax reservesliabilities incomereportedfortaxpurposes netrealizableoperatinglosscarryforwards undistributedforeignearnings globalintangiblelowtaxedincome miscellaneousinternational miscellaneousus totaldeferredincometaxes certainprioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation amountisinclusiveofthebilliondeferredtaxassetestablishedaspartofthereorganizedownershipstructureof certainwhollyownedinternationalsubsidiariesaspreviouslydescribed amountisinclusiveofthebilliondeferredtaxliabilityduetotheacquisitionofabiomed netofvaluationallowancesofbillioninbothand thecompanyhaswhollyownedinternationalsubsidiariesthathavecumulativenetlossesthecompanybelievesthatitis morelikelythannotthatthesesubsidiarieswillgeneratefuturetaxableincomesufficienttoutilizethesedeferredtaxassets howeverincertainjurisdictionsvaluationallowanceshavebeenrecordedagainstdeferredtaxassetsforloss carryforwardsthatarenotmorelikelythannottoberealized thefollowingtablesummarizestheactivityrelatedtounrecognizedtaxbenefits dollarsinmillions beginningofyear increasesrelatedtocurrentyeartaxpositions increasesrelatedtopriorperiodtaxpositions decreasesrelatedtopriorperiodtaxpositions settlements lapseofstatuteoflimitations endofyear theunrecognizedtaxbenefitsofbillionatjanuaryifrecognizedwouldaffectthecompanysannualeffectivetax ratethecompanyconductsbusinessandfilestaxreturnsinnumerouscountriesandcurrentlyhastaxauditsinprogresswith anumberoftaxauthoritieswithrespecttotheunitedstatestheirshascompleteditsauditforthetaxyearsthrough andiscurrentlyauditingtaxyearsthroughinthefiscalyearthecompanymadeitsfinalpaymentsfor approximatelybilliontotheustreasuryrelatedtothefinalsettlementoftaxauditliability inothermajorjurisdictionswherethecompanyconductsbusinesstheyearsthatremainopentotaxauditsgobacktothe yearthecompanybelievesitispossiblethatsometaxauditsmaybecompletedoverthenexttwelvemonthsby taxingauthoritiesinsomejurisdictionsincludingintheunitedstateshoweverthecompanyisnotabletoprovidea reasonablyreliableestimateofthetimingofanyotherfuturetaxpaymentsorchangeinuncertaintaxpositionsifany thecompanyclassifiesliabilitiesforunrecognizedtaxbenefitsandrelatedinterestandpenaltiesaslongtermliabilities interestexpenseandpenaltiesrelatedtounrecognizedtaxbenefitsareclassifiedasincometaxexpensethecompany johnsonjohnsonannualreport recognizedaftertaxinterestexpenseofmillionmillionandmillioninfiscalyearsand respectivelythetotalamountofaccruedinterestwasmillionandmillioninfiscalyearsand respectively employee related obligations attheendoffiscalandfiscalemployeerelatedobligationsrecordedontheconsolidatedbalancesheets dollarsinmillions pensionbenefits postretirementbenefits postemploymentbenefits deferredcompensation totalemployeeobligations lesscurrentbenefitspayable employeerelatedobligationsnoncurrent prepaidemployeerelatedobligationsofmillionandmillionforandrespectivelyareincluded inotherassetsontheconsolidatedbalancesheets pensions benefit plans thecompanysponsorsvariousretirementandpensionplansincludingdefinedbenefitdefinedcontributionand terminationindemnityplanswhichcovermostemployeesworldwidethecompanyalsoprovidespostretirement benefitsprimarilyhealthcaretoalleligibleusretiredemployeesandtheirdependents manyinternationalemployeesarecoveredbygovernmentsponsoredprogramsandthecosttothecompanyisnot significant intheusnonunionpensionbenefitsforemployeeshiredbeforejanuaryareprimarilybasedontheemployees compensationduringthelastfiveyearsbeforeretirementandthenumberofyearsofservicethefinalaveragepay formulauspensionbenefitsforemployeeshiredafterarecalculatedusingadifferentformulabasedonemployee compensationovertotalyearsofservicetheretirementvalueformula injanuarythecompanyannouncedthateffectiveonjanuaryalleligibleusnonunionemployees regardlessofhiredatewillearnbenefitsundertheretirementvalueformulathisamendmentdoesnotaffectthebenefits accruedunderthefinalaveragepayformulaforservicebeforejanuary internationalsubsidiarieshaveplansunderwhichfundsaredepositedwithtrusteesannuitiesarepurchasedundergroup contractsorreservesareprovided thecompanydoesnotfundretireehealthcarebenefitsinadvanceandhastherighttomodifytheseplansinthefuture inandthecompanyuseddecemberanddecemberrespectivelyasthemeasurement dateforallusandinternationalretirementandotherbenefitplans netperiodicbenefitcostsforthecompanysdefinedbenefitretirementplansandotherbenefitplansforand includethefollowingcomponents retirementplans otherbenefitplans dollarsinmillions servicecost interestcost expectedreturnonplanassets amortizationofpriorservicecost recognizedactuariallossesgains curtailmentsandsettlements netperiodicbenefitcostcredit johnsonjohnsonannualreporttheservicecostcomponentofnetperiodicbenefitcostispresentedinthesamelineitemsontheconsolidated statementofearningswhereotheremployeecompensationcostsarereportedincludingcostofproductssoldresearch anddevelopmentexpenseandsellingmarketingandadministrativeexpensesallothercomponentsofnetperiodic benefitcostarepresentedaspartofotherincomeexpensenetontheconsolidatedstatementofearnings unrecognizedgainsandlossesfortheuspensionplansareamortizedovertheaverageremainingfutureserviceforeach planforplanswithnoactiveemployeestheyareamortizedovertheaveragelifeexpectancytheamortizationofgains andlossesfortheotherusbenefitplansisdeterminedbyusingacorridorofthegreaterofthemarketvalueof assetsortheaccumulatedpostretirementbenefitobligationtotalunamortizedgainsandlossesinexcessofthecorridor areamortizedovertheaverageremainingfutureservice priorservicecostsbenefitsfortheuspensionplansareamortizedovertheaverageremainingfutureserviceofplan participantsatthetimeoftheplanamendmentpriorservicecostbenefitfortheotherusbenefitplansisamortizedover theaverageremainingservicetofulleligibilityageofplanparticipantsatthetimeoftheplanamendment thefollowingtablerepresentstheweightedaverageactuarialassumptions retirementplans otherbenefitplans worldwidebenefitplans netperiodicbenefitcost servicecostdiscountrate interestcostdiscountrate rateofincreaseincompensationlevels expectedlongtermrateofreturnonplanassets benefitobligation discountrate rateofincreaseincompensationlevels thecompanysdiscountratesaredeterminedbyconsideringcurrentyieldcurvesrepresentinghighqualitylongterm fixedincomeinstrumentstheresultingdiscountratesareconsistentwiththedurationofplanliabilitiesthecompanys methodologyindeterminingserviceandinterestcostusesdurationspecificspotratesalongthatyieldcurvetotheplans liabilitycashflows theexpectedratesofreturnonplanassetassumptionsrepresentthecompanysassessmentoflongtermreturnson diversifiedinvestmentportfoliosgloballytheassessmentisdeterminedusingprojectionsfromexternalfinancialsources longtermhistoricalaveragesactualreturnsbyassetclassandthevariousassetclassallocationsbymarket thefollowingtabledisplaystheassumedhealthcarecosttrendratesforallindividuals healthcareplans healthcarecosttrendrateassumedfornextyear ratetowhichthecosttrendrateisassumedtodeclineultimatetrend yeartheratereachestheultimatetrendrate johnsonjohnsonannualreport thefollowingtablesetsforthinformationrelatedtothebenefitobligationandthefairvalueofplanassetsatfiscalyearend andforthecompanysdefinedbenefitretirementplansandotherpostretirementplans otherbenefit retirementplans plans dollarsinmillions changeinbenefitobligation projectedbenefitobligationbeginningofyear servicecost interestcost planparticipantcontributions amendments actuarialgainslosses divestituresacquisitions curtailmentssettlementsrestructuring benefitspaidfromplan effectofexchangerates projectedbenefitobligationendofyear changeinplanassets planassetsatfairvaluebeginningofyear actualreturnlossonplanassets companycontributions planparticipantcontributions settlements divestituresacquisitions benefitspaidfromplanassets effectofexchangerates planassetsatfairvalueendofyear fundedstatusendofyear amountsrecognizedinthecompanysbalancesheetconsistofthefollowing noncurrentassets currentliabilities noncurrentliabilities totalrecognizedintheconsolidatedbalancesheetendofyear amountsrecognizedinaccumulatedothercomprehensiveincomeconsistof thefollowing netactuarialloss priorservicecostcredit unrecognizednettransitionobligation totalbeforetaxeffects accumulatedbenefitobligationsendofyear theactuarialgainforretirementplansinandwasprimarilyrelatedtoincreasesindiscountrates johnsonjohnsonannualreportotherbenefit retirementplans plans dollarsinmillions amountsrecognizedinnetperiodicbenefitcostandothercomprehensive income netperiodicbenefitcostcredit netactuarialgainloss amortizationofnetactuarialloss priorservicecostcredit amortizationofpriorservicecostcredit effectofexchangerates totallossincomerecognizedinothercomprehensiveincomebeforetax totalrecognizedinnetperiodicbenefitcostandothercomprehensiveincome thecompanyplanstocontinuetofunditsusqualifiedplanstocomplywiththepensionprotectionactof internationalplansarefundedinaccordancewithlocalregulationsadditionaldiscretionarycontributionsaremadewhen deemedappropriatetomeetthelongtermobligationsoftheplansforcertainplansfundingisnotacommonpracticeas fundingprovidesnoeconomicbenefitconsequentlythecompanyhasseveralpensionplansthatarenotfunded inthecompanycontributedmillionandmilliontoitsusandinternationalpensionplansrespectively thefollowingtabledisplaysthefundedstatusofthecompanysusqualifiednonqualifiedpensionplansand internationalfundedandunfundedpensionplansatdecemberanddecemberrespectively usplans internationalplans qualifiedplans nonqualifiedplans fundedplans unfundedplans dollarsinmillions planassets projectedbenefitobligation accumulatedbenefitobligation overunderfundedstatus projectedbenefitobligation accumulatedbenefitobligation planswithaccumulatedbenefitobligationsinexcessofplanassetshaveanaccumulatedbenefitobligationprojected benefitobligationandplanassetsofbillionbillionandbillionrespectivelyattheendofand billionbillionandbillionrespectivelyattheendof thefollowingtabledisplaystheprojectedfuturebenefitpaymentsfromthecompanysretirementandotherbenefitplans dollarsinmillions projectedfuturebenefitpayments retirementplans otherbenefitplans thefollowingtabledisplaystheprojectedfutureminimumcontributionstotheunfundedretirementplanstheseamounts donotincludeanydiscretionarycontributionsthatthecompanymayelecttomakeinthefuture dollarsinmillions projectedfuturecontributions johnsonjohnsonannualreport eachpensionplanisoverseenbyalocalcommitteeorboardthatisresponsiblefortheoveralladministrationand investmentofthepensionplansindetermininginvestmentpoliciesstrategiesandgoalseachcommitteeorboard considersfactorsincludinglocalpensionrulesandregulationslocaltaxregulationsavailabilityofinvestmentvehicles separateaccountscommingledaccountsinsurancefundsetcfundedstatusoftheplansratioofactivestoretirees durationofliabilitiesandotherrelevantfactorsincludingdiversificationliquidityoflocalmarketsandliquidityofbase currencyamajorityofthecompanyspensionfundsareopentonewentrantsandareexpectedtobeongoingplans permittedinvestmentsareprimarilyliquidandorlistedwithlittlerelianceonilliquidandnontraditionalinvestmentssuch ashedgefunds thecompanysretirementplanassetallocationattheendofandandtargetallocationsforareas follows percentof target planassets allocation worldwideretirementplans equitysecurities debtsecurities totalplanassets determinationoffairvalueofplanassets theplanhasanestablishedandwelldocumentedprocessfordeterminingfairvaluesfairvalueisbaseduponquoted marketpriceswhereavailableiflistedpricesorquotesarenotavailablefairvalueisbaseduponmodelsthatprimarily useasinputsmarketbasedorindependentlysourcedmarketparametersincludingyieldcurvesinterestratesvolatilities equityordebtpricesforeignexchangeratesandcreditcurves whiletheplanbelievesitsvaluationmethodsareappropriateandconsistentwithothermarketparticipantstheuseof differentmethodologiesorassumptionstodeterminethefairvalueofcertainfinancialinstrumentscouldresultinadifferent estimateoffairvalueatthereportingdate valuationhierarchy theauthoritativeliteratureestablishesathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluethelevels withinthehierarchyaredescribedinthetablebelowwithlevelhavingthehighestpriorityandlevelhavingthelowest thenetassetvaluenavisbasedonthevalueoftheunderlyingassetsownedbythefundminusitsliabilitiesandthen dividedbythenumberofsharesoutstanding afinancialinstrumentscategorizationwithinthevaluationhierarchyisbaseduponthelowestlevelofinputthatis significanttothefairvaluemeasurement followingisadescriptionofthevaluationmethodologiesusedfortheinvestmentsmeasuredatfairvalue shortterminvestmentfundscashandquotedshortterminstrumentsarevaluedattheclosingpriceortheamount heldondepositbythecustodianbankotherinvestmentsarethroughinvestmentvehiclesvaluedusingthenav providedbytheadministratorofthefundthenavisaquotedpriceinamarketthatisnotactiveandclassifiedas level governmentandagencysecuritiesalimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedon themajormarketonwhichtheindividualsecuritiesaretradedwherequotedpricesareavailableinanactivemarket theinvestmentsareclassifiedwithinlevelofthevaluationhierarchyifquotedmarketpricesarenotavailableforthe specificsecuritythenfairvaluesareestimatedbyusingpricingmodelsquotedpricesofsecuritieswithsimilar characteristicsordiscountedcashflowswhenquotedmarketpricesforasecurityarenotavailableinanactivemarket theyareclassifiedaslevel debtinstrumentsalimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedonthemajormarket onwhichtheindividualsecuritiesaretradedwherequotedpricesareavailableinanactivemarkettheinvestmentsare classifiedaslevelifquotedmarketpricesarenotavailableforthespecificsecuritythenfairvaluesareestimatedby johnsonjohnsonannualreportusingpricingmodelsquotedpricesofsecuritieswithsimilarcharacteristicsordiscountedcashflowsandareclassified aslevelleveldebtinstrumentsarepricedbasedonunobservableinputs equitysecuritiesequitysecuritiesarevaluedattheclosingpricereportedonthemajormarketonwhichtheindividual securitiesaretradedsubstantiallyallequitysecuritiesareclassifiedwithinlevelofthevaluationhierarchy commingledfundstheseinvestmentvehiclesarevaluedusingthenavprovidedbythefundadministratorassetsin thelevelcategoryhaveaquotedmarketprice otherassetsotherassetsarerepresentedprimarilybylimitedpartnershipstheseinvestmentvehiclesarevalued usingthenavprovidedbythefundadministratorotherassetsthatareexchangelistedandactivelytradedare classifiedaslevelwhileinactivelytradedassetsareclassifiedaslevel thefollowingtablesetsforththeretirementplansinvestmentsmeasuredatfairvalueasofdecemberand december quotedprices significant inactive significant investments marketsfor observable unobservable measuredat identicalassets inputs inputs netasset level level level value totalassets dollarsinmillions shortterminvestmentfunds governmentandagencysecurities debtinstruments equitysecurities commingledfunds otherassets investmentsatfairvalue theactivityforthelevelassetsisnotsignificantforallyearspresented thecompanysotherbenefitplansareunfundedexceptforuscommingledfundslevelofmillionand millionatdecemberanddecemberrespectively thefairvalueofjohnsonjohnsoncommonstockdirectlyheldinplanassetswasmillionoftotalplan assetsatdecemberandmillionoftotalplanassetsatdecember savings plan thecompanyhasvoluntaryksavingsplansdesignedtoenhancetheexistingretirementprogramscoveringeligible employeesthecompanymatchesapercentageofeachemployeescontributionsconsistentwiththeprovisionsofthe planforwhichhesheiseligibletotalcompanymatchingcontributionstotheplansweremillionmillionand millioninfiscalyearsandrespectively johnsonjohnsonannualreport capital treasury stock changesintreasurystockwere treasurystock amountsinmillionsexcepttreasurystocksharesinthousands shares amount balanceatdecember employeecompensationandstockoptionplans repurchaseofcommonstock balanceatjanuary employeecompensationandstockoptionplans repurchaseofcommonstock balanceatjanuary employeecompensationandstockoptionplans repurchaseofcommonstock balanceatjanuary aggregatesharesofcommonstockissuedwereapproximatelysharesattheendoffiscalyears cashdividendspaidwerepershareinfiscalyearcomparedwithdividendsofpershareinfiscalyear andpershareinfiscalyear onjanuarytheboardofdirectorsdeclaredaregularcashdividendofpersharepayableonmarch toshareholdersofrecordasoffebruary onseptemberthecompanyannouncedthatitsboardofdirectorsapprovedasharerepurchaseprogram authorizingthecompanytopurchaseuptobillionofthecompanyssharesofcommonstocksharerepurchases maybemadeatmanagementsdiscretionfromtimetotimeontheopenmarketorthroughprivatelynegotiated transactionstherepurchaseprogramhasnotimelimitandmaybesuspendedforperiodsordiscontinuedatanytime throughjanuaryapproximatelybillionhasbeenrepurchasedundertheprogram accumulated comprehensive income loss componentsofothercomprehensiveincomelossconsistofthefollowing total gainloss accumulated foreign gainloss employee currency benefit derivatives comprehensive dollarsinmillions translation securities plans hedges incomeloss december netchanges january netchanges january netchanges january amountsinaccumulatedothercomprehensiveincomearepresentednetoftherelatedtaximpactforeigncurrency translationisnotadjustedforincometaxeswhereitrelatestopermanentinvestmentsininternationalsubsidiariesfor additionaldetailsoncomprehensiveincomeseetheconsolidatedstatementsofcomprehensiveincome detailsonreclassificationsoutofaccumulatedothercomprehensiveincome gainlossonsecuritiesreclassificationsreleasedtootherincomeexpensenet johnsonjohnsonannualreportemployeebenefitplansreclassificationsareincludedinnetperiodicbenefitcostseenoteforadditionaldetails gainlossonderivativeshedgesreclassificationstoearningsarerecordedinthesameaccountasthehedged transactionseenoteforadditionaldetails international currency translation fortranslationofitssubsidiariesoperatinginnonusdollarcurrenciesthecompanyhasdeterminedthatthelocal currenciesofitsinternationalsubsidiariesarethefunctionalcurrenciesexceptthoseinhighlyinflationaryeconomieswhich aredefinedasthosewhichhavehadcompoundcumulativeratesofinflationoformoreduringthepastthreeyears orwhereasubstantialportionofitscashflowsarenotinthelocalcurrencyforthemajorityofthecompanyssubsidiaries thelocalcurrencyisthefunctionalcurrency inconsolidatinginternationalsubsidiariesbalancesheetcurrencyeffectsarerecordedasacomponentofaccumulated othercomprehensiveincometheothercurrentandnoncurrentassetslinewithinthestatementofcashflowsincludes theimpactofforeigncurrencytranslationthisequityaccountincludestheresultsoftranslatingcertainbalancesheet assetsandliabilitiesatcurrentexchangeratesandsomeaccountsathistoricalratesexceptforthoselocatedinhighly inflationaryeconomiesargentinaandvenezuelabeginninginthefiscalsecondquarterofthecompanyalso accountedforoperationsinturkeyashighlyinflationarythetranslationofbalancesheetaccountsforhighlyinflationary economiesarereflectedintheoperatingresults arollforwardofthechangesduringfiscalyearsandforforeigncurrencytranslationadjustmentsis includedinnote netcurrencytransactiongainsandlossesincludedinotherincomeexpensewerelossesofmillionmillion andmillioninfiscalyearsandrespectively earnings per share thefollowingisareconciliationofbasicnetearningspersharetodilutednetearningspershareforthefiscalyearsended januaryjanuaryandjanuary inmillionsexceptpershareamounts basicnetearningspershare averagesharesoutstandingbasic potentialsharesexercisableunderstockoptionplans lesssharesrepurchasedundertreasurystockmethod adjustedaveragesharesoutstandingdiluted dilutednetearningspershare thedilutednetearningspersharecalculationforthefiscalyearsandincludedallsharesrelatedtostock optionsastheexercisepriceoftheseoptionswaslessthantheaveragemarketvalueofthecompanysstock thedilutednetearningspersharecalculationforfiscalyearexcludedmillionsharesrelatedtostockoptionsas theexercisepriceoftheseoptionswasgreaterthantheaveragemarketvalueofthecompanysstock common stock stock option plans stock compensation agreements atjanuarythecompanyhadonestockbasedcompensationplanthesharesoutstandingareforcontracts underthecompanyslongtermincentiveplanandthelongtermincentiveplanthelongterm incentiveplanexpiredonaprilallawardsstockoptionsrestrictedsharesunitsandperformanceshareunits grantedsubsequenttothatdatewereunderthelongtermincentiveplanunderthelongtermincentive planthecompanymayissueuptomillionsharesofcommonstockofwhichuptomillionsharesofcommon stockmaybeissuedsubjecttostockoptionsorstockappreciationrightsanduptomillionsharesofcommonstock maybeissuedsubjecttofullvalueawardsawardswillgenerallybecountedonaforbasisagainstthesharereserve providedthatifmorethanmillionfullvalueawardsaregrantedeachfullvalueawardinexcessofmillionwillbe countedonaforbasisagainstthesharereservesharesavailableforfuturegrantsunderthelongterm incentiveplanweremillionattheendoffiscalyear johnsonjohnsonannualreport thecompensationcostthathasbeenchargedagainstincomefortheseplanswasmillionmillionand millionforfiscalyearsandrespectivelythetotalincometaxbenefitrecognizedintheincome statementforsharebasedcompensationcostswasmillionmillionandmillionforfiscalyears andrespectivelythecompanyalsorecognizedadditionalincometaxbenefitsofmillionmillion andmillionforfiscalyearsandrespectivelyforwhichoptionswereexercisedorrestrictedshares werevestedthetotalunrecognizedcompensationcostwasmillionmillionandmillionforfiscalyears andrespectivelytheweightedaverageperiodforthiscosttoberecognizedwasyears yearsandyearsforfiscalyearsandrespectivelysharebasedcompensationcosts capitalizedaspartofinventorywereinsignificantinallperiods thecompanysettlesemployeebenefitequityissuanceswithtreasurysharestreasurysharesarereplenishedthrough marketpurchasesthroughouttheyearforthenumberofsharesusedtosettleemployeebenefitequityissuances stockoptions stockoptionsexpireyearsfromthedateofgrantandvestoverserviceperiodsthatrangefrommonthstoyearsall optionsaregrantedattheaverageofthehighandlowpricesofthecompanyscommonstockonthenewyorkstock exchangeonthedateofgrant thefairvalueofeachoptionawardwasestimatedonthedateofgrantusingtheblackscholesoptionvaluationmodel thatusestheassumptionsnotedinthefollowingtableforandgrantsexpectedvolatilityrepresentsa blendedrateofyearweeklyhistoricaloverallvolatilityrateandaweekaverageimpliedvolatilityratebasedonatthe moneytradedjohnsonjohnsonoptionswithalifeofyearsforallgrantshistoricaldataisusedtodeterminethe expectedlifeoftheoptiontheriskfreeratewasbasedontheustreasuryyieldcurveineffectatthetimeofgrant theaveragefairvalueofoptionsgrantedwasandinfiscalyearsand respectivelythefairvaluewasestimatedbasedontheweightedaverageassumptionsof riskfreerate expectedvolatility expectedlifeinyears expecteddividendyield asummaryofoptionactivityundertheplanasofjanuaryjanuaryandjanuaryandchanges duringtheyearsendingonthosedatesispresentedbelow aggregate intrinsic weighted value outstanding average dollarsin sharesinthousands shares exerciseprice millions sharesatdecember optionsgranted optionsexercised optionscanceledforfeited sharesatjanuary optionsgranted optionsexercised optionscanceledforfeited sharesatjanuary optionsgranted optionsexercised optionscanceledforfeited sharesatjanuary johnsonjohnsonannualreportthetotalintrinsicvalueofoptionsexercisedwasmillionmillionandmillioninfiscalyears andrespectively thefollowingtablesummarizesstockoptionsoutstandingandexercisableatjanuary sharesinthousands outstanding exercisable weighted weighted average average average exercise exercise exercisepricerange options life price options price averagecontractualliferemaininginyears stockoptionsoutstandingatjanuaryandjanuarywereandanaveragelifeofyearsand andanaveragelifeofyearsrespectivelystockoptionsexercisableatjanuaryandjanuary wereatanaveragepriceofandatanaveragepriceofrespectively restrictedshareunitsandperformance shareunits thecompanygrantsrestrictedshareunitswhichvestoverserviceperiodsthatrangefrommonthstoyearsthe companyalsograntsperformanceshareunitswhicharepaidinsharesofjohnsonjohnsoncommonstockafterthe endofathreeyearperformanceperiodperformancesharesweregrantedwithtwoequallyweightedgoalsthatdirectly alignwithorhelpdrivelongtermtotalshareholderreturnadjustedoperationalearningspershareandrelativetotal shareholderreturnthenumberofsharesactuallyearnedattheendofthethreeyearperiodwillvarybasedonlyonactual performancefromtoofthetargetnumberofperformanceshareunitsgranted asummaryoftherestrictedshareunitsandperformanceshareunitsactivityundertheplansasofjanuaryis presentedbelow outstanding outstanding restricted performance sharesinthousands shareunits shareunits sharesatjanuary granted issued canceledforfeitedadjusted sharesatjanuary theaveragefairvalueoftherestrictedshareunitsgrantedwasandinfiscalyears andrespectivelyusingthefairmarketvalueatthedateofgrantthefairvalueofrestrictedshareunitswas discountedfordividendswhicharenotpaidontherestrictedshareunitsduringthevestingperiodthefairvalueof restrictedshareunitsissuedwasmillionmillionandmillioninandrespectively theweightedaveragefairvalueoftheperformanceshareunitsgrantedwasandinfiscal yearsandcalculatedusingtheweightedaveragefairmarketvalueforeachofthecomponentgoalsat thedateofgrant thefairvaluesforthesalesandearningspersharegoalsofeachperformanceshareunitwereestimatedonthedateof grantusingthefairmarketvalueofthesharesatthetimeoftheawarddiscountedfordividendswhicharenotpaidonthe performanceshareunitsduringthevestingperiodthefairvaluefortherelativetotalshareholderreturngoalofeach performanceshareunitwasestimatedonthedateofgrantusingthemontecarlovaluationmodelthefairvalueof performanceshareunitsissuedwasmillionmillionandmillioninfiscalyearsand respectively johnsonjohnsonannualreport segments business geographic areas salestocustomers change dollarsinmillions vs vs consumerhealth otc us international worldwide skinhealthbeauty us international worldwide oralcare us international worldwide babycare us international worldwide womenshealth us international worldwide woundcareother us international worldwide totalconsumerhealth us international worldwide johnsonjohnsonannualreportsalestocustomers change dollarsinmillions vs vs pharmaceutical immunology us international worldwide remicade us usexports international worldwide simponisimponiaria us international worldwide stelara us international worldwide tremfya us international worldwide otherimmunology us international worldwide infectiousdiseases us international worldwide covidvaccine us international worldwide edurantrilpivirine us international worldwide prezistaprezcobixrezolstasymtuza us international worldwide johnsonjohnsonannualreport salestocustomers change dollarsinmillions vs vs otherinfectiousdiseases us international worldwide neuroscience us international worldwide concertamethylphenidate us international worldwide invegasustennaxeplioninvegatrinzatrevicta us international worldwide risperdalconsta us international worldwide otherneuroscience us international worldwide oncology us international worldwide darzalex us international worldwide erleada us international worldwide imbruvica us international worldwide zytigaabirateroneacetate us international worldwide johnsonjohnsonannualreportsalestocustomers change dollarsinmillions vs vs otheroncology us international worldwide pulmonaryhypertension us international worldwide opsumit us international worldwide uptravi us international worldwide us international worldwide cardiovascularmetabolismother us international worldwide xarelto us international worldwide invokanainvokamet us international worldwide us international worldwide totalpharmaceutical us international worldwide johnsonjohnsonannualreport salestocustomers change dollarsinmillions vs vs medtech interventionalsolutions us international worldwide orthopaedics us international worldwide hips us international worldwide knees us international worldwide trauma us international worldwide spinesportsother us international worldwide surgery us international worldwide advanced us international worldwide general us international worldwide vision us international worldwide contactlensesother us international worldwide johnsonjohnsonannualreportsalestocustomers change dollarsinmillions vs vs surgical us international worldwide totalmedtech us international worldwide worldwide us international worldwide certainprioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation percentagegreaterthanornotmeaningful approximatelybillioninboththefiscalandofcertaininternationalotcproductsprimarilyinchinawere reclassifiedfromthepharmaceuticalsegmenttotheconsumerhealthsegmentbasedonoperationalchanges inclusiveofprocriteprexwhichwaspreviouslydisclosedseparately previouslyreferredtoasmedicaldevices incomelossbeforetax identifiableassets dollarsinmillions consumerhealth pharmaceutical medtech total lessexpensenotallocatedtosegments lessconsumerhealthseparationcosts generalcorporate worldwidetotal incomebeforetaxofapproximatelybillionandbillioninthefiscalyearsandrespectivelyhasbeenreclassified ascertaininternationalotcproductsprimarilyinchinawerereclassifiedfromthepharmaceuticalsegmenttotheconsumerhealth segmentbasedonoperationalchanges additionstoproperty depreciationand plantequipment amortization dollarsinmillions consumerhealth pharmaceutical medtech segmentstotal generalcorporate worldwidetotal johnsonjohnsonannualreport salestocustomers longlivedassets dollarsinmillions unitedstates europe westernhemisphereexcludingus asiapacificafrica segmentstotal generalcorporate othernonlonglivedassets worldwidetotal seenoteforadescriptionofthesegmentsinwhichthecompanyoperates exportsalesarenotsignificantinfiscalyearthecompanyutilizedthreewholesalersdistributingproductsforall threesegmentsthatrepresentedapproximatelyandofthetotalconsolidatedrevenuesinfiscalyear thecompanyhadthreewholesalersdistributingproductsforallthreesegmentsthatrepresentedapproximately andofthetotalconsolidatedrevenuesinfiscalyearthecompanyhadthreewholesalers distributingproductsforallthreesegmentsthatrepresentedapproximatelyandofthetotal consolidatedrevenues amountsnotallocatedtosegmentsincludeinterestincomeexpenseandgeneralcorporateincomeexpense generalcorporateincludescashcashequivalentsandmarketablesecurities consumerhealthincludes litigationexpenseofbillion arestructuringrelatedchargeofbillion pharmaceuticalincludes onetimecovidvaccinemanufacturingexitrelatedcostsofbillion anintangibleassetimpairmentchargeofapproximatelybillionrelatedtoaninprocessresearchand developmentassetbermekimabjnjaninvestigationaldrugforthetreatmentofatopicdermatitisad andhidradenitissuppurativahsacquiredwiththeacquisitionofxbiotechincinthefiscalyearadditional informationregardingefficacyoftheadandhsindicationsbecameavailablewhichledthecompanytothedecision toterminatethedevelopmentofbermekimabforadandhs litigationexpenseofbillion lossofbillionrelatedtothechangeinthefairvalueofsecurities arestructuringrelatedchargeofbillion medtechincludes litigationexpenseofbillionprimarilyforpelvicmeshrelatedcosts arestructuringrelatedchargeofbillion acquisitionandintegrationrelatedcostsofbillionprimarilyrelatedtotheacquisitionofabiomed amedicaldeviceregulationchargeofbillion consumerhealthincludes litigationexpenseofbillionprimarilytalcrelatedcosts arestructuringrelatedchargeofbillion pharmaceuticalincludes litigationexpenseofbillionprimarilyrelatedtorisperdalgynecomastia divestituregainsofbillion gainsofbillionrelatedtothechangeinthefairvalueofsecurities arestructuringrelatedchargeofbillion johnsonjohnsonannualreportmedtechincludes arestructuringrelatedchargeofbillion aninprocessresearchanddevelopmentexpenseofbillionrelatedtoottava amedicaldeviceregulationchargeofbillion litigationexpenseofbillion consumerhealthincludes litigationexpenseofbillionprimarilytalcrelatedcostsandcertainsettlements pharmaceuticalincludes litigationexpenseofbillionprimarilyrelatedtotheagreementinprincipletosettleopioidlitigation againofbillionrelatedtothechangeinthefairvalueofsecurities arestructuringrelatedchargeofbillion medtechincludes acontingentconsiderationreversalofbillionrelatedtothetimingofcertaindevelopmentalmilestones associatedwiththeaurishealthacquisition litigationexpenseofbillion arestructuringrelatedchargeofbillion aninprocessresearchanddevelopmentexpenseofbillion amedicaldeviceregulationchargeofbillion longlivedassetsincludepropertyplantandequipmentnetforfiscalyearsandofand respectivelyandintangibleassetsandgoodwillnetforfiscalyearsandofand respectively acquisitions divestitures duringthefiscalyearcertainbusinesseswereacquiredforbillionincashandbillionofliabilities assumedtheseacquisitionswereaccountedforusingtheacquisitionmethodandaccordinglyresultsofoperationshave beenincludedinthefinancialstatementsfromtheirrespectivedatesofacquisition theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedtobillionandhas beenassignedtoidentifiableintangibleassetswithanyresidualrecordedtogoodwill thefiscalyearacquisitionsprimarilyincludedabiomedincabiomedtheremainingacquisitionswerenot material ondecemberthecompanycompletedtheacquisitionofabiomedaleadingfirsttomarketproviderof cardiovascularmedicaltechnologywithafirstinkindportfolioforthetreatmentofcoronaryarterydiseaseandheartfailure whichalsohasanextensiveinnovationpipelineoflifesavingtechnologiesthetransactionbroadensthecompanys positionasagrowingcardiovascularinnovatoradvancingthestandardofcareinheartfailureandrecoveryoneof healthcareslargestareasofunmetneedthetransactionwasaccountedforasabusinesscombinationandtheresultsof operationswereincludedinthemedtechsegmentasofthedateoftheacquisitiontheacquisitionwascompleted throughatenderofferforalloutstandingsharestheconsiderationpaidintheacquisitionconsistedofanupfrontpayment ofpershareincashamountingtobillionnetofcashacquiredaswellasanontradeablecontingent valuerightcvrentitlingtheholdertoreceiveuptopershareincashwhichwithrespecttothecvrstotal approximatelybillionintheaggregateifcertaincommercialandclinicalmilestonesareachievedthecorresponding enterprisevaluewithouttakingintoaccountthecvrsofapproximatelybillionincludescashcashequivalentsand marketablesecuritiesacquired themilestonesofthecvrconsistof apersharepayableifnetsalesforabiomedproductsexceedsbillionduringjohnsonjohnsonsfiscal secondquarterofthroughfiscalfirstquarteroforifthisthresholdisnotmetduringthisperiodandis subsequentlymetduringanyrollingfourquarterperioduptotheendofjohnsonjohnsonsfiscalfirstquarterof pershare bpersharepayableuponfdapremarketapplicationapprovaloftheuseofimpellaproductsinstelevated myocardialinfarctionstemipatientswithoutcardiogenicshockbyjanuaryand johnsonjohnsonannualreport cpersharepayableuponthefirstpublicationofaclassirecommendationfortheuseofimpellaproducts inhighriskpciorstemiwithorwithoutcardiogenicshockwithinfouryearsfromtheirrespectiveclinicalendpoint publicationdatesbutinallcasesnolaterthandecember thefairvalueoftheacquisitionwasallocatedtoassetsacquiredofbillionnetofbillioncashacquired primarilytogoodwillforbillionamortizableintangibleassetsforbillioniprdforbillionmarketable securitiesofbillionandliabilitiesassumedofbillionwhichincludesthefairvalueofthecontingent considerationmentionedaboveforbillionanddeferredtaxesofbillionthegoodwillisprimarilyattributableto thecommercialaccelerationandexpansionoftheportfolioandisnotexpectedtobedeductiblefortaxpurposesthe contingentconsiderationwasrecordedinotherliabilitiesontheconsolidatedbalancesheet astheacquisitionoccurredindecemberthecompanyisstillfinalizingtheallocationofthepurchasepricetothe individualassetsacquiredandliabilitiesassumedtheallocationofthepurchasepriceincludedinthecurrentperiod balancesheetisbasedonthebestestimateofmanagementandispreliminaryandsubjecttochangetoassist managementintheallocationthecompanyengagedvaluationspecialiststoprepareappraisalsthecompanywillfinalize theamountsrecognizedastheinformationnecessarytocompletetheanalysisisobtainedthecompanyexpectsto finalizetheseamountsassoonaspossiblebutnolaterthanoneyearfromtheacquisitiondate theamortizableintangibleassetswereprimarilycomprisedofalreadyinmarketproductsoftheimpellaplatformwithan averageweightedlifeofyearstheiprdassetswerevaluedfortechnologyprogramsforunapprovedproductsthe valueoftheiprdwascalculatedusingprobabilityadjustedcashflowprojectionsdiscountedfortheriskinherentinsuch projectstheprobabilityofsuccessfactorrangedfromtothediscountrateappliedwas inthecompanyrecordedacquisitionrelatedcostsbeforetaxofapproximatelybillionwhichwasrecordedin otherincomeexpense duringfiscalyearthecompanydidnotmakeanymaterialacquisitions duringfiscalyearcertainbusinesseswereacquiredforbillionincashandbillionofliabilitiesassumed theseacquisitionswereaccountedforusingtheacquisitionmethodandaccordinglyresultsofoperationshavebeen includedinthefinancialstatementsfromtheirrespectivedatesofacquisition theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedtobillionandhas beenassignedtoidentifiableintangibleassetswithanyresidualrecordedtogoodwill thefiscalyearacquisitionsprimarilyincludedallrightstotheinvestigationalcompoundbermekimabwhichhas multipledermatologicalindicationsalongwithcertainemployeesfromxbiotechincxbiotechmomenta pharmaceuticalsincmomentaacompanythatdiscoversanddevelopsnoveltherapiesforimmunemediateddiseases andtheoutstandingsharesinverbsurgicalincacompanywithsignificantroboticsanddatasciencecapabilities duringthefiscalfirstquarterofthecompanycompletedtheacquisitionofallrightstotheinvestigationalcompound bermekimabwhichhasmultipledermatologicalindicationsalongwithcertainemployeesfromxbiotechincfora purchasepriceofbillionthefairvalueoftheacquisitionwasallocatedprimarilytononamortizableintangibleassets primarilyiprdforbillionapplyingaprobabilityofsuccessfactorthatrangedfromtotoreflectinherent developmentregulatoryandcommercialriskforthedifferentindicationsthediscountrateappliedwasapproximately thetransactionwasaccountedforasabusinesscombinationandincludedinthepharmaceuticalsegmentinfiscal thecompanyrecordedanintangibleassetimpairmentchargeofapproximatelybillionrelatedtothisin processresearchanddevelopmentasset additionallyinthefiscalfirstquarterofthecompanycompletedtheacquisitionofalloutstandingsharesinverb surgicalincacompanywithsignificantroboticsanddatasciencecapabilitiesincludingthosesharespreviouslyheldby verilythetransactionwasaccountedforasabusinesscombinationandincludedinthemedtechsegmentthefairvalue oftheacquisitionwasallocatedprimarilytononamortizableintangibleassetsprimarilyiprdforbilliongoodwillfor billionotherassetsofbillionandliabilitiesassumedofbillionthefairvalueofthecompanyspreviously heldequityinvestmentinverbsurgicalincwasbillion onoctoberthecompanycompletedtheacquisitionofmomentaforapurchasepriceofapproximately billionnetofcashacquiredthefairvalueoftheacquisitionwasallocatedprimarilytononamortizableintangible assetsiprdofbilliongoodwillofbillionotherassetsofbillionandliabilitiesofbilliontheassets acquiredareintendedtoaddresssubstantialunmetmedicalneedinmaternalfetaldisordersneuroinflammatory disordersrheumatologydermatologyandautoimmunehematologydependingontheassetprobabilityofsuccess factorsrangingfromtowereusedinthefairvaluecalculationtoreflectinherentdevelopmentandregulatory johnsonjohnsonannualreportriskoftheiprdthediscountrateappliedwasapproximatelythegoodwillisprimarilyattributabletosynergies expectedtoarisefromthebusinessacquisitionandisnotexpectedtobedeductiblefortaxpurposesthetransactionwas accountedforasabusinesscombinationandincludedinthepharmaceuticalsegment inaccordancewithusgaapstandardsrelatedtobusinesscombinationsandgoodwillandotherintangibleassets supplementalproformainformationforfiscalyearsandisnotprovidedastheimpactofthe aforementionedacquisitionsdidnothaveamaterialeffectonthecompanysresultsofoperations divestitures duringfiscalyearthecompanydidnotmakeanymaterialdivestitures duringfiscalyearinseparatetransactionsthecompanydivestedtwobrandsoutsidetheuswithinthe pharmaceuticalsegmentthecompanyrecognizedapretaxgainrecordedinotherincomeexpensenetof approximatelybillion duringfiscalyearthecompanysoldmillionsharesofidorsialtdidorsiaoritsownershipinthe companyatthattimethetransactionresultedingrossproceedsofapproximatelychfmillionmillionbased onasalespriceofchfshareandresultedinanimmaterialnetlossattheendoffiscalthecompanyhad rightstoapproximatelymillionsharesthroughaconvertibleloanwithaprincipalamountofchfmillionduejune duringfiscalyearthecompanyconvertedchfmillionmillionofthisloanintoapproximately millionsharesofidorsiawhichwerereflectedatfairvalueasofjanuaryduringthefiscalthirdquarterof thecompanysundrawncreditfacilitywithidorsiawasterminated legal proceedings johnsonjohnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability intellectualpropertycommercialindemnificationandothermattersgovernmentalinvestigationsandotherlegal proceedingsthatarisefromtimetotimeintheordinarycourseoftheirbusiness thecompanyrecordsaccrualsforlosscontingenciesassociatedwiththeselegalmatterswhenitisprobablethata liabilitywillbeincurredandtheamountofthelosscanbereasonablyestimatedasofjanuarythecompanyhas determinedthattheliabilitiesassociatedwithcertainlitigationmattersareprobableandcanbereasonablyestimatedthe companyhasaccruedforthesemattersandwillcontinuetomonitoreachrelatedlegalissueandadjustaccrualsasmight bewarrantedbasedonnewinformationandfurtherdevelopmentsinaccordancewithascfortheseand otherlitigationandregulatorymattersdiscussedbelowforwhichalossisprobableorreasonablypossiblethecompany isunabletoestimatethepossiblelossorrangeoflossbeyondtheamountsaccruedamountsaccruedforlegal contingenciesoftenresultfromacomplexseriesofjudgmentsaboutfutureeventsanduncertaintiesthatrelyheavilyon estimatesandassumptionsincludingtimingofrelatedpaymentstheabilitytomakesuchestimatesandjudgmentscanbe affectedbyvariousfactorsincludingamongotherthingswhetherdamagessoughtintheproceedingsare unsubstantiatedorindeterminatescientificandlegaldiscoveryhasnotcommencedorisnotcompleteproceedingsarein earlystagesmatterspresentlegaluncertaintiestherearesignificantfactsindisputeproceduralorjurisdictionalissues theuncertaintyandunpredictabilityofthenumberofpotentialclaimsabilitytoachievecomprehensivemultiparty settlementscomplexityofrelatedcrossclaimsandcounterclaimsandortherearenumerouspartiesinvolvedtothe extentadverseawardsjudgmentsorverdictshavebeenrenderedagainstthecompanythecompanydoesnotrecordan accrualuntilalossisdeterminedtobeprobableandcanbereasonablyestimated inthecompanysopinionbasedonitsexaminationofthesemattersitsexperiencetodateanddiscussionswithcounsel theultimateoutcomeoflegalproceedingsnetofliabilitiesaccruedinthecompanysbalancesheetisnotexpectedto haveamaterialadverseeffectonthecompanysfinancialpositionhowevertheresolutionoforincreaseinaccrualsfor oneormoreofthesemattersinanyreportingperiodmayhaveamaterialadverseeffectonthecompanysresultsof operationsandcashflowsforthatperiod productliability thecompanyandcertainofitssubsidiariesareinvolvedinnumerousproductliabilityclaimsandlawsuitsinvolving multipleproductsclaimantsinthesecasesseeksubstantialcompensatoryandwhereavailablepunitivedamageswhile thecompanybelievesithassubstantialdefensesitisnotfeasibletopredicttheultimateoutcomeoflitigationfromtime totimeevenifithassubstantialdefensesthecompanyconsidersisolatedsettlementsbasedonavarietyof circumstancesthecompanyhasestablishedaccrualsforproductliabilityclaimsandlawsuitsincompliancewith johnsonjohnsonannualreport ascbasedoncurrentlyavailableinformationwhichinsomecasesmaybelimitedthecompanyaccruesan estimateofthelegaldefensecostsneededtodefendeachmatterwhenthosecostsareprobableandcanbereasonably estimatedforcertainofthesemattersthecompanyhasaccruedadditionalamountssuchasestimatedcostsassociated withsettlementsdamagesandotherlossesproductliabilityaccrualscanrepresentprojectedproductliabilityfor thousandsofclaimsaroundtheworldeachindifferentlitigationenvironmentsandwithdifferentfactpatternschangesto theaccrualsmayberequiredinthefutureasadditionalinformationbecomesavailable themostsignificantofthesecasesincludethedepuyasrxlacetabularsystemanddepuyasrhipresurfacing systemthepinnacleacetabularcupsystempelvicmeshesrisperdalbodypowderscontainingtalcprimarily johnsonsbabypowderethiconphysiomeshflexiblecompositemeshelmironandtylenolasof januaryintheunitedstatestherewereapproximatelyplaintiffswithdirectclaimsinpendinglawsuits regardinginjuriesallegedlyduetothedepuyasrxlacetabularsystemanddepuyasrhipresurfacingsystem withrespecttothepinnacleacetabularcupsystemwithrespecttopelvicmesheswithrespectto risperdalwithrespecttobodypowderscontainingtalcwithrespecttoethiconphysiomesh flexiblecompositemeshwithrespecttoelmironandwithrespecttotylenolthenumberofpending lawsuitsisexpectedtofluctuateascertainlawsuitsaresettledordismissedandadditionallawsuitsarefiled inaugustdepuyorthopaedicsincdepuyannouncedaworldwidevoluntaryrecallofitsasrxlacetabular systemanddepuyasrhipresurfacingsystemasrhipusedinhipreplacementsurgeryclaimsforpersonalinjury havebeenmadeagainstdepuyandthecompanycasesfiledinfederalcourtsintheunitedstateshavebeenorganized asamultidistrictlitigationintheunitedstatesdistrictcourtforthenortherndistrictofohiolitigationhasalsobeen filedincountriesoutsideoftheunitedstatesprimarilyintheunitedkingdomcanadaaustraliairelandgermanyindia anditalyinnovemberdepuyreachedanagreementwithacourtappointedcommitteeoflawyersrepresenting asrhipplaintiffstoestablishaprogramtosettleclaimswitheligibleasrhippatientsintheunitedstateswhohad surgerytoreplacetheirasrhipsknownasrevisionsurgeryasofaugustdepuyreachedadditionalagreementsin februaryandmarchwhichfurtherextendedthesettlementprogramtoincludeasrhippatientswhohad revisionsurgeriesafteraugustandpriortofebruarythissettlementprogramhasresolvedmorethan claimstherebybringingtoresolutionsignificantasrhiplitigationactivityintheunitedstateshoweverlawsuits intheunitedstatesremainandthesettlementprogramdoesnotaddresslitigationoutsideoftheunitedstatesin australiaaclassactionsettlementwasreachedthatresolvedtheclaimsofthemajorityofasrhippatientsinthat countryincanadathecompanyhasreachedagreementstosettletheclassactionsfiledinthatcountrythecompany continuestoreceiveinformationwithrespecttopotentialadditionalcostsassociatedwiththisrecallonaworldwidebasis thecompanyhasestablishedaccrualsforthecostsassociatedwiththeunitedstatessettlementprogramandasrhip relatedproductliabilitylitigation claimsforpersonalinjuryhavealsobeenmadeagainstdepuyorthopaedicsincandthecompanycollectivelydepuy relatingtothepinnacleacetabularcupsystemusedinhipreplacementsurgeryproductliabilitylawsuitscontinueto befiledandthecompanycontinuestoreceiveinformationwithrespecttopotentialcostsandtheanticipatednumberof casesmostcasesfiledinfederalcourtsintheunitedstateshavebeenorganizedasamultidistrictlitigationinthe unitedstatesdistrictcourtforthenortherndistrictoftexastexasmdlbeginningonjunethejudicialpanel onmultidistrictlitigationceasedtransferofnewcasesintothetexasmdlandtherearenowcasespendinginfederal courtoutsidethetexasmdllitigationalsohasbeenfiledinstatecourtsandincountriesoutsideoftheunitedstates priortoseveraladverseverdictshadbeenrenderedagainstdepuyoneofwhichwasreversedonappealand remandedforretrialduringthefirstquarterofdepuyestablishedaunitedstatessettlementprogramtoresolve thesecasesaspartofthesettlementprogramadverseverdictshavebeensettledthecompanyhasestablishedan accrualforproductliabilitylitigationassociatedwiththepinnacleacetabularcupsystemandtherelatedsettlement program claimsforpersonalinjuryhavebeenmadeagainstethiconincethiconandthecompanyarisingoutofethiconspelvic meshdevicesusedtotreatstressurinaryincontinenceandpelvicorganprolapsethecompanycontinuestoreceive informationwithrespecttopotentialcostsandadditionalcasescasesfiledinfederalcourtsintheunitedstateshad beenorganizedasamultidistrictlitigationmdlintheunitedstatesdistrictcourtforthesoutherndistrictofwest virginiainmarchthemdlcourtenteredanorderclosingthemdlthemdlcourthasremandedcasesfortrialto thejurisdictionswherethecasewasoriginallyfiledandadditionalpelvicmeshlawsuitshavebeenfiledandremain outsideofthemdlthecompanyhassettledorotherwiseresolvedthemajorityoftheunitedstatescasesandthe estimatedcostsassociatedwiththesesettlementsandtheremainingcasesarereflectedinthecompanysaccrualsin additionclassactionsandindividualpersonalinjurycasesorclaimsseekingdamagesforallegedinjuryresultingfrom ethiconspelvicmeshdeviceshavebeencommencedinvariouscountriesoutsideoftheunitedstatesincludingclaims andcasesintheunitedkingdomthenetherlandsbelgiumfranceirelanditalyspainandsloveniaandclassactionsin israelaustraliacanadaandsouthafricainnovemberthefederalcourtofaustraliaissuedajudgmentregarding johnsonjohnsonannualreportitsfindingswithrespecttoliabilityinrelationtothethreeleadapplicantsandgenerallyinrelationtothedesign manufacturepreandpostmarketassessmentsandtestingandsupplyandpromotionofthedevicesinaustraliausedto treatstressurinaryincontinenceandpelvicorganprolapseinseptemberafterexhaustingitsappealsthecompany reachedaninprincipleagreementtoresolvethetwopelvicmeshclassactionsinaustraliapendingfederalcourt approvalinnovembertheapplicationforapprovalofthesettlementwasfiledandahearingonthesettlementhas beenscheduledfortheendoffebruarytheclassactionsincanadawerediscontinuedinasaresultofa settlementofagroupofcasesandanagreementtoresolvetheisraeliclassactionwasreachedinmaytheparties intheisraeliclassactionarecurrentlyfinalizingthetermsofthesettlementamotiontoapprovethesettlementwasfiled withthecourtthecompanyhasestablishedaccrualswithrespecttoproductliabilitylitigationassociatedwithethicons pelvicmeshproducts followingajuneworldwidemarketwithdrawalofethiconphysiomeshflexiblecompositemesh physiomeshclaimsforpersonalinjuryhavebeenmadeagainstethiconincethiconandthecompanyalleging personalinjuryarisingoutoftheuseofthisherniameshdevicecasesfiledinfederalcourtsintheunitedstateshave beenorganizedasamultidistrictlitigationmdlintheunitedstatesdistrictcourtforthenortherndistrictofgeorgiaa multicountylitigationmclalsohasbeenformedinnewjerseystatecourtandassignedtoatlanticcountyforcases pendinginnewjerseyinadditiontothemattersinthemdlandmclthereareadditionallawsuitspendinginthe unitedstatesdistrictcourtforthesoutherndistrictofohiowhicharepartofthemdlforpolypropylenemeshdevices manufacturedbycrbardincandlawsuitspendingintwonewjerseymclsformedforproceedproceedventral patchandproleneherniasystemsandlawsuitspendingoutsidetheunitedstatesinmayethiconandlead counselfortheplaintiffsenteredintoatermsheettoresolveapproximatelyphysiomeshcasescovering approximatelyplaintiffspendinginthemdlandmclatthattimeamastersettlementagreementmsawas enteredintoinseptemberandincludescasesinthemdlandmclalldeadlinesandtrialsettingsinthose proceedingsarecurrentlystayedpendingthecompletionofthesettlementagreementofthecasessubjecttothemsa havebeendismissedwithprejudicepostsettlementcasesinthephysiomeshmdlandmclaresubjecttodocket controlordersrequiringearlyexpertreportsanddiscoveryrequirementsasofjanuarythereareapproximately activecasessubjecttotheseorderswhicharebeingreviewedandevaluated claimshavealsobeenfiledagainstethiconandthecompanyallegingpersonalinjuriesarisingfromtheproceedmesh andproceedventralpatchherniameshproductsinmarchthenewjerseysupremecourtenteredanorder consolidatingthesecasespendinginnewjerseyasanmclinatlanticcountysuperiorcourtadditionalcaseshave beenfiledinvariousfederalandstatecourtsintheunitedstatesandinjurisdictionsoutsidetheunitedstates ethiconandthecompanyalsohavebeensubjecttoclaimsforpersonalinjuriesarisingfromtheprolenepolypropylene herniasysteminjanuarythenewjerseysupremecourtcreatedanmclinatlanticcountysuperiorcourtto handlesuchcasescasesinvolvingthisproducthavealsobeenfiledinotherfederalandstatecourtsintheunitedstates inoctoberanagreementinprinciplesubjecttovariousconditionswasreachedtosettlethemajorityofthe pendingcasesinvolvingproceedproceedventralpatchproleneherniasystemandrelatedmultilayeredmeshproducts alllitigationactivitiesinthetwonewjerseymclsarestayedpendingresolutionoftheproposedsettlementfuturecases thatarefiledinthenewjerseymclswillbesubjecttodocketcontrolordersrequiringearlyexpertreportsanddiscovery requirements thecompanyhasestablishedaccrualswithrespecttoproductliabilitylitigationassociatedwithethicon physiomeshflexiblecompositemeshproceedmeshandproceedventralpatchandprolenepolypropylene herniasystemproducts claimsforpersonalinjuryhavebeenmadeagainstjanssenpharmaceuticalsincandthecompanyarisingoutoftheuse ofrisperdalandrelatedcompoundsindicatedforthetreatmentofschizophreniaacutemanicormixedepisodes associatedwithbipolaridisorderandirritabilityassociatedwithautismlawsuitsprimarilyhavebeenfiledinstatecourtsin pennsylvaniacaliforniaandmissouriotheractionsarependinginvariouscourtsintheunitedstatesandcanada productliabilitylawsuitscontinuetobefiledandthecompanycontinuestoreceiveinformationwithrespecttopotential costsandtheanticipatednumberofcasesthecompanyhassuccessfullydefendedanumberofthesecasesbutthere havebeenverdictsagainstthecompanyincludingaverdictinoctoberofbillionofpunitivedamagesrelated tooneplaintiffwhichthetrialjudgereducedtomillioninjanuaryinseptemberthecompanyentered intoasettlementinprinciplewiththecounselrepresentingplaintiffsinthismatterandinsubstantiallyalloftheoutstanding casesintheunitedstatesthecostsassociatedwiththisandothersettlementsarereflectedinthecompanysaccruals claimsforpersonalinjuryarisingoutoftheuseofxareltoanoralanticoagulanthavebeenmadeagainstjanssen pharmaceuticalsincjpithecompanyandjpiscollaborationpartnerforxareltobayerhealthcareagandcertain johnsonjohnsonannualreport ofitsaffiliatescasesfiledinfederalcourtsintheunitedstateshavebeenorganizedasamultidistrictlitigationinthe unitedstatesdistrictcourtfortheeasterndistrictoflouisianainadditioncaseswerefiledinstatecourtsacrossthe unitedstatesmanyofthesecaseswereconsolidatedintoastatemasstortlitigationinphiladelphiapennsylvaniaandin acoordinatedproceedinginlosangelescaliforniaclassactionlawsuitsalsohavebeenfiledincanadainmarch jpiandthecompanyannouncedanagreementinprincipletosettlethexareltocasesintheunitedstatesthe settlementagreementwasexecutedinmaythesettlementbecamefinalindecemberandthesettlementwas fundedinjanuarythisresolvedthemajorityofcasespendingintheunitedstatesthecompanyhasestablished accrualsforitscostsassociatedwiththeunitedstatessettlementprogramandxareltorelatedproductliability litigation asignificantnumberofpersonalinjuryclaimsallegingthattalccausescancerweremadeagainstjohnsonjohnson consumerincandthecompanyarisingoutoftheuseofbodypowderscontainingtalcprimarilyjohnsonsbaby powderthenumberofthesepersonalinjurylawsuitsfiledinstateandfederalcourtsintheunitedstatesaswellas outsideoftheunitedstatescontinuedtoincrease intalccasesthatpreviouslyhavegonetotrialthecompanyhasobtainedanumberofdefenseverdictsbuttherealso havebeenverdictsagainstthecompanymanyofwhichhavebeenreversedonappealinjunethemissouricourt ofappealsreversedinpartandaffirmedinpartajulyverdictofbillionininghamvjohnsonjohnsonetal noedmoappreducingtheoverallawardtobillionanapplicationfortransferofthecasetothe missourisupremecourtwassubsequentlydeniedandinjuneapetitionforcertiorariseekingareviewofthe inghamdecisionbytheunitedstatessupremecourtwasdeniedinjunethecompanypaidtheawardwhich includinginteresttotaledapproximatelybillionthefactsandcircumstancesincludingthetermsoftheawardwere uniquetotheinghamdecisionandnotrepresentativeofotherclaimsbroughtagainstthecompanythecompany continuestobelievethatithasstronglegalgroundstocontesttheothertalcverdictsthatithasappealed notwithstandingthecompanysconfidenceinthesafetyofitstalcproductsincertaincircumstancesthecompanyhas settledcases inoctoberjohnsonjohnsonconsumerincoldjjciimplementedacorporaterestructuringthe corporaterestructuringasaresultofthatrestructuringoldjjciceasedtoexistandthreenewentitieswerecreated altlmanagementllcanorthcarolinalimitedliabilitycompanyltlordebtorbroyaltyamllcanorth carolinalimitedliabilitycompanyandadirectsubsidiaryofltlramandcthedebtorsdirectparentjohnson johnsonconsumerincanewjerseycompanynewjjcithedebtorreceivedcertainofoldjjcisassetsandbecame solelyresponsibleforthetalcrelatedliabilitiesofoldjjciincludingallliabilitiesrelatedinanywaytoinjuryordamageor allegedinjuryordamagesustainedorincurredinthepurchaseoruseoforexposuretotalcincludingtalccontainedin anyproductortotheriskoforresponsibilityforanysuchdamageorinjuryexceptforanyliabilitiesforwhichthe exclusiveremedyisprovidedunderaworkerscompensationstatuteoractthetalcrelatedliabilities inoctobernotwithstandingthecompanysconfidenceinthesafetyofitstalcproductsthedebtorfiledavoluntary petitionwiththeunitedstatesbankruptcycourtforthewesterndistrictofnorthcarolinacharlottedivisionseeking reliefunderchapterofthebankruptcycodetheltlbankruptcycaseasaresultoftheltlbankruptcycasethe northcarolinabankruptcycourtenteredatemporaryrestrainingorderstayingalllitigationagainstltlandoldjjcion novemberthenorthcarolinabankruptcycourtconfirmedthescopeofthestayissuingapreliminaryinjunction piprohibitingandenjoiningthecommencementandprosecutionoftalcrelatedclaimsagainstltloldjjcinewjjci thecompanyotheroftheircorporateaffiliatesidentifiedretailersinsurancecompaniesandcertainotherpartiesthe protectedpartiestheltlbankruptcycasewastransferredtotheunitedstatesbankruptcycourtforthedistrictof newjerseyinnovemberandthatcourtextendedthepithroughtheendoffebruaryclaimantsfiledmotions todismisstheltlbankruptcycaseandfollowingamultipledayhearingthenewjerseybankruptcycourtdeniedthose motionsbyorderissuedinmarchthenewjerseybankruptcycourtsimultaneouslyissuedanotherorderextending thestayastotheprotectedpartiestheclaimantssubsequentlyfilednoticesofappealastothedenialofthemotionsto dismissandtheextensionofthestayinmaythethirdcircuitcourtofappealsgrantedthepetitionstoappealthe briefingandoralargumentontheappealwerecompletedinseptemberonjanuarythethirdcircuit reversedthebankruptcycourtsrulingandremandedtothebankruptcycourttodismisstheltlbankruptcyltlfileda petitionforrehearingonthedecision whilethenewjerseybankruptcycourtsordereffectivelystaysallofthecompanystalcrelatedpersonalinjurylitigation ltlhasagreedtoliftthestayonasmallnumberofappealswhereappealbondshavebeenfiled thecompanyhasagreedtoprovidefundingtoltlforthepaymentofamountsthenewjerseybankruptcycourt determinesareowedbyltlandtheestablishmentofabilliontrustinfurtheranceofthispurposethecompanyhas establishedareserveforapproximatelybillioninconnectionwiththeaforementionedtrustafterandasaresultofthe johnsonjohnsonannualreportfilingoftheltlbankruptcycasethecompanydeconsolidatedltlwhichisarelatedpartytheimpactofthede consolidationisnotmaterialtothecompanythepartieshavenotyetreachedaresolutionofalltalcmattersintheltl bankruptcycaseandthecompanyisunabletoestimatethepossiblelossorrangeoflossbeyondtheamountaccrued aclassactionadvancingclaimsrelatingtoindustrialtalcwasfiledagainstthecompanyandothersinnewjerseystate courtinmaytheedleyclassactiontheedleyclassactionassertsamongotherthingsthatthecompany fraudulentlydefendedpastasbestospersonalinjurylawsuitsarisingfromexposuretoindustrialtalcminedmilledand manufacturedbeforejanuarybythecompanysthenwhollyownedsubsidiarywindsormineralsincwhichis currentlyadebtorintheimerysbankruptcydescribedhereafterthecompanyremovedtheedleyclassactiontofederal courtinthedistrictofnewjerseyinjulyimerysfiledamotionintheimerysbankruptcytostaytheedleyclass actionwhichwasdeniedinaugustinoctoberthecompanyfiledmotionstodismissandtodeny certificationofaclasstopursuetheedleyclassactioninthenewjerseydistrictcourt infebruarythecompanystalcsupplierimerystalcamericaincandtwoofitsaffiliatesimerystalcvermontinc andimerystalccanadainccollectivelyimerysfiledavoluntarypetitionunderchapteroftheunitedstatescode thebankruptcycodeintheunitedstatesbankruptcycourtforthedistrictofdelawareimerysbankruptcytheimerys bankruptcyrelatestoimerysspotentialliabilityforpersonalinjuryfromexposuretotalcumpowdersoldbyimerysinits bankruptcyimerysallegesithasclaimsagainstthecompanyforindemnificationandrightstojointinsuranceproceedsin mayimerysitsparentimeryssathetortclaimantscommitteetccandthefutureclaimantsrepresentative fcrcollectivelytheplanproponentsfiledtheirplanofreorganizationtheplanandthedisclosurestatementrelated theretotheplanproponentshavesincefilednumerousamendmentstotheplananddisclosurestatementahearingon theplanproponentsdisclosurestatementwasheldinjanuaryandthecourtenteredanorderapprovingthe disclosurestatementallowingimerystoproceedwithsolicitingvotesontheplan inmarchthecompanyvotedtorejecttheplanandoptedoutoftheconsensualreleasesintheplaninapril theplanproponentsannouncedtheplanhadreceivedtherequisitenumberofacceptingvotestoconfirmtheplanthe companychallengedcertainimproprietieswithrespecttoportionsofthevoteandsoughttodisqualifythosevotesin octoberthebankruptcycourtissuedarulingdeemingthousandsofvotesaswithdrawn inoctoberimeryscancelledtheconfirmationhearingontheplanimerysthetccthefcrcertainofimeryss insurersandcertainpartiesinthecyprusmineschaptercasedescribedbelowcollectivelythemediationparties agreedtoengageinmediationthemostrecenttermofthemediationendedondecember injulyimeryscommencedanadversaryproceedingagainstthecompanyintheimerysbankruptcytheimerys adversaryproceedingtheimerysadversaryproceedingsoughtamongotherthingscertaindeclarationswithrespectto theindemnificationobligationsallegedlyowedbythecompanytoimerysthetccandfcrsimultaneouslyfiledamotion fortemporaryrestrainingorderandpreliminaryinjunctionseekingtoenjointhecompanyfromundergoingacorporate restructuringthatwouldseparatethecompanystalcliabilitiesfromitsotherassetsthebankruptcycourtdeniedthe motionthecompanythereafterfiledamotiontodismisstheadversaryproceedingthebankruptcycourthasnotyet decidedthemotiontodismissinoctoberthecompanyfiledanoticeofbankruptcyfilingandstayof proceedingsclarifyingthattheautomaticstayarisinguponthefilingoftheltlbankruptcycaseshouldapplytothe imerysadversaryproceeding injunecyprusminescorporationanditsparentcyprusamaxmineralscompanycamctogethercyprus whichhadownedcertainimerystalcminesfiledanadversaryproceedingagainstthecompanyandimerysintheimerys bankruptcyseekingadeclarationofindemnityrightsundercertaincontractualagreementsthecyprusadversary proceedingthecompanydeniessuchindemnificationisowedandfiledamotiontodismisstheadversarycomplaintin februarycyprusfiledavoluntarypetitionforreliefunderchapterofthebankruptcycodeandfileditsdisclosure statementandplanthecyprusplanthecyprusplancontemplatesasettlementwithimerysandtalcclaimantswhere cypruswouldmakeamonetarycontributiontoatrustestablishedundertheimerysplaninexchangeforaninjunction againsttalcclaimsassertedagainstitandcertainprotectedpartiescyprushasnotyetsoughtapprovalofitsdisclosure statementandplancyprusalongwiththetccandfcrappointedinthecypruschaptercasehaveagreedto participateinthemediationwiththemediationpartiesinoctoberthecompanyfiledanoticeofbankruptcyfiling andstayofproceedingsclarifyingthattheautomaticstayarisinguponthefilingoftheltlbankruptcycaseshouldapply tothecyprusadversaryproceedinginjunecypruscommencedanadversaryproceedinginitschaptercase seekinganorderenforcingtheautomaticstaybyenjoiningpartiesfromcommencingorcontinuingtalcrelatedclaims againstcamcinjunethecourtenteredapreliminaryinjunctionorderenjoiningclaimantsfrompursuingtalc relatedclaimsagainstcamcthroughjanuary johnsonjohnsonannualreport infebruaryseveralofthecompanysinsurersinvolvedincoveragelitigationinnewjerseystatecourtthe coverageactionfiledamotionintheimerysbankruptcycourtproceedingseekingadeterminationthattheautomatic staydoesnotapplytothecoverageactionandinthealternativeseekingrelieffromtheautomaticstaytoallowthemto continuetolitigatetheirclaimsinthecoverageactioninmarchthecompanyfiledalimitedresponseand reservationofrightswithrespecttothemotionthecourtenteredanagreedordermodifyingthestaytoallowthe litigationinthecoverageactiontocontinueinoctoberltlfiledanoticeofbankruptcyfilingandstayof proceedingsclarifyingthattheautomaticstayarisinguponthefilingoftheltlbankruptcycaseshouldapplytothe coverageactioninmarchthenewjerseybankruptcycourtruledthattheltlautomaticstayappliedtothe coverageaction infebruaryasecuritiesclassactionlawsuitwasfiledagainstthecompanyandcertainnamedofficersinthe unitedstatesdistrictcourtforthedistrictofnewjerseyallegingthatthecompanyviolatedthefederalsecuritieslawsby failingtodiscloseallegedasbestoscontaminationinbodypowderscontainingtalcprimarilyjohnsonsbabypowder andthatpurchasersofthecompanyssharessufferedlossesasaresultplaintiffisseekingdamagesinaprilthe companymovedtodismissthecomplaintandbriefingonthemotionwascompleteasofaugustindecember thecourtdeniedinpartthemotiontodismissinmarchthecompanyansweredthecomplaintinapril briefingonplaintiffsmotionforclasscertificationwascompletedinjulythecompanyfiledanoticeofsupplemental authorityinoppositiontoplaintiffsmotionforclasscertificationandplaintifffiledaresponseindecemberthe companyfiledamotiontosupplementtheclasscertificationrecordandinjanuaryplaintiffrespondedin marchltlaskedthenewjerseybankruptcycourttostaythesecuritiesclassactioninaprildefendantsfiled asecondmotiontosupplementtheclasscertificationrecordinmaythenewjerseybankruptcycourtenteredan orderstayingthesecuritiesclassactionplaintiffhasappealedthebankruptcycourtsorder alawsuitwasbroughtagainstthecompanyinthesuperiorcourtofcaliforniaforthecountyofsandiegoalleging violationsofcaliforniasconsumerlegalremediesactclrarelatingtojohnsonsbabypowderinthatlawsuitthe plaintiffsallegethatthecompanyviolatedtheclrabyfailingtoproviderequiredpropositionwarningsinjuly thecompanyfiledanoticeofremovaltotheunitedstatesdistrictcourtforthesoutherndistrictofcaliforniaand plaintiffsfiledasecondamendedcomplaintshortlythereafterinoctoberthecompanymovedtodismissthe secondamendedcomplaintforfailuretostateaclaimuponwhichreliefmaybegrantedinresponsetothosemotions plaintiffsfiledathirdamendedcomplaintindecemberthecompanymovedtodismissthethirdamendedcomplaint forfailuretostateaclaimuponwhichreliefmaybegrantedinaprilthecourtgrantedthemotiontodismissbut grantedleavetoamendinmayplaintiffsfiledafourthamendedcomplaintbutindicatedthattheywouldbefilinga motionforleavetofileafifthamendedcomplaintplaintiffsfiledafifthamendedcomplaintinaugustthecompany movedtodismissthefifthamendedcomplaintforfailuretostateaclaimuponwhichreliefmaybegrantedin januarythecourtissuedanorderandopinionrulinginthecompanysfavorandgrantingthemotiontodismiss withprejudiceinfebruaryplaintiffsfiledanoticeofappealwiththeninthcircuitplaintiffsfiledtheiropeningbrief injulythecompanyfileditsresponsivebriefinoctoberinoctobernoticeofsuggestionof bankruptcywasfiledwiththeninthcircuitabankruptcystaywasimposedindecemberandthecourtheldthe replydeadlineinabeyanceinfebruarythebankruptcycourtissuedanorderextendingthestaytheappeal continuestobeheldinabeyancewiththecompanybeingrequiredtofileperiodicstatusupdates inadditionthecompanyhasreceivedinquiriessubpoenasandrequeststoproducedocumentsregardingtalcmatters andtheltlbankruptcycasefromvariousgovernmentalauthoritiesthecompanyhasproduceddocumentsand respondedtoinquiriesandwillcontinuetocooperatewithgovernmentinquiries claimsforpersonalinjuryhavebeenmadeagainstanumberofjohnsonjohnsoncompaniesincludingjanssen pharmaceuticalsincandthecompanyarisingoutoftheuseofinvokanaaprescriptionmedicationindicatedto improveglycemiccontrolinadultswithtypediabetesindecemberlawsuitsfiledinfederalcourtsinthe unitedstateswereorganizedasamultidistrictlitigationintheunitedstatesdistrictcourtforthedistrictofnewjersey caseshavealsobeenfiledinstatecourtsclassactionlawsuitshavebeenfiledincanadaproductliabilitylawsuits continuetobefiledandthecompanycontinuestoreceiveinformationwithrespecttopotentialcostsandtheanticipated numberofcasesthecompanyhassettledorotherwiseresolvedmanyofthecasesandclaimsintheunitedstatesand thecostsassociatedwiththesesettlementsarereflectedinthecompanysaccruals claimsforpersonalinjuryhavebeenmadeagainstanumberofjohnsonjohnsoncompaniesincludingjanssen pharmaceuticalsincandthecompanyarisingoutoftheuseofelmironaprescriptionmedicationindicatedforthe reliefofbladderpainordiscomfortassociatedwithinterstitialcystitistheselawsuitswhichallegethatelmiron contributestothedevelopmentofpermanentretinalinjuryandvisionlosshavebeenfiledinbothstateandfederalcourts acrosstheunitedstatesindecemberlawsuitsfiledinfederalcourtsintheunitedstatesincludingputativeclass johnsonjohnsonannualreportactioncasesseekingmedicalmonitoringwereorganizedasamultidistrictlitigationintheunitedstatesdistrictcourtfor thedistrictofnewjerseyinadditioncaseshavebeenfiledinvariousstatecourtsofnewjerseywhichhavebeen coordinatedinamulticountylitigationinbergencountyaswellasthecourtofcommonpleasinphiladelphiawhich havebeencoordinatedandgrantedmasstortdesignationinadditionthreeclassactionlawsuitshavebeenfiledin canadaproductliabilitylawsuitscontinuetobefiledandthecompanycontinuestoreceiveinformationwithrespectto potentialcostsandtheanticipatednumberofcasesthecompanyhasestablishedaccrualsfordefenseandindemnity costsassociatedwithelmironrelatedproductliabilitylitigation claimsforpersonalinjuryhavebeenmadeagainstjohnsonandjohnsonconsumerincjjciarisingoutoftheuseof tylenolanoverthecounterpainmedicationallegingthatprenatalexposuretoacetaminophenisassociatedwiththe developmentofautismspectrumdisorderandorattentiondeficithyperactivitydisorderinoctoberlawsuitsfiledin federalcourtsintheunitedstateswereorganizedasamultidistrictlitigationintheunitedstatesdistrictcourtforthe southerndistrictofnewyorkinadditionlawsuitshavebeenfiledincanadaproductliabilitylawsuitscontinuetobe filedandthecompanycontinuestoreceiveinformationwithrespecttopotentialcostsandtheanticipatednumberof casesthecompanyhasestablishedaccrualsfordefensecostsassociatedwithtylenolrelatedproductliability litigation intellectualproperty certainsubsidiariesofthecompanyaresubjectfromtimetotimetolegalproceedingsandclaimsrelatedtopatent trademarkandotherintellectualpropertymattersarisingoutoftheirbusinessesmanyofthesemattersinvolvechallenges tothecoverageandorvalidityofthepatentsonvariousproductsandallegationsthatcertainofthecompanysproducts infringethepatentsofthirdpartiesalthoughthesesubsidiariesbelievethattheyhavesubstantialdefensestothese challengesandallegationswithrespecttoallsignificantpatentstherecanbenoassuranceastotheoutcomeofthese mattersalossinanyofthesecasescouldadverselyaffecttheabilityofthesesubsidiariestoselltheirproductsresultin lossofsalesduetolossofmarketexclusivityrequirethepaymentofpastdamagesandfutureroyaltiesandmayresultin anoncashimpairmentchargeforanyassociatedintangibleassetsignificantmattersaredescribedbelow medtech inaugustintuitivesurgicalincandintuitivesurgicaloperationsinccollectivelyintuitivefiledapatent infringementsuitagainstaurishealthincaurisinunitedstatesdistrictcourtforthedistrictofdelawareinthesuit intuitiveallegeswillfulinfringementofuspatentnosand basedonaurismonarchplatformaurisfilediprpetitionswiththeuspatentandtrademark officeusptoregardingtheandpatentsindecembertheusptodeniedreviewofthe patentinfebruaryandmarchtheusptoinstitutedreviewoftheandpatentsanddeniedreview ofthepatentinmarchtheusptoruledthatthechallengedclaimsoftheandpatentsarenot invalidaurisappealedandinapriltheunitedstatescourtofappealsforthefederalcircuitvacatedthedecision thatthepatentwasnotinvalidandremandedthedecisiontotheusptoforfurtherreviewinmaythe unitedstatescourtofappealsforthefederalcircuitconfirmedtherulingthatclaimofthepatentwasnot invalidvacatedthedecisionthattheremainingclaimsofthepatentwerenotinvalidandremandedthedecisionto theusptoforfurtherreviewaurisfiledarequestforreexaminationofthepatentinnovemberandin januarytheusptograntedthereexaminationrequesttrialisscheduledtobegininseptember inaugustrsbspinellcrsbspinefiledapatentinfringementsuitagainstdepuysynthesincinthe unitedstatesdistrictcourtforthedistrictofdelawareinoctoberrsbspineamendedthecomplainttochange thenameddefendantstodepuysynthessalesincanddepuysynthesproductsincinthesuitrsbspinealleges willfulinfringementofuspatentnosandbyoneormoreofthefollowingproducts zeropvaspacerzeropspacerzeropnaturalplatesynfixlrspacerandsynfixevolutionsystemrsb spineseeksmonetarydamagesandinjunctivereliefinnovemberthesuitwasconsolidatedforpretrialpurposes withotherpatentinfringementsuitsbroughtbyrsbspineintheunitedstatesdistrictcourtforthedistrictofdelaware againstlifespineincmedactausaincandprecisionspineincinjunedepuyfiledpotentiallydispositive summaryjudgmentmotionsthatthepatentisinvalidasanticipatedandthepatentisnotinfringedin novemberthecourtgranteddepuyssummaryjudgmentmotionthatthepatentisinvalidasanticipatedand denieddepuysmotionthatthepatentisnotinfringedindecemberthecourtconductedajurytrialonthe patentwherethejuryfoundthatthepatentwasnotliterallyinfringedbutthatdepuyinfringedunderthe doctrineofequivalentsdoethejuryawardedrsbmillionindamagessubjecttoposttrialmotionsandappeals johnsonjohnsonannualreport inoctoberrasmusseninstrumentsllcrasmussenfiledapatentinfringementsuitagainstdepuysynthes productsincdepuysynthessalesincandmedicaldevicebusinessservicesinccollectivelydepuyinthe unitedstatesdistrictcourtforthedistrictofmassachusettsrasmussenallegesthatdepuywillfullyinfringesuspatent nosandbymakingandsellingtheattunebalancedsizerinapril rasmussensoughtpermissiontoamenditsinfringementcontentionstoallegethatdepuyalsowillfullyinfringesthe patentbymakingandsellingtheattunebalancingblocksrasmussenseekstrebledamagesforwillfulinfringement trialconcludedinmarchwiththejuryreturningaverdictinfavorofrasmussenfindingwillfulinfringementofthe patentandawardingdamagesintheamountofmilliondepuychallengedtheverdictinitsposttrialmotionsin julyahearingwasheldontheposttrialmotions pharmaceutical litigationagainstfilersofabbreviatednewdrugapplicationsandas thefollowingsummarizeslawsuitsthecompanyssubsidiarieshavebroughtagainstgenericcompaniesthathavefiled andaswiththeusfdaorundertakensimilarregulatoryprocessesoutsideoftheunitedstatesseekingtomarket genericformsofproductssoldbyvarioussubsidiariesofthecompanypriortoexpirationoftheapplicablepatents coveringthoseproductstheseandastypicallyincludeallegationsofnoninfringementandinvalidityoftheapplicable patentstheinterpartesreviewiprprocesswiththeusptocreatedundertheamericainventsactisalso beingusedattimesbygenericcompaniesinconjunctionwithandasandlawsuitstochallengetheapplicablepatentsin theeventthecompanyssubsidiariesarenotsuccessfulinanactionortheautomaticstatutorystayoftheandasexpires beforetheunitedstatesdistrictcourtrulingsareobtainedthegenericcompaniesinvolvedwouldhavetheabilityupon approvaloftheusfdatointroducegenericversionsoftheirproductstothemarketresultinginthepotentialfor substantialmarketshareandrevenuelossesfortheapplicableproductsandwhichmayresultinanoncashimpairment chargeinanyassociatedintangibleassetinadditionfromtimetotimethecompanyssubsidiariesmaysettlethesetypes ofactionsandsuchsettlementscaninvolvetheintroductionofgenericversionsoftheproductsatissuetothemarket priortotheexpirationoftherelevantpatents zytiga beginninginjanuaryjanssenincjanssenoncologyincandbtginternationalltdcollectivelyjanssen initiatedstatementsofclaimundersectionofthepatentedmedicinesnoticeofcomplianceregulationsincanada againstapotexincapotexpharmascienceincpharmascienceanddrreddyslaboratoriesltdanddrreddys laboratoriesinccollectivelydrlinresponsetothosepartiesfilingofabbreviatednewdrugsubmissionsands seekingapprovaltomarketgenericversionsofzytigabeforetheexpirationofthecanadianpatentno thetrialintheseactionsconcludedinnovemberandthecourtissuedadecisionholdingthepatent invalidinjanuaryinfebruaryjanssenappealedthedecisiontheappealhearingtookplacein septemberinnovemberjanssensappealwasdismissed inapriljulyandaprilrespectivelyapotexdrlandpharmascienceinitiatedstatementsofclaim undersectionofthepatentedmedicinesnoticeofcomplianceregulationsagainstjanssenseekingdamagesin respectofthosepartiesgenericzytigatabletstrialsagainstapotexanddrlarescheduledforjuneatrialdatefor thepharmascienceactionhasnotbeenset xarelto beginninginmarchjanssenpharmaceuticalsincjpiandbayerpharmaagandbayeragcollectivelybayer filedpatentinfringementlawsuitsintheunitedstatesdistrictcourtforthedistrictofdelawareagainstanumberof genericcompanieswhofiledandasseekingapprovaltomarketgenericversionsofxareltomgbeforeexpiration ofuspatentnothefollowinggenericdrugcompaniesarenameddefendantsdrreddys laboratoriesincanddrreddyslaboratoriesltdlupinlimitedandlupinpharmaceuticalsinctaropharmaceutical industriesltdandtaropharmaceuticalsusaincandtevapharmaceuticalsusaincinoctoberthecourt consolidatedthedelawarelawsuitsforallpurposesincludingtrialtrialfortheconsolidateddelawarelawsuitsis scheduledtobegininmay injulyjpiandbayerfiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthenortherndistrict ofwestvirginiaagainstmylanpharmaceuticalsincandmylaninccollectivelymylanwhichfiledanandaseeking approvaltomarketagenericversionofxareltomgbeforeexpirationofthepatentinaugustjpiand bayerfiledamotionbeforetheunitedstatesjudicialpanelonmultidistrictlitigationthemdlpaneltotransferthis johnsonjohnsonannualreportlawsuittotheunitedstatesdistrictcourtforthedistrictofdelawareforcoordinatedandconsolidatedpretrial proceedingsindecemberthemdlpanelgrantedthemotioninaugustafterreceivingasecondnotice letterfrommylanregardingthesameandajpiandbayerfiledasecondpatentinfringementlawsuitintheunitedstates districtcourtforthenortherndistrictofwestvirginiaagainstmylaninseptembermylanmovedtodismissthe secondlawsuitinseptemberthemdlpaneltransferredthesecondlawsuittothedistrictofdelawarenotrial datehasbeensetforthesetwolawsuitsinoctobermylanvoluntarilywithdrewitsmotiontodismiss ineachoftheselawsuitsjpiandbayerareseekinganorderenjoiningdefendantsfrommarketingtheirgenericversionof xareltomgbeforetheexpirationofthepatentinjanuarythecourtissuedanorderstayingthe lawsuitsuntilafterafinalwrittendecisionisissuedintheinterpartesreviewproceedingsonthepatent infebruarymylanpharmaceuticalsincfiledapetitionforinterpartesreviewiprwiththeunitedstatespatent andtrademarkofficeusptoseekingtoinvalidatethepatentinaugustthepatenttrialandappealboard ptabissuedadecisioninstitutingipr inseptemberinvagenpharmaceuticalsincfiledapetitionforiprwiththeusptoseekingtoinvalidatethe patentalsoinseptembertevapharmaceuticalsusaincfiledapetitionforiprwiththeusptoseekingto invalidatethepatentinoctobertheptabissueddecisionsinstitutingiprinbothproceedingsandjoining themwiththeearlieriprproceedingfiledbymylanpharmaceuticalsinc inseptemberjpibayerandbayerintellectualpropertygmbhbipinitiatedapatentinfringementlawsuitinthe unitedstatesdistrictcourtforthedistrictofnewjerseyagainstusvprivatelimitedusvwhofiledanandaseeking approvaltomarketgenericversionsofxareltomgmgmgandmgbeforetheexpirationofthe patentanduspatentnojpibayerandbipareseekinganorderenjoiningusvfrommarketing itsgenericversionofxareltomgbeforetheexpirationofthepatentanditsgenericversionsofxarelto mgmgandmgbeforetheexpirationofthepatentinnovemberthemdlpaneltransferredthis lawsuittotheunitedstatesdistrictcourtforthedistrictofdelaware inseptemberjpibayeragandbipinitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtfor thedistrictofnewjerseyagainstmankindpharmalimitedmankindwhofiledanandaseekingapprovaltomarket genericversionsofxareltomgmgandmgbeforetheexpirationofthepatentjpibayeragandbip areseekinganorderenjoiningmankindfrommarketingitsgenericversionsofxareltobeforetheexpirationofthe patent innovemberjpibayerandbipinitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtforthe districtofdelawareagainstepicpharmallcepicwhofiledanandaseekingapprovaltomarketgenericversionsof xareltomgmgmgandmgbeforetheexpirationofthepatentandthepatentjpibayer andbipareseekinganorderenjoiningepicfrommarketingitsgenericversionofxareltomgbeforetheexpiration ofthepatentanditsgenericversionsofxareltomgmgandmgbeforetheexpirationofthe patent indecemberjpiandbayerinitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrict ofdelawareagainstapotexincandapotexcorpcollectivelyapotexwhofiledanandaseekingapprovaltomarket genericversionsofxareltomgbeforetheexpirationofthepatentjpiandbayerareseekinganorder enjoiningapotexfrommarketingitsgenericversionofxareltomgbeforetheexpirationofthepatent opsumit inmayjanssenincjanssenandactelionpharmaceuticalsltdactelioninitiatedastatementofclaimunder sectionofthepatentedmedicinesnoticeofcomplianceregulationsagainstsandozcanadaincsandozincanada inresponsetosandozsfilingofanandsseekingapprovaltomarketagenericversionofopsumitmgbeforethe expirationofcanadianpatentnosandozstipulatedtoinfringementofthepatenttrialagainst sandozontheissueofvalidityconcludedinfebruaryandinmaythecourtissuedadecisioninfavorof janssenandactelioninjunesandozappealedthedecision inmayjanssenandactelioninitiatedastatementofclaimundersectionofthepatentedmedicinesnoticeof complianceregulationsagainstapotexincapotexincanadainresponsetoapotexsfilingofanandsseeking approvaltomarketagenericversionofopsumitmgbeforetheexpirationofthepatentapotexstipulatedto validityofthepatenttrialagainstapotexontheissueofinfringementconcludedinmarchandinmay thecourtissuedadecisioninfavorofjanssenandactelioninjuneapotexappealedthedecision johnsonjohnsonannualreport injanuaryjanssenandactelioninitiatedastatementofclaimundersectionofthepatentedmedicinesnotice ofcomplianceregulationsagainstgenericmedicalpartnersincgmpincanadainresponsetogmpsfilingofan andsseekingapprovaltomarketagenericversionofopsumitmgbeforetheexpirationofcanadianpatentnos ineachofthesecanadianactionsjanssenandactelionareseekinganorderenjoiningthedefendantsfrommarketing theirgenericversionsofopsumitbeforetheexpirationoftherelevantpatents injanuaryactelionpharmaceuticalsltdandactelionpharmaceuticalsusinccollectivelyactelioninitiateda patentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictofnewjerseyagainstsunpharmaceutical industrieslimitedandsunpharmaceuticalindustriesinccollectivelysunwhofiledanandaseekingapprovalto marketagenericversionofopsumitbeforetheexpirationofuspatentnosand actelionisseekinganorderenjoiningsunfrommarketingtheirgenericversionsofopsumitbeforetheexpirationofthe andpatents invegasustenna injanuaryjanssenpharmaceuticanvandjanssenpharmaceuticalsinccollectivelyjansseninitiatedapatent infringementlawsuitintheunitedstatesdistrictcourtforthedistrictofnewjerseyagainsttevapharmaceuticalsusa inctevawhichfiledanandaseekingapprovaltomarketagenericversionofinvegasustennabeforethe expirationofuspatentnotrialconcludedinoctoberinoctoberthecourtissueda decisioninjanssensfavortevahasappealedthedecision inaugustjansseninitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictof newjerseyagainstmylanlaboratorieslimitedmylanwhichfiledanandaseekingapprovaltomarketagenericversion ofinvegasustennabeforetheexpirationofthepatentpursuanttoanagreementbythepartiesjudgmentin favorofjanssenwasenteredindecembermylanappealed indecemberjansseninitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtsforthedistrictsof newjerseyanddelawareagainstpharmascienceincmallinckrodtplcandspecgxllccollectivelypharmascience whichfiledanandaseekingapprovaltomarketagenericversionofinvegasustennabeforetheexpirationofthe patent innovemberjansseninitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictof delawareagainsttolmarinctolmartherapeuticsinctolmarpharmaceuticalsincandtolmarholdinginc collectivelytolmarwhichfiledanandaseekingapprovaltomarketagenericversionofinvegasustennabefore theexpirationofthepatentatrialisscheduledtobegininoctober infebruaryjansseninitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictof newjerseyagainstaccordhealthcareincaccordhealthcareltdandintaspharmaceuticalsltdcollectivelyaccord whofiledanandaseekingapprovaltomarketagenericversionofinvegasustennabeforetheexpirationofthe patent ineachoftheseuslawsuitsjanssenisseekinganorderenjoiningthedefendantfrommarketingagenericversionof invegasustennabeforetheexpirationoftherelevantpatents infebruaryjanssenincandjanssenpharmaceuticanvcollectivelyjanssencanadainitiatedastatementof claimundersectionofthepatentedmedicinesnoticeofcomplianceregulationsagainsttevacanadalimited tevacanadainresponsetotevasfilingofanandsseekingapprovaltomarketagenericversionofinvega sustennabeforetheexpirationofcanadianpatentnosandjanssensubsequently discontinuedtheportionofthelawsuitrelatingtothepatentinmaythecanadianfederalcourtissueda publicjudgmentandreasonsdeclaringthattevacanadasgenericversionofinvegasustennaifapprovedwould infringecertainclaimsofthepatentandthattheclaimsofthepatentarenotinvalidtevacanadaappealed innovemberjanssencanadainitiatedastatementofclaimundersectionofthepatentedmedicinesnoticeof complianceregulationsagainstpharmascienceincinresponsetopharmascienceincsfilingofanandsseeking approvaltomarketagenericversionofinvegasustennabeforetheexpirationofthepatentasummarytrialon theissueofinfringementtookplaceinnovemberinjanuarythecourtissuedadecisioninfavorofjanssen ontheissueofinfringementpharmasciencefiledanappealinmarchjanssencanadainitiatedastatementof claimundersectionofthepatentedmedicinesnoticeofcomplianceregulationsagainstpharmascienceinresponse topharmasciencesfilingofanandsseekingapprovaltomarketagenericversionofanadditionalstrengthof johnsonjohnsonannualreportinvegasustennabeforetheexpirationofthepatenttheactionhasbeenconsolidatedwiththenovember actionfortrialwhichtookplaceinjulyinaugustthecourtissuedadecisionfindingtheclaimsof thepatentarenotinvalidpharmascienceappealed injanuaryjanssencanadainitiatedastatementofclaimundersectionofthepatentedmedicinesnoticeof complianceregulationsagainstapotexincapotexinresponsetoapotexsfilingofanandsoriginalandsseeking approvaltomarketagenericversionofinvegasustennabeforetheexpirationofthepatentasummarytrialon theissueofinfringementtookplaceindecemberinjanuarythecourtissuedadecisioninfavorofjanssen ontheissueofinfringementapotexappealed injunejanssencanadainitiatedstatementsofclaimundersectionofthepatentedmedicinesnoticeof complianceregulationsagainstapotexinresponsetoapotexsnoticeofallegationofinvaliditywithrespecttothe originalandsandinresponsetoapotexsfilingofanandsseekingapprovaltomarketagenericversionofanadditional strengthofinvegasustennabeforetheexpirationofthepatentatrialisscheduledtobegininmarch ineachofthesecanadianlawsuitsjanssencanadaisseekinganorderenjoiningthedefendantfrommarketingageneric versionofinvegasustennabeforetheexpirationoftherelevantpatents invegatrinza inseptemberjanssenpharmaceuticalsincjanssenpharmaceuticanvandjanssenresearchdevelopment llccollectivelyjansseninitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictof newjerseyagainstmylanlaboratorieslimitedmylanpharmaceuticalsincandmylaninstitutionalllccollectively mylanmylanfiledanandaseekingapprovaltomarketgenericversionsofinvegatrinzamgbeforeexpiration ofuspatentnorelatingtoinvegatrinzamg inaugustjansseninitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictofnew jerseyagainstmylanmylanfiledanandaseekingapprovaltomarketgenericversionsofinvegatrinzamg beforeexpirationofthepatent inoctoberjansseninitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictofnew jerseyagainstmylanmylanfiledanandaseekingapprovaltomarketgenericversionsofinvegatrinzamgand mgbeforeexpirationofthepatent injanuarythecourtconsolidatedthethreecasesintothecasefiledinseptemberineachofthese consolidatedcasesjanssenisseekinganorderenjoiningmylanfrommarketingitsgenericversionsofinvegatrinza beforeexpirationofthepatenttrialwasconductedinnovemberanddecemberandposttrialbriefingis proceedingclosingargumentswillbeheldinmarch imbruvica inmarchpharmacyclicsllcpharmacyclicsandjanssenbiotechincjbifiledapatentinfringementlawsuitin theunitedstatesdistrictcourtforthedistrictofdelawareagainstalvogenpinebrookllcandnatcopharmaltd collectivelyalvogenwhichfiledanandaseekingapprovaltomarketgenericversionsofimbruvicatabletsasserting infringementofuspatentnos injunepharmacyclicsandjbiamendedtheircomplaintagainstalvogentofurtherallegeinfringement ofuspatentno trialagainstalvogentookplaceinoctoberinaugustthedistrictcourtissuedadecisioninfavorof pharmacyclicsandjanssenfindingtheassertedclaimsagainstalvogentobeinfringedandnotinvalidinnovember theunitedstatescourtofappealsforthefederalcircuitaffirmedthedistrictcourtsdecision inseptemberpharmacyclicsandjanssenincjanssencanadainitiatedstatementsofclaimundersectionof thepatentedmedicinesnoticeofcomplianceregulationsagainstnatcopharmacanadaincnatcoinresponseto natcosfilingoftwoandssseekingapprovaltomarketgenericversionsofimbruvicacapsulesbeforetheexpirationof canadianpatentnos andinthislawsuitpharmacyclicsandjanssencanadaareseekinganorder enjoiningnatcofrommarketingitsgenericversionofimbruvicabeforetheexpirationoftherelevantpatentstrialis scheduledtobegininjuly johnsonjohnsonannualreport inoctoberpharmacyclicsandjanssencanadainitiatedasecondstatementofclaimundersectionofthe patentedmedicinesnoticeofcomplianceregulationsagainstnatcoinresponsetonatcosfilingofanandsseeking approvaltomarketagenericversionofimbruvicacapsulesbeforetheexpirationoftheand patentsandcanadianpatentnointhislawsuitpharmacyclicsandjanssencanadaareseekinganorder enjoiningnatcofrommarketingitsgenericversionofimbruvicacapsulesbeforetheexpirationoftherelevantpatents trialinthissecondactionisscheduledtobegininaugust infebruarypharmacyclicsandjanssencanadainitiatedastatementofclaimundersectionofthepatented medicinesnoticeofcomplianceregulationsagainstsandozcanadaincsandozinresponsetosandozsfilingofan andsseekingapprovaltomarketagenericversionofimbruvicacapsulesbeforetheexpirationofthe andpatentsalsoinfebruarypharmacyclicsandjansseninitiatedastatementofclaimundersectionof thepatentedmedicinesnoticeofcomplianceregulationsagainstsandozassertingtheandpatentswhich arealsolistedinhealthcanadaspatentregisterforimbruvicaintheselawsuitspharmacyclicsandjanssencanada areseekinganorderenjoiningsandozfrommarketingitsgenericversionofimbruvicacapsulesbeforetheexpirationof therelevantpatentsatrialdatefortheseactionshasnotbeenset symtuza innovemberjanssenproductslpandjanssensciencesirelandunlimitedcompanycollectivelyjanssenand gileadsciencesincandgileadsciencesirelanduccollectivelygileadinitiatedapatentinfringementlawsuitinthe unitedstatesdistrictcourtforthedistrictofdelawareagainstlupinlimitedlupinpharmaceuticalsincmsn laboratoriesprivateltdmsnlifesciencesprivateltdandmsnpharmaceuticalsinccollectivelylupinwhichfiled anandaseekingapprovaltomarketagenericversionofsymtuzabeforetheexpirationofuspatentnos andthetrialisscheduledtobegininoctober inoctoberjanssenproductslpandjanssensciencesirelandunlimitedcompanycollectivelyjanssenand gileadsciencesincandgileadsciencesirelanduccollectivelygileadinitiatedapatentinfringementlawsuitinthe unitedstatesdistrictcourtforthedistrictofdelawareagainstapotexincandapotexcorpcollectivelyapotexwhich filedanandaseekingapprovaltomarketagenericversionofsymtuzabeforetheexpirationoftheand patents ineachoftheseuslawsuitsjanssenisseekinganorderenjoiningthedefendantfrommarketingagenericversionof symtuzabeforetheexpirationoftherelevantpatents erleada inmayaragonpharmaceuticalsincandjanssenbiotechinccollectivelyjanssenandsloanketteringinstitute forcancerresearchskiinitiatedpatentinfringementlawsuitsinunitedstatesdistrictcourtforthedistrictsof newjerseyanddelawareagainstlupinlimitedandlupinpharmaceuticalsinccollectivelylupinwhichfiledananda seekingapprovaltomarketagenericversionoferleadabeforetheexpirationofuspatentnoin augustjanssenandskifiledafirstamendedcomplaintagainstlupinaddinguspatentnos andtothesuitjanssenandskiareseekinganorderenjoining lupinfrommarketingitsgenericversionoferleadabeforetheexpirationoftheandpatents inaugustjanssenandskivoluntarilydismissedthedelawarecomplaintthenewjerseyactionisproceeding inmayjanssenandskiinitiatedapatentinfringementlawsuitinunitedstatesdistrictcourtforthedistrictof newjerseyagainstzydusworldwidedmcczyduspharmaceuticalsusaincandzyduslifescienceslimited collectivelyzyduswhichfiledanandaseekingapprovaltomarketagenericversionoferleadabeforetheexpiration oftheandpatentsjanssenandskiareseekinganorderenjoiningzydusfrommarketingits genericversionoferleadabeforetheexpirationoftheandpatents inmayjanssentheregentsoftheuniversityofcaliforniaucandskiinitiatedpatentinfringementlawsuitsin unitedstatesdistrictcourtforthedistrictsofnewjerseyanddelawareagainstsandozincsandozwhichfiledan andaseekingapprovaltomarketagenericversionoferleadabeforetheexpirationofthepatentanduspatent nosandinaugustjanssenucand skifiledafirstamendedcomplaintagainstsandozaddingtheandpatentstothesuitinaugust janssenucandskivoluntarilydismissedthedelawarecomplaintindecemberjanssenucandskifiled asecondamendedcomplaintagainstsandozwithdrawingtheandpatentsfromthesuitwithout prejudicejanssenucandskiareseekinganorderenjoiningsandozfrommarketingitsgenericversionoferleada beforetheexpirationoftheandpatentsthenewjerseyactionisproceeding johnsonjohnsonannualreportinmayjanssenucandskiinitiatedpatentinfringementlawsuitsinunitedstatesdistrictcourtforthedistrictsof newjerseyanddelawareagainsteugiapharmaspecialitieslimitedaurobindopharmausaincandauromedics pharmallccollectivelyeugiawhichfiledanandaseekingapprovaltomarketagenericversionoferleadabefore theexpirationoftheandpatentsinseptemberjanssenucandskifiledafirst amendedcomplaintagainsteugiaaddinguspatentnosand tothesuitinseptemberjanssenucandskivoluntarilydismissedthedelawarecomplaint janssenucandskiareseekinganorderenjoiningeugiafrommarketingitsgenericversionoferleadabeforethe expirationoftheandpatentsthenewjerseyactionisproceeding inmayjanssenucandskiinitiatedpatentinfringementlawsuitsinunitedstatesdistrictcourtforthedistrictsof newjerseyanddelawareagainstheterolabslimitedunitvandheterousainccollectivelyheterowhichfiledan andaseekingapprovaltomarketagenericversionoferleadabeforetheexpirationofthe andpatentsjanssenucandskiareseekinganorderenjoiningheterofrommarketingitsgenericversionof erleadabeforetheexpirationoftheandpatentsinaugustjanssenucand skivoluntarilydismissedthedelawarecomplaintthenewjerseyactionisproceeding uptravi inaugustactelionpharmaceuticalsltdandjansseninccollectivelyjanssenandnipponshinyakuconippon shinyakuinitiatedastatementofclaimundersectionofthepatentedmedicinesnoticeofcomplianceregulations againstsandozcanadaincinresponsetosandozsfilingofanandsseekingapprovaltomarketgenericversionsof uptravitabletsbeforetheexpirationofcanadianpatentnosandinthislawsuitjanssenand nipponshinyakuareseekinganorderenjoiningsandozfrommarketingitsgenericversionofuptravibeforethe expirationoftherelevantpatentsatrialisscheduledtobegininmay innovemberactelionpharmaceuticalsusincandactelionpharmaceuticalsltdcollectivelyactelionandnippon shinyakucoltdnipponshinyakuinitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtforthe districtofdelawareagainstalembicpharmaceuticalslimitedandalembicpharmaceuticalsinccollectivelyalembic whofiledanandaseekingapprovaltomarketgenericversionsofuptraviinjectionforintravenoususebeforeexpiration ofuspatentnosandrelatingtouptraviinthislawsuitactelionandnippon shinyakuareseekinganorderenjoiningalembicfrommarketingagenericversionofuptravibeforetheexpirationofthe relevantpatentsatrialdatehasnotbeenset infebruaryactelionandnipponshinyakuinitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourt forthedistrictofdelawareagainstlupinltdandlupinpharmaceuticalsinccollectivelylupinwhofiledananda seekingapprovaltomarketgenericversionsofuptraviinjectionforintravenoususebeforeexpirationoftheand patentsrelatingtouptraviinthislawsuitactelionandnipponshinyakuareseekinganorderenjoininglupinfrom marketingagenericversionofuptravibeforetheexpirationoftherelevantpatentsatrialdatehasnotbeenset otherlitigation innovemberjanssenpharmaceuticanvjanssenprovidedtoalkermespharmairelandlimitedelanpharma internationallimitedandelandrugdeliveryincthreemonthsnoticeofterminationofalicenseagreementbyand amongelanpharmaceuticalresearchcorpdbananosystemselanpharmainternationallimitedandjanssen executedinmarchinnovemberjanssenalsoprovidedtoalkermespharmairelandlimitedthreemonths noticeofterminationofalicenseagreementbetweenelanpharmainternationallimitedandjanssenexecutedinjuly inaprilinresponsetothesenoticesalkermespharmairelandlimitedalkermesinitiatedarbitrationinthe internationalinstituteforconflictpreventionandresolutionthepartiesexchangedopeningbriefsinjulyand responsivebriefsinseptemberindecemberthearbitrationtribunalissuedaninterimdecisionfindingthat janssenmayterminatetheagreementsbutitmaynotcontinuetosellproductsdevelopedduringthetermofthe agreementswithoutcontinuingtopayroyaltiestoalkermes governmentproceedings likeothercompaniesinthepharmaceuticalconsumerhealthandmedicaldevicesindustriesthecompanyandcertainof itssubsidiariesaresubjecttoextensiveregulationbynationalstateandlocalgovernmentagenciesintheunitedstates andothercountriesinwhichtheyoperatesuchregulationhasbeenthebasisofgovernmentinvestigationsandlitigations themostsignificantlitigationbroughtbyandinvestigationsconductedbygovernmentagenciesarelistedbelowitis possiblethatcriminalchargesandsubstantialfinesandorcivilpenaltiesordamagescouldresultfromgovernment investigationsorlitigation johnsonjohnsonannualreport averagewholesalepriceawplitigation thecompanyandseveralofitspharmaceuticalsubsidiariesthejjawpdefendantsalongwithnumerousother pharmaceuticalcompanieswerenamedasdefendantsinaseriesoflawsuitsinstateandfederalcourtsinvolving allegationsthatthepricingandmarketingofcertainpharmaceuticalproductsamountedtofraudulentandotherwise actionableconductbecauseamongotherthingsthecompaniesallegedlyreportedaninflatedaveragewholesaleprice awpforthedrugsatissuepayorsallegedthattheyusedthoseawpsincalculatingproviderreimbursementlevelsthe plaintiffsinthesecasesincludedthreeclassesofprivatepersonsorentitiesthatpaidforanyportionofthepurchaseof thedrugsatissuebasedonawpandstategovernmententitiesthatmademedicaidpaymentsforthedrugsatissue basedonawpmanyofthesecasesbothfederalactionsandstateactionsremovedtofederalcourtwereconsolidated forpretrialpurposesinamultidistrictlitigationintheunitedstatesdistrictcourtforthedistrictofmassachusettswhere allclaimsagainstthejjawpdefendantswereultimatelydismissedthejjawpdefendantsalsoprevailedinacase broughtbythecommonwealthofpennsylvaniaotherawpcaseshavebeenresolvedthroughcourtorderorsettlement thecasebroughtbyillinoiswassettledaftertrialinnewjerseyaputativeclassactionbaseduponawpallegationsis pendingagainstcentocorincandorthobiotechincbothnowjanssenbiotechincthecompanyandalza corporationallothercaseshavebeenresolved opioidlitigation beginninginandcontinuingtothepresentthecompanyandjanssenpharmaceuticalsincjpialongwithother pharmaceuticalcompanieshavebeennamedinclosetolawsuitsrelatedtothemarketingofopioidsincluding duragesicnucyntaandnucyntaerthesuitsalsoraiseallegationsrelatedtopreviouslyownedactive pharmaceuticalingredientsuppliersubsidiariestasmanianalkaloidsptyltdandnoramcoincbothsubsidiarieswere divestedinthemajorityofthecaseshavebeenfiledbystateandlocalgovernmentssimilarlawsuitshavealso beenfiledbyprivateplaintiffsandorganizationsincludingbutnotlimitedtothefollowingindividualplaintiffsonbehalfof childrenbornwithneonatalabstinencesyndromehospitalsandhealthinsurerspayorstodatecomplaintsagainst pharmaceuticalmanufacturersincludingthecompanyandjpihavebeenfiledbythestateattorneysgeneralin arkansasfloridaidahoillinoiskentuckylouisianamississippimissourinevadanewhampshirenewjerseynew mexiconewyorkohiooklahomasouthdakotatexaswashingtonandwestvirginiacomplaintsagainstthe manufacturersalsohavebeenfiledinstateorfederalcourtbycitycountyandlocalgovernmentagenciesineverystate butalaskathegovernmentofpuertoricofiledsuitinsuperiorcourtofsanjuan thecompanyjpiandotherpharmaceuticalcompanieshadalsoreceivedsubpoenasorrequestsforinformationrelated toopioidsmarketingpracticesfromthefollowingstateattorneysgeneralalaskaindianamontananewhampshire southcarolinatennesseetexasandwashingtoninseptemberthecompanyandjpiwerecontactedbythe texasandcoloradoattorneygeneralsofficesonbehalfofapproximatelystatesregardingamultistateattorney generalinvestigation inthetrialinthematterfiledbytheoklahomaattorneygeneralresultedinajudgmentagainstthecompanyandjpi intheamountofmillionthecompanyandjpiappealedthejudgmentandinnovembertheoklahoma supremecourtreversedthetrialcourtsjudgmentanddirectedentryofjudgmentfordefendantsinoctoberthe companyandjpiannouncedasettlementofthefirstcasesetfortrialinthemdlwithtwocountiesinohioinapril threecaliforniacountiesandthecityofoaklandcommencedatrialincaliforniastatecourtagainstthecompanyandjpi andotheraffiliatesaswellasthreeotherpharmaceuticalmanufacturersthetrialconcludedinoctoberandin decemberthecourtenteredafinaltrialjudgmentinfavorofdefendantsonallclaimsinfebruaryplaintiffs motiontosetasideandvacatethejudgmentwasdeniedplaintiffsappealedthejudgmentbutlaterfiledarequestto dismisstheappealafterelectingtoparticipateinthenationalsettlementagreement inoctoberthecompanyannouncedaproposedagreementinprinciplethatwouldincludethecompanypaying billionassettlementofthesemattersthathadnotbeentriedorsettledinoctoberthecompanyagreedto contributeuptoanadditionalbilliontoanallinsettlementamountthatwouldresolveopioidlawsuitsfiledandfuture claimsbystatescitiescountiesandtribalgovernmentsforatotalofbillionwhichhasbeenaccruedsubjectto variousconditionsandanagreementbeingfinalizedthisagreementisnotanadmissionofliabilityorwrongdoingin julythecompanyannouncedthatthetermsoftheagreementtosettlethestateandsubdivisionclaimshadbeen finalizedandapproximatelyhalfoftheallinsettlementwasexpectedtobepaidbytheendoffiscalyeardepending uponthelevelofparticipationbythestatesandtheirsubdivisionsthetermsprovidedaperiodoftimeforstatestoelect toparticipateintheagreementandthereafteraperiodforthesubdivisionsoftheparticipatingstatestooptinbasedon expectedparticipationthecompanycommittedinadvancetoproceedwiththesettlementinfiveoftheparticipating statesnewyorktexasfloridanevadaandnewmexicoandwithtribalgovernmentsbylatefebruarystates johnsonjohnsonannualreportfiveterritoriesthedistrictofcolumbiaandthevastmajorityofeligiblesubdivisionshadelectedtoparticipateinthe settlementandthecompanyconfirmedthatthelevelofparticipationwassufficienttoproceedwiththeagreementasto allparticipantstheagreementwaseffectiveinaprilalsoinaprilthecompanyenteredintosettlement agreementswiththestatesofalabamaandwestvirginiaandtheirparticipatingsubdivisionsinjulythecompany reachedasettlementagreementwithalllitigatingoklahomasubdivisionsandinseptemberthecompanysettled withthestateofnewhampshireanditsparticipatingsubdivisionsconsequentlybytheendofthefiscalyearthe companyhadsettledtheopioidclaimsadvancedbyallstatesexceptwashington thereareapproximatelycasesremainingpostsettlementinvariousstatecourtsthereareapproximately remainingfederalcasesagainstthecompanyandjpicoordinatedinafederalmultidistrictlitigationmdlpendingin theusdistrictcourtforthenortherndistrictofohioandapproximatelyadditionalcasespendingagainstthe companyandjpiinotherfederalcourtsinadditiontheprovinceofbritishcolumbiafiledsuitagainstthecompanyand itscanadianaffiliatejanssenincandmanyotherindustrymembersincanadaandisseekingtohavethataction certifiedasanoptinclassactiononbehalfofotherprovincialterritorialandthefederalgovernmentsincanadaadditional proposedclassactionshavebeenfiledincanadaagainstthecompanyandjanssenincandmanyotherindustry membersbyandonbehalfofpeoplewhousedopioidsforpersonalinjuriesmunicipalitiesandfirstnationsbandsin octoberanantitrustcomplaintwasfiledbyprivateplaintiffsinfederalcourtintennesseeandispendingtransferto themdltheseactionsallegeavarietyofclaimsrelatedtoopioidmarketingpracticesincludingfalseadvertisingunfair competitionpublicnuisanceconsumerfraudviolationsdeceptiveactsandpracticesfalseclaimsandunjustenrichment thesuitsgenerallyseekpenaltiesandorinjunctiveandmonetaryreliefandinsomeofthesuitstheplaintiffsareseeking jointandseveralliabilityamongthedefendantsanadversejudgmentinanyoftheselawsuitscouldresultintheimposition oflargemonetarypenaltiesandsignificantdamagesincludingpunitivedamagescostofabatementsubstantialfines equitableremediesandothersanctions inaugustthecompanyreceivedagrandjurysubpoenafromtheunitedstatesattorneysofficefortheeastern districtofnewyorkfordocumentsrelatedtothecompanysantidiversionpoliciesandproceduresanddistributionofits opioidmedicationsinwhatthecompanyunderstandstobepartofabroaderinvestigationintomanufacturersand distributorsmonitoringprogramsandreportingunderthecontrolledsubstancesact fromjunethroughdecemberthecompanysboardofdirectorsreceivedaseriesofshareholderdemand lettersallegingbreachesoffiduciarydutiesrelatedtothemarketingofopioidstheboardretainedindependentcounselto investigatetheallegationsinthedemandsandinaprilindependentcounseldeliveredareporttotheboard recommendingthatthecompanyrejecttheshareholderdemandsandtakethestepsthatarenecessaryorappropriateto securedismissalofrelatedderivativelitigationtheboardunanimouslyadoptedtherecommendationsoftheindependent counselsreport innovemberoneoftheshareholderswhosentademandfiledaderivativecomplaintagainstthecompanyasthe nominaldefendantandcertaincurrentandformerdirectorsandofficersasdefendantsinthesuperiorcourtofnew jerseythecomplaintallegesbreachesoffiduciarydutiesrelatedtothemarketingofopioidsandthatthecompanyhas suffereddamagesasaresultofthoseallegedbreachesaseriesofadditionalderivativecomplaintsmakingsimilar allegationsagainstthesameandsimilardefendantswerefiledinnewjerseystateandfederalcourtsinand byallbuttwostatecourtcaseshadbeenvoluntarilydismissedinfebruarythestatecourtgrantedthe companysmotiontodismissoneofthetwocasesandtheshareholderthatbroughtthesecondcasefiledanoticeof dismissaltheshareholderwhosecomplaintwasdismissedfiledamotionforreconsiderationinmaythestatecourt heldoralargumentonthemotionforreconsiderationandsubsequentlydeniedthemotiontheshareholderhasappealed thestatecourtsdismissalorder inaugustdepuyorthopaedicsincdepuyincnowknownasdepuysynthesincandjohnsonjohnson servicesinccollectivelydepuyreceivedaninformalrequestfromtheunitedstatesattorneysofficeforthedistrictof massachusettsandthecivildivisionoftheunitedstatesdepartmentofjusticetheunitedstatesfortheproductionof materialsrelatingtothedepuyasrxlhipdeviceinjulytheunitedstatesnotifiedtheunitedstatesdistrict courtforthedistrictofmassachusettsthatithaddeclinedtointerveneinaquitamcasefiledpursuanttothefalseclaims actagainstthecompaniesconcerningthehipdevicesinfebruarythedistrictcourtgrantedthecompanies motiontodismisswithprejudiceunsealedthequitamcomplaintanddeniedthequitamrelatorsrequestforleavetofilea furtheramendedcomplaintthequitamrelatorsappealedthecasetotheunitedstatescourtofappealsforthefirst circuitinjulythefirstcircuitaffirmedthedistrictcourtsdismissalinpartreversedinpartandaffirmedthe decisiontodenytherelatorsrequesttofileathirdamendedcomplaintinmarchdepuyfileditsmotiontostrikeand johnsonjohnsonannualreport dismisstherelatorssecondamendedcomplaintthedistrictcourtdenieddepuysmotiontostrikeanddismissin julydepuyfiledamotionforreconsiderationofthedistrictcourtsjulyrulinginnovemberthedistrict courtgranteddepuysmotionforreconsiderationanddismissedthecasewithprejudicethedistrictcourtsorderwas unsealedindecembertherelatorsfiledseveralpostdismissalmotionsincludingajanuaryomnibusmotion forreconsiderationwhichthedistrictcourtdeniedfollowingthedistrictcourtsorderdismissingthecasewith prejudicedepuyfiledadecembermotionseekingtherecoveryofattorneysfeesandcostswhichthedistrict courtdeniedexceptastocoststherelatorshaveappealedthedistrictcourtsdismissalofthecasetothefirstcircuit thebriefingontheappealiscompletethefirstcircuitheldoralargumentondecemberandthefirstcircuits decisionremainspending inoctoberthecompanywascontactedbythecaliforniaattorneygeneralsofficeregardingamultistateattorney generalinvestigationofthemarketingofsurgicalmeshproductsforherniaandurogynecologicalpurposesbythe companyssubsidiaryethiconincethiconinmaycaliforniaandwashingtonfiledcivilcomplaintsagainstthe companyethiconandethiconusllcallegingviolationsoftheirconsumerprotectionstatutessimilarcomplaintswere filedagainstthecompaniesbythefollowingstateskentuckymississippiwestvirginiaandoregoninaprilthe companyandethiconsettledthewashingtoncaseinoctoberthecompanyandethiconsettledthemultistate investigationwithotherstatesandthedistrictofcolumbiainaprilthecompanysettledthewestvirginiacase inoctoberthecompanysettledwiththeattorneygeneraloforegoninnovemberthecompanysettled withtheattorneygeneralofmississippitrialinthekentuckymatterisscheduledforjunethecaliforniacase startedtrialinjulyandconcludedinseptemberinjanuarythecourtincaliforniaissuedastatementof decisionfindinginfavorofthestateofcaliforniaandawardedcivilpenaltiesintheamountofmillioninapril thecourtincaliforniadeniedthecompanysmotionforanewtrialinaugustthecourtenteredjudgmentwith respecttothepenaltiesofmillionbutdeniedtheattorneygeneralsrequestforinjunctivereliefthecompany appealedthepenaltyjudgmentinaprilthecourtofappealsreducedthejudgmenttomillionbutotherwise deniedtheappealinjulythesupremecourtofcaliforniadeniedthecompanyspetitiontoreviewthecourtof appealsdecisionandthecompanyrecordedachargetoreflectthejudgmentinthesecondquarterofin novemberthecompanypetitionedtheunitedstatessupremecourtforreview injunethemississippiattorneygeneralfiledacomplaintinchancerycourtofthefirstjudicialdistrictofhinds countymississippiagainstthecompanyandjohnsonjohnsonconsumercompaniesincnowknownasjohnson johnsonconsumerinccollectivelyjjcithecomplaintallegesthatjjciviolatedthemississippiconsumerprotection actbyfailingtodiscloseallegedhealthrisksassociatedwithfemaleconsumersuseoftalccontainedinjohnsons babypowderandjohnsonsshowertoshoweraproductdivestedinandseeksinjunctiveandmonetaryrelief thecompanyandjjcimovedforsummaryjudgmentonthegroundsthatthestatesclaimwasbarredbypreemption whichthetrialcourtdeniedthemississippisupremecourtgrantedthecompanyandjjcisrequesttofilean interlocutoryappealofthedenialofthemotionforsummaryjudgmentinlatebriefingandoralargumentwere completedthereafterthecourtrejectedtheinterlocutoryappealinaprilandremandedthemattertothetrialcourt inaugustjjcifiledapetitionforwritofcertiorariintheunitedstatessupremecourtastothemississippi supremecourtsrulingofaprilindecembertheunitedstatessupremecourtdeniedthepetitionforwritof certiorariafterthemississippisupremecourtremandedthemattertothetrialcourtthestatemovedforatrialsetting jjciobjectedtoanytrialsettingasbarredbythestayarisingfromtheltlbankruptcycasereferencedabovewhilethe statearguedthatthestaydidnotapplyinjanuarythecourtgrantedthestatesmotionfortrialsettingand directedthepartiestoconsultwiththecourtadministratortosecureatrialdateinfebruarythetrialcourtsetthe casefortrialtobegininfebruaryhowevergiventheeffortstoresolvetalcrelatedclaimsintheltlbankruptcy casethecompanyandthestateagreedtoatemporarystayofdiscoveryuntilmaythetemporarystayexpiredin mayltlthereaftermovedtoenjoinprosecutionofthecaseintheltlbankruptcycaseinoctoberthe bankruptcycourtissuedanorderstayingthecasethestatefiledanappealtothethirdcircuitconcerningthestayorder injanuarythestateofnewmexicofiledaconsumerprotectioncaseallegingthatthecompanydeceptively marketedandsolditstalcumpowderproductsbymakingmisrepresentationsaboutthesafetyoftheproductsandthe presenceofcarcinogensincludingasbestosthestateofnewmexicofiledanamendedcomplaintinmarchthe companymovedtodismisscertainoftheclaimsintheamendedcomplaintwhichwasgrantedthecompanythenfiled amotionforpartialjudgmentonthepleadingsindecemberwhichwasdeniedinmarchthenewmexico courtdeniedthecompanysmotiontocompelthestateofnewmexicotoengageindiscoveryofstateagenciesand deniedthecompanysrequestforinterlocutoryappealofthatdecisionthecompanythenfiledapetitionforwritof superintendingcontrolandarequestforastaytothenewmexicosupremecourtontheissueofthestateof newmexicosdiscoveryobligationsinaprilinviewoftheeffortstoresolvetalcrelatedclaimsintheltl bankruptcycasethecompanyandthestateagreedtoadaystayofallmattersexceptforthependingwritbeforethe johnsonjohnsonannualreportnewmexicosupremecourtwhichexpiredinjunethereafterthecompanymovedtoenjoinprosecutionofthe caseintheltlbankruptcycaseinoctoberthebankruptcycourtissuedanorderstayingthecaseindecember thestatefiledanappealtothethirdcircuitconcerningthestayorderseparatelyinseptemberthe newmexicosupremecourtgrantedthecompanysrequestforastaypendingfurtherbriefingonthescopeofthestate ofnewmexicosdiscoveryobligations fortytwostatesandthedistrictofcolumbiahavecommencedajointinvestigationintothecompanysmarketingofits talcumpowderproductsatthistimethemultistategrouphasnotassertedanyclaimsagainstthecompanyfivestates haveissuedcivilinvestigativedemandsseekingdocumentsandotherinformationthecompanyhasproduced documentstoarizonanorthcarolinatexasandwashingtonandenteredintoconfidentialityagreementsthecompany hasnotreceivedanyfollowuprequestsfromthosestatesinmarcheachofthefortytwostatesincluding mississippiandnewmexicoagreedtomediationoftheirclaimsintheltlbankruptcycaseinjulynewmexico andmississippiindicatedtheywouldnolongervoluntarilysubmittofurthermediationintheltlbankruptcyandwould proceedwiththeirrespectivecasesinstatecourtltlmovedthenewjerseybankruptcycourtforanorderstaying furtherproceedingsinthosetwoactionswhichthebankruptcycourtgrantedinoctoberindecemberthe bankruptcycourtallowednewmexicoandmississippitofileadirectappealofitsstay injulythecompanyandjanssenproductslpwereservedwithaquitamcomplaintpursuanttothefalseclaims actfiledintheunitedstatesdistrictcourtforthedistrictofnewjerseyallegingtheofflabelpromotionoftwohiv productsprezistaandintelenceandantikickbackviolationsinconnectionwiththepromotionoftheseproducts thecomplaintwasfiledundersealindecemberthefederalandstategovernmentshavedeclinedtointerveneand thelawsuitisbeingprosecutedbytherelatorsthecourtdeniedsummaryjudgmentonallclaimsindecember daubertmotionsweregrantedinpartanddeniedinpartinjanuaryandthecaseisproceedingtotrial inmarchjanssenbiotechincjbireceivedacivilinvestigativedemandfromtheunitedstatesdepartmentof justiceregardingafalseclaimsactinvestigationconcerningmanagementandadvisoryservicesprovidedto rheumatologyandgastroenterologypracticesthatpurchasedremicadeorsimponiariainaugustthe unitedstatesdepartmentofjusticenotifiedjbithatitwasclosingtheinvestigationsubsequentlytheunitedstates districtcourtforthedistrictofmassachusettsunsealedaquitamfalseclaimsactcomplaintwhichwasservedonthe companythedepartmentofjusticehaddeclinedtointerveneinthequitamlawsuitinaugustthecompanyfiled amotiontodismisswhichwasgrantedinpartanddeniedinpartdiscoveryisunderway inaprilandseptemberthecompanyreceivedsubpoenasfromtheunitedstatesattorneyforthedistrictof massachusettsseekingdocumentsbroadlyrelatingtopharmaceuticalcopaymentsupportprogramsfordarzalex olysioremicadesimponistelaraandzytigathesubpoenasalsoseekdocumentsrelatingtoaverage manufacturerpriceandbestpricereportingtothecenterformedicareandmedicaidservicesrelatedtothoseproducts aswellasrebatepaymentstostatemedicaidagenciesthecompanyhasprovideddocumentsinresponsetothe subpoenas injunethecompanyreceivedasubpoenafromtheunitedstatesattorneysofficeforthedistrictof massachusettsseekinginformationregardingpracticespertainingtothesterilizationofdepuysynthesincdepuyspinal implantsatthreehospitalsinbostonaswellasinteractionsofemployeesofcompanysubsidiarieswithphysiciansat thesehospitalsthecompanyanddepuyfullycooperatedwiththegovernmentsinvestigationinjanuarythe companydepuysynthesincanddepuysynthessalesincenteredintoasettlementagreementwiththeunitedstates resolvingthematterforanimmaterialamount injulythepublicprosecutionserviceinriodejaneiroandrepresentativesfromthebrazilianantitrustauthority cadeinspectedtheofficesofmorethancompaniesincludingjohnsonjohnsondobrasilindstriaecomrciode produtosparasadeltdatheauthoritiesappeartobeinvestigatingallegationsofpossibleanticompetitivebehaviorand possibleimproperpaymentsinthemedicaldeviceindustrythecompanycontinuestorespondtoinquiriesregardingthe foreigncorruptpracticesactfromtheunitedstatesdepartmentofjusticeandtheunitedstatessecuritiesand exchangecommission fromtimetotimethecompanyhasreceivedrequestsfromavarietyofunitedstatescongressionalcommitteesto produceinformationrelevanttoongoingcongressionalinquiriesitisthepolicyofjohnsonjohnsontocooperatewith theseinquiriesbyproducingtherequestedinformation johnsonjohnsonannualreport generallitigation beginninginseptembermultiplepurportedclassactionswerefiledonbehalfofindirectpurchasersofremicade againstthecompanyandjanssenbiotechinccollectivelyjanssenallegingthatjanssenhasviolatedfederalantitrust lawsthroughitscontractingstrategiesforremicadethecaseswereconsolidatedforpretrialpurposesasinre remicadeantitrustlitigationinunitedstatesdistrictcourtfortheeasterndistrictofpennsylvaniathiscasewassettled infebruarythefinalapprovalhearingisscheduledforfebruary injunetheunitedstatesfederaltradecommissionftcissuedacivilinvestigativedemandtothecompany andjanssenbiotechinccollectivelyjansseninconnectionwithitsinvestigationofwhetherjanssensremicade contractingpracticesviolatefederalantitrustlawsthecompanyhasproduceddocumentsandinformationresponsiveto thecivilinvestigativedemandjanssenisinongoingdiscussionswiththeftcstaffregardingitsinquiry infebruarytheunitedstatesfederaltradecommissionftcissuedcivilinvestigativedemandstojohnson johnsonandjanssenbiotechinccollectivelyjansseninconnectionwithitsinvestigationofwhetheradvertising practicesforremicadeviolatefederallawjanssenhasproduceddocumentsandinformationresponsivetothecivil investigativedemandsjanssenisinongoingdiscussionswiththeftcstaffregardingtheinquiry injunegenmabasfiledanoticeforarbitrationwithinternationalinstituteforconflictpreventionandresolution cpragainstjanssenbiotechincseekingmilestonesandanextendedroyaltytermfordarzalexfasprojanssenfiled itsnoticeofdefenseinjulygenmabandjanssenhavecrossmovedforearlydispositionofthearbitration argumentwashadinjanuary inoctobercertainunitedstatesservicemembersandtheirfamiliesbroughtacomplaintagainstanumberof pharmaceuticalandmedicaldevicescompaniesincludingjohnsonjohnsonandcertainofitssubsidiariesinunited statesdistrictcourtforthedistrictofcolumbiaallegingthatthedefendantsviolatedtheunitedstatesantiterrorism actthecomplaintallegesthatthedefendantsprovidedfundingforterroristorganizationsthroughtheirsalespractices pursuanttopharmaceuticalandmedicaldevicecontractswiththeiraqiministryofhealthinjulythedistrictcourt dismissedthecomplaintinjanuarytheunitedstatescourtofappealsforthedistrictofcolumbiacircuitreversed thedistrictcourtsdecisioninfebruarydefendantspetitionedforrehearingenbanc inoctobertwoseparateputativeclassactionswerefiledagainstactelionpharmaceuticalltdactelion pharmaceuticalsusincandactelionclinicalresearchinccollectivelyactelioninunitedstatesdistrictcourtforthe districtofmarylandandunitedstatesdistrictcourtforthedistrictofcolumbiathecomplaintsallegethatactelion violatedstateandfederalantitrustandunfaircompetitionlawsbyallegedlyrefusingtosupplygenericpharmaceutical manufacturerswithsamplesoftracleertracleerissubjecttoariskevaluationandmitigationstrategyrequiredby thefoodanddrugadministrationwhichimposesrestrictionsondistributionoftheproductinjanuarytheplaintiffs dismissedthedistrictofcolumbiacaseandfiledaconsolidatedcomplaintintheunitedstatesdistrictcourtforthe districtofmarylandinoctoberthecourtgrantedactelionsmotiontodismisstheamendedcomplaintin apriltheunitedstatescourtofappealsforthefourthcircuitreversedandremandeddiscoveryisongoing inmayaclassactionantitrustcomplaintwasfiledagainstjanssenrdirelandjanssenandjohnsonjohnsonin theunitedstatesdistrictcourtforthenortherndistrictofcaliforniathecomplaintallegesthatjanssenviolatedfederal andstateantitrustandconsumerprotectionlawsbyagreeingtoexclusivityprovisionsinitsagreementswithgilead concerningthedevelopmentandmarketingofcombinationantiretroviraltherapiescarttotreathivthecomplaintalso allegesthatgileadenteredintosimilaragreementswithbristolmyerssquibbandjapantobaccoinmarchthe courtgrantedinpartanddeniedinpartdefendantsmotionstodismissplaintiffsfiledanamendedcomplaintin aprildefendantsmovedtodismisstheamendedcomplaintinjulythecourtgrantedinpartanddeniedin parttherenewedmotiontodismissindecemberseveralinsurancecompaniesandotherpayersfiledindividual optoutcomplaintscontainingallegationssimilartotheoriginalcomplaintinseptemberthecourtgrantedin partanddeniedinpartplaintiffsmotionforclasscertificationinjanuarythecourtgrantedinpartanddeniedin partdefendantsmotionforsummaryjudgmenttrialisscheduledformay inoctoberinnovativehealthllcfiledacomplaintagainstbiosensewebsterincbwiintheunitedstates districtcourtforthemiddledistrictofcaliforniathecomplaintallegesthatcertainofbwisbusinesspracticesand contractualtermsviolatetheantitrustlawsoftheunitedstatesandthestateofcaliforniabyrestrictingcompetitioninthe saleofhighdensitymappingcathetersandultrasoundcathetersinjanuarybwifiledamotiontodismissthe complaintinaugustthecourtgrantedinpartanddeniedinpartbwismotiontodismissindecember bwifiledamotionforsummaryjudgmentinmarchthecourtgrantedbwismotionforsummaryjudgmentin aprilinnovativeappealedthisrulingtotheunitedstatescourtofappealsfortheninthcircuit johnsonjohnsonannualreportinnovemberthecompanyreceivedademandforindemnificationfrompfizerincpfizerpursuanttothe stockandassetpurchaseagreementbetweenthecompanyandpfizeralsoinnovemberjohnsonjohnsoninc receivednoticereservingrightstoclaimindemnificationfromsanoficonsumerhealthincsanofipursuanttothe assetpurchaseagreementbetweenjohnsonjohnsonincandsanofiinjanuaryjohnsonjohnsonreceiveda demandforindemnificationfromboehringeringelheimpharmaceuticalsincboehringeringelheimpursuanttothe assetpurchaseagreementamongthecompanypfizerandboehringeringelheiminnovemberjohnson johnsonreceivedademandforindemnificationfromglaxosmithklinellcgskpursuanttothestockandasset purchaseagreementbetweenthecompanyandpfizerandcertainandagreementsbetweenglaxo wellcomeandwarnerlambertentitiesthenoticesseekindemnificationforlegalclaimsrelatedtooverthecounter zantacranitidineproductsplaintiffsintheunderlyingactionsallegethatzantacandotheroverthecounter ranitidinemedicationscontainunsafelevelsofndmannitrosodimethylamineandcancauseandorhavecausedvarious cancersinpatientsusingtheproductsandseekinjunctiveandmonetaryreliefthecompanyandjohnsonjohnsoninc havealsobeennamedinputativeclassactionsfiledincanadawithsimilarallegationsregardingzantacorranitidine usejohnsonjohnsonincwasalsonamedasadefendantalongwithothermanufacturersinvariouspersonalinjury actionsincanadarelatedtozantacproductsjohnsonjohnsoninchasprovidedsanofinoticereservingrightsto claimindemnificationpursuanttotheassetpurchaseagreementrelatedtotheclassactionsandpersonalinjury actions inoctoberfortisadvisorsllcfortisinitscapacityasrepresentativeoftheformerstockholdersofaurishealth incaurisfiledacomplaintagainstthecompanyethiconincandcertainnamedofficersandemployeescollectively ethiconinthecourtofchanceryofthestateofdelawarethecomplaintallegesbreachofcontractfraudandother causesofactionagainstethiconinconnectionwithethiconsacquisitionofaurisinthecomplaintseeksdamages andotherreliefindecemberthecourtgrantedinpartanddeniedinpartdefendantsmotiontodismisscertain causesofactionallclaimsagainsttheindividualdefendantsweredismissedthetrialisscheduledforjanuary injunejanssenpharmaceuticalsincfiledademandforarbitrationagainstemergentbiosolutionsincetal ebsiwiththeamericanarbitrationassociationallegingthatebsibreachedthepartiesmanufacturingservices agreementforthecompanyscovidvaccineinjulyemergentfileditsansweringstatementand counterclaims inoctoberjanssenpharmaceuticalsincfiledademandforarbitrationagainstmercksharpdohmecorpwith theamericanarbitrationassociationpursuanttothepartiesagreementsrelatingtoproductionofdrugsubstanceand drugproductforthecompanyscovidvaccinealsoinoctobermerckfileditsanswerandcounterclaims beginninginmaymultipleputativeclassactionswerefiledinstateandfederalcourtscaliforniafloridanewyork andnewjerseyagainstvariousjohnsonjohnsonentitiesallegingviolationsofstateconsumerfraudstatutesbasedon nondisclosureofallegedbenzenecontaminationofcertainneutrogenaandaveenosunscreenproductsandthe affirmativepromotionofthoseproductsassafeandinatleastonecaseallegingastrictliabilitymanufacturingdefect andfailuretowarnclaimsassertingthatthenamedplaintiffssufferedunspecifiedinjuriesasaresultofallegedexposure tobenzenethejudicialpanelonmultidistrictlitigationhasconsolidatedallpendingactionsexceptoneproductliability caseandonecasependinginnewjerseystatecourtintheunitedstatesdistrictcourtforthesoutherndistrictof floridafortlauderdaledivisioninoctoberthecompanyreachedanagreementinprincipleforthesettlementofa nationwideclassencompassingtheclaimsoftheconsolidatedactionssubjecttoapprovalbythefloridafederalcourtin decemberplaintiffsintheconsolidatedactionsfiledamotionforpreliminaryapprovalofanationwideclass settlementthesettlementwaspreliminarilyapprovedbythecourtinmarch thecompanysubsequentlysubstitutedbyjohnsonjohnsonconsumerincjjcialongwithmorethanother companiesisadefendantinacostrecoveryandcontributionactionbroughtbyoccidentalchemicalcorporationin juneintheunitedstatesdistrictcourtforthedistrictofnewjerseyrelatedtothecleanupofasectionofthe lowerpassaicriverinnewjersey thecompanyoritssubsidiariesarealsopartiestovariousproceedingsbroughtunderthecomprehensiveenvironmental responsecompensationandliabilityactcommonlyknownassuperfundandcomparablestatelocalorforeignlawsin whichtheprimaryreliefsoughtisthecostofpastandorfutureremediation johnsonjohnsonannualreport restructuring inthefiscalsecondquarterofthecompanyannouncedplanstoimplementaseriesofactionsacrossitsglobal supplychainthatareintendedtofocusresourcesandincreaseinvestmentsinthecriticalcapabilitiestechnologiesand solutionsnecessarytomanufactureandsupplyitsproductportfolioenhanceagilityanddrivegrowththeglobalsupply chainactionsincludeexpandingtheuseofstrategiccollaborationsandbolsteringinitiativestoreducecomplexityimprove costcompetitivenessenhancecapabilitiesandoptimizethesupplychainnetworkinfiscalyearthecompany recordedapretaxchargeofbillionwhichisincludedonthefollowinglinesoftheconsolidatedstatementof earningsbillioninrestructuringbillioninotherincomeexpenseandbillionincostofproductssoldtotal projectcostsofapproximatelybillionhavebeenrecordedsincetherestructuringwasannouncedtheprogramwas completedinthefiscalfourthquarterof thefollowingtablesummarizestheseverancechargesandtheassociatedspendingundertheseinitiativesthroughthe fiscalyearended dollarsinmillions severance assetwriteoffssales total reservebalancejanuary activity reservebalancejanuary currentyearactivity charges cashsettlements settlednoncash reservebalancejanuary althoughtherestructuringprogramhasbeencompletedinthefiscalyearthecompanyexpectsthatseverancechargeswill continuebeyondthatdatethereservebalanceasofjanuaryisrecordedintheemployeerelatedobligationaccountinthe consolidatedbalancesheet otherincludesprojectexpensesuchassalariesforemployeessupportingtheseinitiativesandconsultingexpenses representsgainonsaleofassets johnsonjohnsonannualreportreport independent registered public accounting firm totheboardofdirectorsandshareholdersofjohnsonjohnson opinionsonthefinancialstatementsandinternalcontroloverfinancialreporting wehaveauditedtheaccompanyingconsolidatedbalancesheetsofjohnsonjohnsonanditssubsidiariesthe companyasofjanuaryandjanuaryandtherelatedconsolidatedstatementsofearningsof comprehensiveincomeofequityandofcashflowsforeachofthethreefiscalyearsintheperiodendedjanuary includingtherelatednotescollectivelyreferredtoastheconsolidatedfinancialstatementswealsohaveauditedthe companysinternalcontroloverfinancialreportingasofjanuarybasedoncriteriaestablishedininternalcontrol integratedframeworkissuedbythecommitteeofsponsoringorganizationsofthetreadwaycommission coso inouropiniontheconsolidatedfinancialstatementsreferredtoabovepresentfairlyinallmaterialrespectsthefinancial positionofthecompanyasofjanuaryandjanuaryandtheresultsofitsoperationsanditscashflows foreachofthethreefiscalyearsintheperiodendedjanuaryinconformitywithaccountingprinciplesgenerally acceptedintheunitedstatesofamericaalsoinouropinionthecompanymaintainedinallmaterialrespectseffective internalcontroloverfinancialreportingasofjanuarybasedoncriteriaestablishedininternalcontrolintegrated frameworkissuedbythecoso basisforopinions thecompanysmanagementisresponsiblefortheseconsolidatedfinancialstatementsformaintainingeffectiveinternal controloverfinancialreportingandforitsassessmentoftheeffectivenessofinternalcontroloverfinancialreporting includedintheaccompanyingmanagementsreportoninternalcontroloverfinancialreportingourresponsibilityisto expressopinionsonthecompanysconsolidatedfinancialstatementsandonthecompanysinternalcontroloverfinancial reportingbasedonourauditsweareapublicaccountingfirmregisteredwiththepubliccompanyaccountingoversight boardunitedstatespcaobandarerequiredtobeindependentwithrespecttothecompanyinaccordancewiththe usfederalsecuritieslawsandtheapplicablerulesandregulationsofthesecuritiesandexchangecommissionandthe pcaob weconductedourauditsinaccordancewiththestandardsofthepcaobthosestandardsrequirethatweplanand performtheauditstoobtainreasonableassuranceaboutwhethertheconsolidatedfinancialstatementsarefreeofmaterial misstatementwhetherduetoerrororfraudandwhethereffectiveinternalcontroloverfinancialreportingwasmaintained inallmaterialrespects ourauditsoftheconsolidatedfinancialstatementsincludedperformingprocedurestoassesstherisksofmaterial misstatementoftheconsolidatedfinancialstatementswhetherduetoerrororfraudandperformingproceduresthat respondtothoseriskssuchproceduresincludedexaminingonatestbasisevidenceregardingtheamountsand disclosuresintheconsolidatedfinancialstatementsourauditsalsoincludedevaluatingtheaccountingprinciplesused andsignificantestimatesmadebymanagementaswellasevaluatingtheoverallpresentationoftheconsolidatedfinancial statementsourauditofinternalcontroloverfinancialreportingincludedobtaininganunderstandingofinternalcontrol overfinancialreportingassessingtheriskthatamaterialweaknessexistsandtestingandevaluatingthedesignand operatingeffectivenessofinternalcontrolbasedontheassessedriskourauditsalsoincludedperformingsuchother proceduresasweconsiderednecessaryinthecircumstanceswebelievethatourauditsprovideareasonablebasisfor ouropinions asdescribedinmanagementsreportoninternalcontroloverfinancialreportingmanagementhasexcludedabiomed incabiomedfromitsassessmentofinternalcontroloverfinancialreportingasofjanuarybecauseitwas acquiredbythecompanyinabusinesscombinationduringwehavealsoexcludedabiomedfromourauditof internalcontroloverfinancialreportingabiomedisawhollyownedsubsidiarywhosetotalassetsandtotalsalesexcluded frommanagementsassessmentandourauditofinternalcontroloverfinancialreportingrepresentlessthanofeachof therelatedconsolidatedfinancialstatementamountsasofandforthefiscalyearendedjanuary definitionandlimitationsofinternalcontroloverfinancialreporting acompanysinternalcontroloverfinancialreportingisaprocessdesignedtoprovidereasonableassuranceregardingthe reliabilityoffinancialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewith johnsonjohnsonannualreport generallyacceptedaccountingprinciplesacompanysinternalcontroloverfinancialreportingincludesthosepoliciesand proceduresthatipertaintothemaintenanceofrecordsthatinreasonabledetailaccuratelyandfairlyreflectthe transactionsanddispositionsoftheassetsofthecompanyiiprovidereasonableassurancethattransactionsare recordedasnecessarytopermitpreparationoffinancialstatementsinaccordancewithgenerallyacceptedaccounting principlesandthatreceiptsandexpendituresofthecompanyarebeingmadeonlyinaccordancewithauthorizationsof managementanddirectorsofthecompanyandiiiprovidereasonableassuranceregardingpreventionortimelydetection ofunauthorizedacquisitionuseordispositionofthecompanysassetsthatcouldhaveamaterialeffectonthefinancial statements becauseofitsinherentlimitationsinternalcontroloverfinancialreportingmaynotpreventordetectmisstatementsalso projectionsofanyevaluationofeffectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequate becauseofchangesinconditionsorthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate criticalauditmatters thecriticalauditmatterscommunicatedbelowaremattersarisingfromthecurrentperiodauditoftheconsolidated financialstatementsthatwerecommunicatedorrequiredtobecommunicatedtotheauditcommitteeandthatirelateto accountsordisclosuresthatarematerialtotheconsolidatedfinancialstatementsandiiinvolvedourespecially challengingsubjectiveorcomplexjudgmentsthecommunicationofcriticalauditmattersdoesnotalterinanywayour opinionontheconsolidatedfinancialstatementstakenasawholeandwearenotbycommunicatingthecriticalaudit mattersbelowprovidingseparateopinionsonthecriticalauditmattersorontheaccountsordisclosurestowhichthey relate uspharmaceuticalrebatereservesmanagedcaremedicareandmedicaid asdescribedinnotetotheconsolidatedfinancialstatementsthecompanyrecognizesrevenuefromproductsales whenobligationsunderthetermsofacontractwiththecustomeraresatisfiedrebatesanddiscountsprovidedto customersareaccountedforasvariableconsiderationandrecordedasareductioninsalestheliabilityforsuchrebates anddiscountsisrecognizedwithinaccruedrebatesreturnsandpromotionsontheconsolidatedbalancesheeta significantportionoftheliabilityrelatedtorebatesisfromthesaleofpharmaceuticalgoodswithintheusprimarilythe managedcaremedicareandmedicaidprogramswhichamountedtobillionasofjanuaryforsignificant rebateprogramswhichincludetheusmanagedcaremedicareandmedicaidrebateprogramsrebatesanddiscounts estimatedbymanagementarebasedoncontractualtermshistoricalexperiencepatientoutcomestrendanalysisand projectedmarketconditionsintheuspharmaceuticalmarket theprincipalconsiderationsforourdeterminationthatperformingproceduresrelatingtouspharmaceuticalrebate reservesmanagedcaremedicareandmedicaidisacriticalauditmatterarethesignificantjudgmentbymanagement duetothesignificantmeasurementuncertaintyinvolvedindevelopingthesereservesandthehighdegreeofauditor judgmentsubjectivityandauditeffortinperformingproceduresandevaluatingtheassumptionsrelatedtocontractual termshistoricalexperiencepatientoutcomestrendanalysisandprojectedmarketconditionsintheuspharmaceutical market addressingthematterinvolvedperformingproceduresandevaluatingauditevidenceinconnectionwithformingour overallopinionontheconsolidatedfinancialstatementstheseproceduresincludedtestingtheeffectivenessofcontrols relatingtouspharmaceuticalrebatereservesmanagedcaremedicareandmedicaidincludingcontrolsoverthe assumptionsusedtoestimatetheserebatestheseproceduresalsoincludedamongothersidevelopingan independentestimateoftherebatesbyutilizingthirdpartyinformationonpriceandmarketconditionsintheus pharmaceuticalmarketthetermsofthespecificrebateprogramsandthehistoricalexperienceandtrendanalysisof actualrebateclaimspaidiitestingrebateclaimsprocessedbythecompanyincludingevaluatingthoseclaimsfor consistencywiththecontractualandmandatedtermsofthecompanysrebatearrangementsandiiicomparingthe independentestimatestomanagementsestimates litigationcontingenciestalc asdescribedinnotesandtotheconsolidatedfinancialstatementsthecompanyrecordsaccrualsforloss contingenciesassociatedwithlegalmattersincludingtalcwhenitisprobablethataliabilitywillbeincurredandthe amountofthelosscanbereasonablyestimatedtotheextentadverseawardsjudgmentsorverdictshavebeenrendered againstthecompanymanagementdoesnotrecordanaccrualuntilalossisdeterminedtobeprobableandcanbe reasonablyestimatedforthesemattersmanagementisunabletoestimatethepossiblelossorrangeoflossbeyondthe johnsonjohnsonannualreportamountsaccruedamountsaccruedforlegalcontingenciesoftenresultfromacomplexseriesofjudgmentsaboutfuture eventsanduncertaintiesthatrelyheavilyonestimatesandassumptionsincludingtimingofrelatedpaymentstheabilityto makesuchestimatesandjudgmentscanbeaffectedbyvariousfactorsincludingamongotherthingswhetherdamages soughtintheproceedingsareunsubstantiatedorindeterminatescientificandlegaldiscoveryhasnotcommencedoris notcompleteproceedingsareinearlystagesmatterspresentlegaluncertaintiestherearesignificantfactsindispute proceduralorjurisdictionalissuestheuncertaintyandunpredictabilityofthenumberofpotentialclaimsabilitytoachieve comprehensivemultipartysettlementscomplexityofrelatedcrossclaimsandcounterclaimsandortherearenumerous partiesinvolvedmanagementcontinuestobelievethatthecompanyhasstronglegalgroundstocontestthetalcverdicts ithasappealednotwithstandingmanagementsconfidenceinthesafetyofthecompanystalcproductsincertain circumstancesthecompanyhassettledcasesinoctoberjohnsonjohnsonconsumerincoldjjciawholly ownedsubsidiaryofjohnsonjohnsonimplementedacorporaterestructuringandcreatedasubsidiaryltl managementllcltlwhichbecamesolelyresponsibleforthetalcrelatedliabilitiesandanothersubsidiarynewjjci whichbecameresponsiblefortheremainingbusinessofoldjjciltlfiledavoluntarypetitionseekingreliefunder chapterofthebankruptcycodeasaresultoftheltlbankruptcycasethecourtenteredatemporaryrestraining orderstayingalllitigationagainstltlandoldjjcionnovemberthenorthcarolinabankruptcycourt confirmedthescopeofthestayissuingapreliminaryinjunctionpiprohibitingandenjoiningthecommencementand prosecutionoftalcrelatedclaimsagainstltloldjjcinewjjcijohnsonjohnsonotheroftheircorporateaffiliates identifiedretailersinsurancecompaniesandcertainotherpartiestheltlbankruptcycasewastransferredtothe unitedstatesbankruptcycourtforthedistrictofnewjerseyinnovemberandthatcourtextendedthepithrough theendoffebruaryclaimantsfiledmotionstodismisstheltlbankruptcycaseandfollowingamultipleday hearingthenewjerseybankruptcycourtdeniedthosemotionsbyorderissuedinmarchthenewjersey bankruptcycourtsimultaneouslyissuedanotherorderextendingthestayastotheprotectedpartiestheclaimants subsequentlyfilednoticesofappealastothedenialofthemotionstodismissandtheextensionofthestayinmay thethirdcircuitcourtofappealsgrantedthepetitionstoappealthebriefingandoralargumentontheappeal werecompletedinseptemberonjanuarythethirdcircuitreversedthebankruptcycourtsrulingand remandedtothebankruptcycourttodismisstheltlbankruptcyltlhasfiledapetitionforrehearingonthedecision theprincipalconsiderationsforourdeterminationthatperformingproceduresrelatingtothetalclitigationisacriticalaudit matterarethesignificantjudgmentbymanagementwhenassessingthelikelihoodofalossbeingincurredandwhen determiningwhetherareasonableestimateofthelossorrangeoflossforthefutureandexistingtalcclaimscanbemade whichinturnledtoahighdegreeofauditorjudgmentsubjectivityandeffortinperformingproceduresandevaluating managementsassessmentofthelosscontingenciesassociatedwiththislitigation addressingthematterinvolvedperformingproceduresandevaluatingauditevidenceinconnectionwithformingour overallopinionontheconsolidatedfinancialstatementstheseproceduresincludedtestingtheeffectivenessofcontrols relatingtomanagementsevaluationofthetalclitigationincludingcontrolsoverdeterminingwhetheralossisprobable andwhethertheamountoflosscanbereasonablyestimatedaswellasfinancialstatementdisclosuresthese proceduresalsoincludedamongothersigaininganunderstandingofthecompanysprocessaroundtheaccounting andreportingforthetalclitigationiidiscussingthestatusofsignificantknownactualandpotentiallitigationandthe ongoingltlbankruptcyproceedingswiththecompanysinhouselegalcounselaswellasexternalcounselwhen deemednecessaryiiiobtainingandevaluatingthelettersofauditinquirywithinternalandexternallegalcounselfor significantlitigationivevaluatingthereasonablenessofmanagementsassessmentregardingwhetheranunfavorable outcomeisreasonablypossibleorprobableandreasonablyestimableandvevaluatingthesufficiencyofthecompanys litigationcontingenciesdisclosures spricewaterhousecoopersllp florhamparknewjersey february wehaveservedasthecompanysauditorsinceatleastwehavenotbeenabletodeterminethespecificyearwe beganservingasauditorofthecompany johnsonjohnsonannualreport managements report internal control financial reporting undersectionofthesarbanesoxleyactofmanagementisrequiredtoassesstheeffectivenessofthe companysinternalcontroloverfinancialreportingasoftheendofeachfiscalyearandreportbasedonthatassessment whetherthecompanysinternalcontroloverfinancialreportingiseffective managementofthecompanyisresponsibleforestablishingandmaintainingadequateinternalcontroloverfinancial reportingthecompanysinternalcontroloverfinancialreportingisdesignedtoprovidereasonableassuranceastothe reliabilityofthecompanysfinancialreportingandthepreparationofexternalfinancialstatementsinaccordancewith generallyacceptedaccountingprinciples internalcontrolsoverfinancialreportingnomatterhowwelldesignedhaveinherentlimitationsthereforeinternalcontrol overfinancialreportingdeterminedtobeeffectivecanprovideonlyreasonableassurancewithrespecttofinancial statementpreparationandmaynotpreventordetectallmisstatementsmoreoverprojectionsofanyevaluationof effectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequatebecauseofchangesin conditionsorthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate thecompanysmanagementhasassessedtheeffectivenessofthecompanysinternalcontroloverfinancialreportingas ofjanuaryinmakingthisassessmentthecompanyusedthecriteriaestablishedbythecommitteeof sponsoringorganizationsofthetreadwaycommissioncosoininternalcontrolintegratedframework thesecriteriaareintheareasofcontrolenvironmentriskassessmentcontrolactivitiesinformationandcommunication andmonitoringthecompanysassessmentincludedextensivedocumentingevaluatingandtestingthedesignand operatingeffectivenessofitsinternalcontrolsoverfinancialreporting thecompanyacquiredabiomedincabiomedinabusinesscombinationindecemberabiomedstotalassets excludingintangibleassetsandgoodwillandtotalsalesrepresentedlessthanofeachoftherelatedconsolidated financialstatementamountsasofandforthefiscalyearendedjanuaryastheacquisitionoccurredinthefiscal yearthescopeofthecompanysassessmentofthedesignandeffectivenessofinternalcontroloverfinancial reportingforthefiscalyearexcludedtheabovementionedacquisitionthisexclusionisinaccordancewiththe secsgeneralguidancethatanassessmentofarecentlyacquiredbusinessmaybeomittedfromthescopeintheyearof acquisition basedonthecompanysprocessesandassessmentasdescribedabovemanagementhasconcludedthatasof januarythecompanysinternalcontroloverfinancialreportingwaseffective theeffectivenessofthecompanysinternalcontroloverfinancialreportingasofjanuaryhasbeenauditedby pricewaterhousecoopersllpanindependentregisteredpublicaccountingfirmasstatedintheirreportwhichappears herein sjduato sjosephjwolk joaquinduato josephjwolk chairmanboardofdirectors executivevicepresident chiefexecutiveofficer chieffinancialofficer johnsonjohnsonannualreportshareholder return performance graphs setforthbelowarelinegraphscomparingthecumulativetotalshareholderreturnonthecompanyscommonstockfor periodsoffiveyearsandtenyearsendingjanuaryagainstthecumulativetotalreturnofthestandardpoors stockindexthestandardpoorspharmaceuticalindexandthestandardpoorshealthcareequipmentindex thegraphsandtablesassumethatwasinvestedondecemberanddecemberineachofthe companyscommonstockthestandardpoorsstockindexthestandardpoorspharmaceuticalindexandthe standardpoorshealthcareequipmentindexandthatalldividendswerereinvested yearshareholderreturn performancejjvsindices johnson johnson sp index sp pharmaceucidcal index sp healthcare equipment index year cagr jj sp sp pharm sp hc equip johnsonjohnson spindex sppharmaceuticalindex sphealthcareequipmentindex yearshareholderreturn performancejjvsindices johnson johnson sp index sp pharmaceucidcal index sp healthcare equipment index year cagr jj sp sp pharm sp hc equip johnsonjohnson spindex sppharmaceuticalindex sphealthcareequipmentindex johnsonjohnsonannualreport item changes disagreements accountants accounting financial disclosure notapplicable item controls procedures disclosurecontrolsandproceduresattheendoftheperiodcoveredbythisreportthecompanyevaluatedthe effectivenessofthedesignandoperationofitsdisclosurecontrolsandproceduresthecompanysdisclosurecontrols andproceduresaredesignedtoensurethatinformationrequiredtobedisclosedbythecompanyinthereportsthatit filesorsubmitsundertheexchangeactisrecordedprocessedsummarizedandreportedwithinthetimeperiods specifiedinthesecsrulesandformsdisclosurecontrolsandproceduresincludewithoutlimitationcontrolsand proceduresdesignedtoensurethatinformationrequiredtobedisclosedbythecompanyinthereportsthatitfilesor submitsundertheexchangeactisaccumulatedandcommunicatedtothecompanysmanagementincludingitsprincipal executiveandprincipalfinancialofficersorpersonsperformingsimilarfunctionsasappropriatetoallowtimelydecisions regardingrequireddisclosurejoaquinduatochairmanandchiefexecutiveofficerandjosephjwolkexecutivevice presidentchieffinancialofficerreviewedandparticipatedinthisevaluationbasedonthisevaluationmessrsduato andwolkconcludedthatasoftheendoftheperiodcoveredbythisreportthecompanysdisclosurecontrolsand procedureswereeffective reportsoninternalcontroloverfinancialreportingtheinformationcalledforbythisitemisincorporatedhereinby referencetomanagementsreportoninternalcontroloverfinancialreportingandtheattestationregardinginternal controlsoverfinancialreportingincludedinthereportofindependentregisteredpublicaccountingfirmincludedin itemofthisreport changesininternalcontroloverfinancialreportingduringthefiscalquarterendedjanuarytherewereno changesinthecompanysinternalcontroloverfinancialreportingidentifiedinconnectionwiththeevaluationrequired underrulesaanddundertheexchangeactthathavemateriallyaffectedorarereasonablylikelyto materiallyaffectthecompanysinternalcontroloverfinancialreportingthecompanycontinuestomonitorandassess theeffectivenessofthedesignandoperationofitsdisclosurecontrolsandprocedures thecompanyisimplementingamultiyearenterprisewideinitiativetointegratesimplifyandstandardizeprocessesand systemsforthehumanresourcesinformationtechnologyprocurementsupplychainandfinancefunctionstheseare enhancementstosupportthegrowthofthecompanysfinancialsharedservicecapabilitiesandstandardizefinancial systemsthisinitiativeisnotinresponsetoanyidentifieddeficiencyorweaknessinthecompanysinternalcontrolover financialreportinginresponsetothisinitiativethecompanyhasandwillcontinuetoalignandstreamlinethedesignand operationofitsfinancialcontrolenvironment item b information notapplicable item c disclosure regarding foreign jurisdictions prevent inspections notapplicable johnsonjohnsonannualreportpart iii item directors executive officers corporate governance theinformationcalledforbythisitemisincorporatedhereinbyreferencetothediscussionoftheauditcommitteeunder thecaptionitemelectionofdirectorsboardcommitteesandthematerialunderthecaptionsitemelectionof directorsandifapplicablestockownershipandsectioncompliancedelinquentsectionareportsinthe proxystatementandthematerialunderthecaptionexecutiveofficersoftheregistrantinpartiofthisreport thecompanyscodeofbusinessconductwhichcoversallemployeesincludingthechiefexecutiveofficerchief financialofficerandcontrollermeetstherequirementsofthesecrulespromulgatedundersectionofthe sarbanesoxleyactofthecodeofbusinessconductisavailableonthecompanyswebsiteatwwwjnjcom codeofbusinessconductandcopiesareavailabletoshareholderswithoutchargeuponwrittenrequesttothesecretary atthecompanysprincipalexecutiveofficesanysubstantiveamendmenttothecodeofbusinessconductoranywaiver ofthecodegrantedtothechiefexecutiveofficerthechieffinancialofficerorthecontrollerwillbepostedonthe companyswebsiteatwwwinvestorjnjcomgovcfmwithinfivebusinessdaysandretainedonthewebsiteforatleastone year inadditionthecompanyhasadoptedacodeofbusinessconductethicsformembersoftheboardofdirectorsand executiveofficersthecodeofbusinessconductethicsformembersoftheboardofdirectorsandexecutiveofficers isavailableonthecompanyswebsiteatwwwinvestorjnjcomgovboardconductcfmandcopiesareavailableto shareholderswithoutchargeuponwrittenrequesttothesecretaryatthecompanysprincipalexecutiveofficesany substantiveamendmenttothecodeoranywaiverofthecodegrantedtoanymemberoftheboardofdirectorsorany executiveofficerwillbepostedonthecompanyswebsiteatwwwinvestorjnjcomgovcfmwithinfivebusinessdaysand retainedonthewebsiteforatleastoneyear item executive compensation theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptionsitem electionofdirectorsdirectorcompensationanditemcompensationbenefitscommitteereport compensationdiscussionandanalysisandexecutivecompensationtablesintheproxystatement thematerialincorporatedhereinbyreferencetothematerialunderthecaptioncompensationbenefitscommittee reportintheproxystatementshallbedeemedfurnishedandnotfiledinthisreportandshallnotbedeemed incorporatedbyreferenceintoanyfilingunderthesecuritiesactofasamendedorthesecuritiesexchangeactof asamendedasaresultofthisfurnishingexcepttotheextentthatthecompanyspecificallyincorporatesitby reference item security ownership certain beneficial owners management related stockholder matters theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptionitem stockownershipandsectioncomplianceintheproxystatementandnotecommonstockstockoptionplans andstockcompensationagreementsofthenotestoconsolidatedfinancialstatementsinitemofthisreport johnsonjohnsonannualreport equity compensation plan information thefollowingtableprovidescertaininformationasofjanuaryconcerningthesharesofthecompanyscommon stockthatmaybeissuedunderexistingequitycompensationplans numberof securitiesto beissuedupon weightedaverage numberofsecurities exerciseof exercisepriceof remainingavailablefor outstanding outstanding futureissuanceunderequity plancategory optionsandrights optionsandrights compensationplans equitycompensationplansapprovedbysecurity holders equitycompensationplansnotapprovedbysecurity holders total includedinthiscategoryarethefollowingequitycompensationplanswhichhavebeenapprovedbythecompanysshareholders longtermincentiveplanandlongtermincentiveplan thiscolumnexcludessharesreflectedunderthecolumnnumberofsecuritiestobeissueduponexerciseofoutstandingoptions andrights thelongtermincentiveplanexpiredaprilalloptionsandrestrictedsharesgrantedsubsequenttothatdatewere underthelongtermincentiveplan item certain relationships related transactions director independence theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptionsitem electionofdirectorsdirectorindependenceandrelatedpersontransactionsintheproxystatement item principal accountant fees services theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptionitem ratificationofappointmentofindependentregisteredpublicaccountingfirmintheproxystatement johnsonjohnsonannualreportpart iv item exhibits financial statement schedules thefollowingdocumentsarefiledaspartofthisreport financialstatements consolidatedbalancesheetsatendoffiscalyearsand consolidatedstatementsofearningsforfiscalyearsand consolidatedstatementsofcomprehensiveincomeforfiscalyearsand consolidatedstatementsofequityforfiscalyearsand consolidatedstatementsofcashflowsforfiscalyearsand notestoconsolidatedfinancialstatements reportofindependentregisteredpublicaccountingfirm allschedulesareomittedbecausetheyarenotapplicableortherequiredinformationisincludedinthefinancial statementsornotes exhibitsrequiredtobefiledbyitemlofregulationsk theinformationcalledforbythisitemisincorporatedhereinbyreferencetotheexhibitindexinthisreport item summary registrantsmayvoluntarilyincludeasummaryofinformationrequiredbyformkunderthisitemthecompanyhas electednottoincludesuchsummaryinformation johnsonjohnsonannualreport signatures pursuanttotherequirementsofsectionofthesecuritiesexchangeactoftheregistranthasdulycausedthis reporttobesignedonitsbehalfbytheundersignedthereuntodulyauthorized datefebruary johnsonjohnson registrant sjduato jduatochairmanoftheboard andchiefexecutiveofficer pursuanttotherequirementsofthesecuritiesexchangeactofthisreporthasbeensignedbelowbythefollowing personsonbehalfoftheregistrantandinthecapacitiesandonthedatesindicated signature title date sjduato chairmanoftheboard february jduato chiefexecutiveofficer principalexecutiveofficer sjjwolk chieffinancialofficer february jjwolk principalfinancialofficer srjdeckerjr controllerandchiefaccountingofficer february rjdeckerjr principalaccountingofficer sdadamczyk director february dadamczyk smcbeckerle director february mcbeckerle sdsdavis director february dsdavis sieldavis director february ieldavis sjadoudna director february jadoudna smahewson director february mahewson shjoly director february hjoly smbmcclellan director february mbmcclellan johnsonjohnsonannualreportsignature title date sammulcahy director february ammulcahy saewashington director february aewashington smaweinberger director february maweinberger snywest director february nywest johnsonjohnsonannualreport exhibit index regsk exhibittable itemno descriptionofexhibit agreementandplanofmergerdatedasofoctoberbyandamongjohnsonjohnsonathosmergersubincand abiomedincincorporatedhereinbyreferencetoexhibitoftheregistrantsformkcurrentreportfilednovember restatedcertificateofincorporationeffectivefebruaryincorporatedhereinbyreferencetoexhibitiofthe registrantsformkannualreportforthefiscalyearendedjanuary ii certificateofamendmenttothecertificateofincorporationofjohnsonjohnsoneffectiveaprilincorporatedherein byreferencetoexhibitoftheregistrantsformkcurrentreportfiledapril iii bylawsofthecompanyasamendedeffectivejuneincorporatedhereinbyreferencetoexhibitofthe registrantsformkcurrentreportfiledjune upontherequestofthesecuritiesandexchangecommissiontheregistrantwillfurnishacopyofallinstrumentsdefiningthe rightsofholdersoflongtermdebtoftheregistrant b descriptionofsecuritiesregisteredpursuanttosectionofthesecuritiesexchangeactofincorporatedhereinby referencetoexhibitoftheregistrantsformkcurrentreportfiledaugust longtermincentiveplanincorporatedhereinbyreferencetoexhibitoftheregistrantssregistrationstatement filedonmayfileno b formofstockoptioncertificateunderthelongtermincentiveplanincorporatedhereinbyreferencetoexhibitof theregistrantsformkcurrentreportfiledjanuary c longtermincentiveplanincorporatedhereinbyreferencetoappendixaoftheregistrantsproxystatementfiledon march formofstockoptioncertificaterestrictedshareunitcertificateandperformanceshareunitcertificateunderthe longtermincentiveplanincorporatedhereinbyreferencetoexhibitsandoftheregistrantsformq quarterlyreportforthequarterendedapril e globalnonqualifiedstockoptionawardagreementglobalrestrictedshareunitawardagreementandglobalperformance shareunitawardagreementunderthelongtermincentiveplanincorporatedhereinbyreferencetoexhibits andoftheregistrantsformqquarterlyreportforthequarterendedapril f johnsonjohnsonexecutiveincentiveplanamendedasofnovemberincorporatedhereinbyreferenceto exhibitaoftheregistrantsformqquarterlyreportforthequarterendedmarch g domesticdeferredcompensationcertificateofextracompensationplanincorporatedhereinbyreferencetoexhibitg oftheregistrantsformkannualreportfortheyearendeddecember h amendmentstothecertificateofextracompensationplaneffectiveasofjanuaryincorporatedhereinbyreferenceto exhibitjoftheregistrantsformkannualreportfortheyearendeddecember certificatesoflongtermperformanceplanincorporatedhereinbyreferencetoexhibitoftheregistrants formqquarterlyreportforthequarterendedseptember j amendedandrestateddeferredfeeplanfordirectorsamendedasofjanuaryincorporatedhereinbyreference toexhibitkoftheregistrantsformkannualreportforthefiscalyearendedjanuary k thejohnsonjohnsonexecutiveincomedeferralplanamendedandrestatedeffectivejanuaryincorporatedherein byreferencetoexhibitoftheregistrantsformqquarterlyreportforthequarterendedseptember l thejohnsonjohnsonexcesssavingsplanamendedandrestatedasofjanuaryfiledwiththisdocument excessbenefitplanofjohnsonjohnsonandaffiliatedcompaniesamendedandrestatedasofjanuary incorporatedbyreferencetoexhibitnoftheregistrantsformkannualreportforthefiscalyearendedjanuary n executivelifeplanagreementincorporatedhereinbyreferencetoexhibitioftheregistrantsformkannualreport forthefiscalyearendedjanuary executivelifeplanagreementclosureletterincorporatedhereinbyreferencetoexhibitoftheregistrantsformq quarterlyreportforthequarterendedmarch p longtermincentiveplanincorporatedbyreferencetoappendixaoftheregistrantsproxystatementfiledon march q severancepayplanofjohnsonjohnsonandusaffiliatedcompaniesamendedandrestatedasofoctober incorporatedhereinbyreferencetoexhibitoftheregistrantsformqquarterlyreportforthequarterended september johnsonjohnsonannualreportregsk exhibittable itemno descriptionofexhibit r firstamendmenttotheseverancepayplanofjohnsonjohnsonandusaffiliatedcompaniesasamendedandrestated effectiveoctoberincorporatedhereinbyreferencetoexhibitoftheregistrantsformqquarterlyreport forthequarterendedjune secondamendmenttotheseverancepayplanofjohnsonjohnsonandusaffiliatedcompaniesasamendedandrestated effectiveoctoberincorporatedhereinbyreferencetoexhibitxoftheregistrantsformkannualreportfor thefiscalyearendedjanuary contingentvaluerightsagreementdatedasofdecemberbyandbetweenjohnsonjohnsonandamericanstock transfertrustcompanyllcincorporatedhereinbyreferencetoexhibitoftheregistrantsformkcurrentreport fileddecember subsidiariesfiledwiththisdocument consentofindependentregisteredpublicaccountingfirmfiledwiththisdocument certificationofchiefexecutiveofficerpursuanttosectionofthesarbanesoxleyactfiledwiththisdocument certificationofchieffinancialofficerpursuanttosectionofthesarbanesoxleyactfiledwiththisdocument certificationofchiefexecutiveofficerpursuanttosectionofthesarbanesoxleyactfurnishedwiththisdocument certificationofchieffinancialofficerpursuanttosectionofthesarbanesoxleyactfurnishedwiththisdocument exhibit exins instancedocumenttheinstancedocumentdoesnotappearintheinteractivedatafilebecauseitsxbrltagsareembedded withintheinlinexbrldocument exsch inlinexbrltaxonomyextensionschema excal inlinexbrltaxonomyextensioncalculationlinkbase exlab inlinexbrltaxonomyextensionlabellinkbase expre inlinexbrltaxonomyextensionpresentationlinkbase exdef inlinexbrltaxonomyextensiondefinitiondocument exhibit coverpageinteractivedatafilethecoverpageinteractivedatafiledoesnotappearintheinteractivedatafilebecauseits xbrltagsareembeddedwithintheinlinexbrldocument managementcontractorcompensatoryplan paperfiling certainexhibitsandscheduleshavebeenomittedpursuanttoitembiiorbivofregulationskasapplicable acopyofanyoftheexhibitslistedabovewillbeprovidedwithoutchargetoanyshareholdersubmittingawrittenrequest specifyingthedesiredexhibitstothesecretaryattheprincipalexecutiveofficesofthecompanypursuantto itembiiiaofregulationskthecompanyhasnotfiledasexhibitstothisformkcertainlongtermdebt instrumentsincludingindenturesunderwhichthetotalamountofsecuritiesauthorizeddoesnotexceedofthetotal assetsofthecompanyanditssubsidiariesonaconsolidatedbasisthecompanyherebyagreestofurnishacopyofany suchinstrumenttothesecuponrequest thefollowingexhibitsindicatedasbeingfiledwiththisdocumentareomittedfromtheprintedversionofthis annualreport exhibitl exhibit exhibit johnsonjohnsonannualreport thispageintentionallyleftblankexhibit certificationofchiefexecutiveofficer pursuanttosectionofthesarbanesoxleyact ijoaquinduatocertifythat ihavereviewedthisannualreportonformkforthefiscalyearendedjanuarythereportofjohnson johnsonthecompany basedonmyknowledgethisreportdoesnotcontainanyuntruestatementofamaterialfactoromittostateamaterial factnecessarytomakethestatementsmadeinlightofthecircumstancesunderwhichsuchstatementsweremadenot misleadingwithrespecttotheperiodcoveredbythisreport basedonmyknowledgethefinancialstatementsandotherfinancialinformationincludedinthisreportfairlypresentin allmaterialrespectsthefinancialconditionresultsofoperationsandcashflowsofthecompanyasofandfortheperiods presentedinthisreport thecompanysothercertifyingofficersandiareresponsibleforestablishingandmaintainingdisclosurecontrolsand proceduresasdefinedinexchangeactrulesaeanddeandinternalcontroloverfinancialreportingas definedinexchangeactrulesafanddfforthecompanyandhave adesignedsuchdisclosurecontrolsandproceduresorcausedsuchdisclosurecontrolsandproceduresto bedesignedunderoursupervisiontoensurethatmaterialinformationrelatingtothecompanyincludingits consolidatedsubsidiariesismadeknowntousbyotherswithinthoseentitiesparticularlyduringtheperiodinwhich thisreportisbeingprepared bdesignedsuchinternalcontroloverfinancialreportingorcausedsuchinternalcontroloverfinancial reportingtobedesignedunderoursupervisiontoprovidereasonableassuranceregardingthereliabilityoffinancial reportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewithgenerallyaccepted accountingprinciples cevaluatedtheeffectivenessofthecompanysdisclosurecontrolsandproceduresandpresentedinthis reportourconclusionsabouttheeffectivenessofthedisclosurecontrolsandproceduresasoftheendoftheperiod coveredbythisreportbasedonsuchevaluationand ddisclosedinthisreportanychangeinthecompanysinternalcontroloverfinancialreportingthatoccurred duringthecompanysmostrecentfiscalquarterthecompanysfourthfiscalquarterinthecaseofanannualreport thathasmateriallyaffectedorisreasonablylikelytomateriallyaffectthecompanysinternalcontroloverfinancial reportingand thecompanysothercertifyingofficersandihavedisclosedbasedonourmostrecentevaluationofinternalcontrol overfinancialreportingtothecompanysauditorsandtheauditcommitteeofthecompanysboardofdirectorsor personsperformingtheequivalentfunctions aallsignificantdeficienciesandmaterialweaknessesinthedesignoroperationofinternalcontrolover financialreportingwhicharereasonablylikelytoadverselyaffectthecompanysabilitytorecordprocesssummarize andreportfinancialinformationand banyfraudwhetherornotmaterialthatinvolvesmanagementorotheremployeeswhohaveasignificantrole inthecompanysinternalcontroloverfinancialreporting sjoaquinduato joaquinduato chiefexecutiveofficer datefebruary johnsonjohnsonannualreportexhibit certificationofchieffinancialofficer pursuanttosectionofthesarbanesoxleyact ijosephjwolkcertifythat ihavereviewedthisannualreportonformkforthefiscalyearendedjanuarythereportofjohnson johnsonthecompany basedonmyknowledgethisreportdoesnotcontainanyuntruestatementofamaterialfactoromittostateamaterial factnecessarytomakethestatementsmadeinlightofthecircumstancesunderwhichsuchstatementsweremadenot misleadingwithrespecttotheperiodcoveredbythisreport basedonmyknowledgethefinancialstatementsandotherfinancialinformationincludedinthisreportfairlypresentin allmaterialrespectsthefinancialconditionresultsofoperationsandcashflowsofthecompanyasofandfortheperiods presentedinthisreport thecompanysothercertifyingofficersandiareresponsibleforestablishingandmaintainingdisclosurecontrolsand proceduresasdefinedinexchangeactrulesaeanddeandinternalcontroloverfinancialreportingas definedinexchangeactrulesafanddfforthecompanyandhave adesignedsuchdisclosurecontrolsandproceduresorcausedsuchdisclosurecontrolsandproceduresto bedesignedunderoursupervisiontoensurethatmaterialinformationrelatingtothecompanyincludingits consolidatedsubsidiariesismadeknowntousbyotherswithinthoseentitiesparticularlyduringtheperiodinwhich thisreportisbeingprepared bdesignedsuchinternalcontroloverfinancialreportingorcausedsuchinternalcontroloverfinancial reportingtobedesignedunderoursupervisiontoprovidereasonableassuranceregardingthereliabilityoffinancial reportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewithgenerallyaccepted accountingprinciples cevaluatedtheeffectivenessofthecompanysdisclosurecontrolsandproceduresandpresentedinthis reportourconclusionsabouttheeffectivenessofthedisclosurecontrolsandproceduresasoftheendoftheperiod coveredbythisreportbasedonsuchevaluationand ddisclosedinthisreportanychangeinthecompanysinternalcontroloverfinancialreportingthatoccurred duringthecompanysmostrecentfiscalquarterthecompanysfourthfiscalquarterinthecaseofanannualreport thathasmateriallyaffectedorisreasonablylikelytomateriallyaffectthecompanysinternalcontroloverfinancial reportingand thecompanysothercertifyingofficersandihavedisclosedbasedonourmostrecentevaluationofinternalcontrol overfinancialreportingtothecompanysauditorsandtheauditcommitteeofthecompanysboardofdirectorsor personsperformingtheequivalentfunctions aallsignificantdeficienciesandmaterialweaknessesinthedesignoroperationofinternalcontrolover financialreportingwhicharereasonablylikelytoadverselyaffectthecompanysabilitytorecordprocesssummarize andreportfinancialinformationand banyfraudwhetherornotmaterialthatinvolvesmanagementorotheremployeeswhohaveasignificantrole inthecompanysinternalcontroloverfinancialreporting sjosephjwolk josephjwolk chieffinancialofficer datefebruary johnsonjohnsonannualreportexhibit certificationofchiefexecutiveofficer pursuanttosectionofthesarbanesoxleyact theundersignedjoaquinduatothechiefexecutiveofficerofjohnsonjohnsonanewjerseycorporationthe companypursuanttouscasadoptedpursuanttosectionofthesarbanesoxleyactof herebycertifiesthattothebestofmyknowledge thecompanysannualreportonformkforthefiscalyearendedjanuarythereportfullycomplies withtherequirementsofsectionaofthesecuritiesexchangeactofand theinformationcontainedinthereportfairlypresentsinallmaterialrespectsthefinancialconditionandresultsof operationsofthecompany sjoaquinduato joaquinduato chiefexecutiveofficer datedfebruary thiscertificationisbeingfurnishedtothesecwiththisreportonformkpursuanttosectionofthesarbanes oxleyactofandshallnotexcepttotheextentrequiredbysuchactbedeemedfiledbythecompanyforpurposes ofsectionofthesecuritiesexchangeactofasamendedorotherwisesubjecttotheliabilityofthatsection johnsonjohnsonannualreportexhibit certificationofchieffinancialofficer pursuanttosectionofthesarbanesoxleyact theundersignedjosephjwolkthechieffinancialofficerofjohnsonjohnsonanewjerseycorporationthe companypursuanttouscasadoptedpursuanttosectionofthesarbanesoxleyactof herebycertifiesthattothebestofmyknowledge thecompanysannualreportonformkforthefiscalyearendedjanuarythereportfullycomplies withtherequirementsofsectionaofthesecuritiesexchangeactofand theinformationcontainedinthereportfairlypresentsinallmaterialrespectsthefinancialconditionandresultsof operationsofthecompany sjosephjwolk josephjwolk chieffinancialofficer datedfebruary thiscertificationisbeingfurnishedtothesecwiththisreportonformkpursuanttosectionofthesarbanes oxleyactofandshallnotexcepttotheextentrequiredbysuchactbedeemedfiledbythecompanyforpurposes ofsectionofthesecuritiesexchangeactofasamendedorotherwisesubjecttotheliabilityofthatsection johnsonjohnsonannualreportthispageintentionallyleftblankthispageintentionallyleftblankthetablesbelowareprovidedtoreconcilecertainnongaapfinancialdisclosuresinthe chairmansletter reconciliationofnongaapfinancialmeasures dollarsinmillionsexceptpersharedata change netearningsaftertaxasreported pretaxadjustments intangibleassetamortizationexpense litigationrelated iprd restructuringrelated acquisitionintegrationanddivestiturerelated gainslossesonsecurities medicaldeviceregulation covidvaccinerelatedcosts consumerhealthseparationcosts taxadjustments taximpactonspecialitemadjustments consumerhealthseparationtaxrelatedcosts taxlegislationandothertaxrelated adjustednetearningsaftertax averagesharesoutstandingdiluted adjustednetearningspersharediluted operationaladjustednetearningspersharediluted growth inc salesgrowthvs dec wwtotalasreported operational currency board directors senior management joaquinduato joaquinduato chairmanboardofdirectors chiefexecutiveofficer chairmanexecutivecommittee dariusadamczyk chairmanandchiefexecutiveofficer vanessabroadhurst honeywellinternational executivevicepresidentglobalcorporateaffairs marycbeckerle robertjdeckerjr chiefexecutiveofficerhuntsmancancerinstitute corporatecontrollerchiefaccountingofficer attheuniversityofutah distinguishedprofessorofbiology petermfasolo collegeofscienceuniversityofutah executivevicepresidentchiefhumanresourcesofficer dscottdavis formerchairmanandchiefexecutiveofficer elizabethforminard unitedparcelserviceinc executivevicepresidentgeneralcounsel ianeldavis williamnhait formernonexecutivechairman executivevicepresidentchiefexternalinnovationand rollsroyceholdingsplc medicalsafetyofficerinterimheadjanssenrd formerchairmanandworldwidemanagingdirector mckinseycompany marclarkins corporatesecretary jenniferadoudna worldwidevicepresidentcorporategovernance professorofchemistryprofessorofbiochemistry molecularbiology ashleymcevoy likashingchancellorsprofessorinbiomedical executivevicepresidentworldwidechairman andhealthuniversityofcaliforniaberkeley medtech marillynahewson thibautmongon formerchairandchiefexecutiveofficer executivevicepresidentworldwidechairman lockheedmartincorporation consumerhealthceodesignatetheplanned paulaajohnson newconsumerhealthcompany presidentwellesleycollege jamesswanson hubertjoly executivevicepresidentchiefinformationofficer formerchairmanandchiefexecutiveofficer bestbuycoinc jennifertaubert markbmcclellan executivevicepresidentworldwidechairman directordukerobertjmargolismd pharmaceuticals centerforhealthpolicydukeuniversity duanevanarsdale annemmulcahy treasurer formerchairmanandchiefexecutiveofficer xeroxcorporation kathrynewengel executivevicepresidentchieftechnicaloperations aeugenewashington riskofficer dukeuniversityschancellorforhealthaffairs presidentandchiefexecutiveofficer josephjwolk dukeuniversityhealthsystem executivevicepresidentchieffinancialofficer markaweinberger formerchairmanandchiefexecutiveofficer memberexecutivecommittee ernstyoung nadjaywest formerlieutenantgeneralusarmy johnsonjohnsonannualreportprincipaloffice stocklisting johnsonjohnsononline onejohnsonjohnsonplaza johnsonjohnsoncommonstock newbrunswicknewjersey listedonnewyorkstockexchange ourwebsitewwwjnjcom stocksymboljnj httpwwwjnjcommediacenter annualmeetingofshareholders shareholderrelationscontact thursdayapril marclarkins corporatesecretary wwwfacebookcomjnj ameasternstandardtime meetingheldvirtuallyat wwwtwittercomjnjnews wwwtwittercomjnjcares wwwvirtualshareholdermeetingcomjnj investorrelationscontact allshareholdersasoftherecorddateof jessicamoore wwwyoutubecomjnj februaryareinvitedtoattend vicepresidentinvestorrelations aformalnoticeofannualmeeting investorrelationsitsjnjcom httpwwwlinkedincomcompany proxystatementandproxyhavebeen johnsonjohnson madeavailabletoshareholders stocktransferagentandregistrar annualreportonformkand questionsregardingstockholdings proxystatement certificatereplacementtransferdividends johnsonjohnsonsannualreportonformk andaddresschangesshouldbedirectedto forthefiscalyearendedjanuaryis ourstocktransferagentandregistrarat thelatestnewsconferenceannouncements includedinthisannualreportinitsentiretywith computersharetrustcompanyna pressreleasesandcompanyperformance theexceptionofcertainexhibitstheformk pobox completewithallofitsexhibitsisavailableonour providenceri informationcanbefoundatinvestorjnjcom websiteatwwwinvestorjnjcomseccfmandthe overnightmail theinformationonthesewebsitesshouldnot secswebsiteatwwwsecgov computersharetrustcompanyna bedeemedtobepartofthisannualreport royalstreetsuite shareholdersmayalsoobtaincopiesofthe cantonma exhibitsourannualreporton formkandourproxystatement withoutchargeuponwrittenrequesttothe shareholderwebsite wwwcomputersharecominvestor officeofthecorporatesecretaryatour principalofficeaddressorbycalling dividendreinvestmentplan theplanallowsforfullorpartialdividend electronicdeliverynotification reinvestmentandadditionalcash investmentsuptoperyearin theproxystatementandourannual johnsonjohnsoncommonstockwithout reportareavailableonourwebsite pershareorservicechargesonstock investorjnjcomasmshareholderswhoreceive purchasesifyouareinterestedin papercopiesofourproxystatementandannual participatingintheplanandneedan reportbymailcanelecttoreceiveinsteadane enrollmentformandormoreinformation mailmessagewithalinktothosedocumentsonthe pleasecalltheplanadministrator internetregisteredshareholdersmayenrollin computersharetrustcompanynaat electronicdeliveryatwwwcomputersharenacom c greenbeneficialshareholderswhoholdsharesof outsidetheusoraccessonlineat johnsonjohnsoncommonstockthroughabank wwwcomputersharecominvestor brokerorotherholderofrecordgenerallycan enrollforelectronicdeliveryat hearingimpaired johnsonjohnsonallrights enrollicsdeliverycomjnj shareholderswhohaveinquiriesregarding reserved stockrelatedmatterscancommunicate directlywithcomputersharetrustcompany naviaatelecommunicationsdevicetdd thetelephonenumberforthisserviceis outsidetheus